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Abstract 
 
Oxaliplatin based chemotherapy has demonstrated remarkable efficacy in down staging 
colorectal liver metastases such that patients initially considered to have inoperable disease 
are able to undergo a potentially curative resection.  In addition the use of neoadjuvant 
Oxaliplatin based chemotherapy has been shown to improve progression free survival 
following liver resection.  Taken together this means that ever increasing numbers of 
patients are presenting for liver resection having received multiple cycles of chemotherapy. 
Whilst this approach has many advantages the use of pre-operative chemotherapy has been 
associated with the development of sinusoidal obstruction syndrome (SOS) in the liver 
parenchyma in up to 40% of patients. It is thought that the presence of SOS significantly 
increase the risks associated with major liver resection.  More recent data also suggests that 
the presence of SOS within the liver may result in poorer disease specific outcomes in the 
long term and in particular a higher risk of early intra-hepatic recurrence.  At present the 
pathogenesis of SOS in this context is not understood and no treatment exists to either 
prevent its development or reverse the histological changes in the liver associated with it. 
The aim of the current study was to develop a reproducible in vivo experimental model of 
Oxaliplatin induced SOS and to interrogate this to identify the pathophysiological 
mechanisms which underpin its development.  With this knowledge it was hoped that 
potential therapeutic strategies could be suggested to ameliorate the development of SOS 
in patients treated with Oxaliplatin based chemotherapy. 
C57BL/6J mice treated with weekly intraperitoneal injections of Oxaliplatin and 5-
FU/Leucovorin for 5 weeks develop histological changes of SOS when maintained on a 
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purified, but not chow, diet.  This is associated with increased expression of key matrix 
remodelling genes within the liver parenchyma such as MMP2, MMP9, TIMP1, TGFβ and 
Procollagen I.  The development of these gene expression changes is accelerated in the 
presence of tumour within the liver perhaps as a consequence of increased production of 
inflammatory mediators such as CXCL1. 
The presence of SOS is associated with a dramatic increase in expression of the serine 
protease family member PAI-1 which is involved in a variety of processes including matrix 
remodelling, thrombus formation and cellular senescence.  Immunohistochemistry revealed 
endothelial cells in areas of sinusoidal injury stained positive for the cell cycle inhibitor 
p21
CIP1/WAF1
 in keeping with senescence in these cells.  This process was associated with 
depletion of hepatic glutathione and decreased expression of the antioxidant transcription 
factor NRF2 suggesting a role for oxidative stress in the pathogenesis of SOS.  
To explore this further the experiment was repeated but this time using dietary 
supplementation with either the thiol donor N-Acetylcysteine (NAC) or the NRF2 activator 
butyrated hydroxyanisole (BHA) alongside FOLFOX treatment.  Whilst supplementation with 
NAC had no effect on the development of SOS its development was completely prevented 
by supplementation with BHA suggesting that NRF2 activating antioxidants may be a useful 
therapeutic strategy in preventing the development of SOS. 
In conclusion this study has described the first reproducible experimental model of 
Oxaliplatin induced SOS which accurately reflects the pathogenesis of the disease in 
humans.  Through interrogation of this it has been possible to identify therapeutic strategies 
which may be of value in preventing the development of SOS in patients with colorectal liver 
metastases. 
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Chapter 1 
 Contemporary Management of Colorectal Liver Metastases 
 
1.1  Background 
Colorectal cancer is the third most commonly diagnosed malignancy in the UK and in 2008 a 
new diagnosis of this disease was made in 39,991 patients and was listed as the primary 
cause of death in 16,259 patients.  The incidence of colorectal cancer begins to rise from the 
age of 50 and peaks between the ages of 70 and 80. (Cancer Research UK 2011) A large 
population based survey of 13,463 patients presenting with a primary colorectal cancer over 
a 14 year period demonstrated that 15% of patients had liver metastases present at the 
time of diagnosis.  In the vast majority of these cases (77%) the liver was the only site of 
metastatic disease.(Manfredi, Lepage et al. 2006)   A similar registry based study reported 
that overall  27% of patients with colorectal cancer will develop liver metastases at some 
point in the course of their disease with 19% developing this within 6 months of the primary 
diagnosis.(Leporrier, Maurel et al. 2006)   
Untreated the prognosis for patients with liver metastases is extremely poor with the 
median survival being as low as 7.5 months.(Stangl, Altendorf-Hofmann et al. 1994)  As early 
as 1963 the concept of resecting isolated colorectal liver metastases began to emerge with a 
series of 25 patients, published by George Woodington and colleagues at the Mayo clinic. 
These patients had a median survival of 35.1 months.(Woodington and Waugh 1963) A later 
series from the same centre  in 1976 confirmed these positive results in a larger series of 60 
patients with a 5 year survival of 28%.(Wilson and Adson 1976)  A seminal paper from Stangl 
et al. published in 1994 firmly established surgical resection of liver metastases as the bench 
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mark against which other treatments would be judged.  In this series of 1099 consecutive 
patients with colorectal liver metastases 261 underwent surgical resection of all disease, 
achieving an overall 5 year survival rate of 41% (median survival 41 months).  In comparison 
there were no 5 year survivors in those treated with either systemic chemotherapy (n=71; 
median survival 11.1 months) or those who received no treatment at all (n=484; median 
survival 7.5 months).(Stangl, Altendorf-Hofmann et al. 1994) 
The five year survival rates for colorectal cancer have improved significantly in the UK over 
the last few decades being a little over 20% during the period 1971 – 1975 to almost 50% 
during the period 2001 – 2006.(Cancer Research UK 2011)   Whilst advances in the surgical 
treatment of metastatic disease may account for some of these improvements it is by no 
means the only factor.  Another significant advance in the management of this disease has 
been the development of effective systemic chemotherapy.  The adoption of systemic 
chemotherapy as a treatment option for metastatic colorectal metastases is highlighted in a 
study from the Cote D’Or cancer registry.  This demonstrated that for those patients 
presenting with distant metastatic disease during the period 1976 – 1984 only 8% received 
systemic chemotherapy as compared to 30% of patients during the period 1994 – 
2003.(Guyot, Faivre et al. 2005) 
In 2009 Kopetz et al. published a retrospective review of survival in a series of 2471 patients 
with metastatic colorectal cancer treated at either MD Anderson or the Mayo Clinic over a 
17 year period from 1990 until 2006.  In this study there was a dramatic increase in overall 5 
year survival from 9% during the period 1990 – 1997 to 19% during the period 2001 – 2003.  
Only 20% of patients in this series were able to undergo a curative hepatic resection for 
their metastatic disease but for those who did, the 5 year survival during the period 1998 – 
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2006 was 55% as compared to 20% in those who did not. In the group that did not undergo 
hepatic resection there was a dramatic improvement in overall survival during the period 
2004 to 2006 as compared to those patients treated prior to 1998 (Hazard Ratio 0.53, 95% 
CI 0.45 – 0.62; p<0.001).  It was noteworthy that this improvement was temporally linked 
with the widespread adoption of modern systemic chemotherapeutic agents such as 
Oxaliplatin and Irinotecan.(Kopetz, Chang et al. 2009) 
The advances made in systemic chemotherapy for metastatic colorectal cancer have 
undoubtedly played a significant role in the improvements in 5 year survival that have been 
observed for this disease.  This has lead to an increasing recognition that a multimodal 
approach optimising the use of both surgery and chemotherapeutic agents together is 
required in order to achieve long term survival.(Alberts and Poston 2011)  In the remainder 
of this chapter the current trends in the surgical management of colorectal liver metastases 
and how this is complemented by systemic therapy in patients with both operable and 
inoperable disease at the time of presentation will be discussed. 
  
17 
 
1.2  Surgical Resection of Colorectal Liver Metastases 
1.2.1 Defining Resectability 
As surgical resection of colorectal liver metastases began to emerge as a viable treatment 
strategy in the 1970’s and 80’s it became important to define which patient groups would 
benefit from this treatment option and which would not.  In 1986 Ekberg et al. reported an 
analysis of factors predicting survival in 72 patients undergoing resection of colorectal liver 
metastases.(Ekberg, Tranberg et al. 1986)  On the basis of this study it was concluded that 
the following should be considered contra-indications to surgical treatment: 
1) The presence of 4 or more liver metastases 
2) The presence of extra-hepatic disease 
3) The inability to obtain a clear hepatic resection margin of at least 1cm 
These criteria were subsequently adopted by the surgical community as defining what 
constituted resectable disease.  The difficulty with these criteria is that when they are 
applied only 10% of patients with colorectal liver metastases will be considered suitable 
candidates for liver resection.(Poston, Adam et al. 2006)   
The concept that tumour number is a limiting factor in determining resectability has been 
challenged in recent years.  In 1995 Scheele reported a series of 469 patients who 
underwent liver resection for colorectal metastases.  The presence of five or more 
metastases was identified in this series as being an indicator of poor prognosis but if all 
evidence of other disease was removed then the prognostic effect of this variable was 
lost.(Scheele, Stang et al. 1995) In a direct challenge to the dogma that 4 or more 
metastases are a contraindication to surgery Pawlik et al. published a series of 159 patients 
undergoing surgical resection for colorectal metastases all of whom had a minimum of 4 
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tumour deposits (median 5).  In this series an overall 5 year survival of 51% was achieved 
and the authors concluded that this group of patients should not be excluded from surgical 
treatment on the basis of tumour number alone.(Pawlik, Abdalla et al. 2006)  Kornprat et al. 
also published a series of 98 patients with 4 or more colorectal liver metastases undergoing 
curative intent surgery over an 8 year period in whom an actuarial 5 year survival of 31% 
was achieved.  It is of note that in those patients with fewer than 6 tumours the actuarial 5 
year survival was 39% as compared to 19% in those with 6 or more tumours. (Kornprat, 
Jarnagin et al. 2007) 
In 2009 de Jong et al. published a multi-institutional analysis of 1669 patients who had 
undergone curative intent surgery for colorectal metastases with a specific focus on 
identifying those factors able to predict recurrence.  On multivariate analysis it was 
identified that the presence of 4 or more tumours at the time of surgery was associated 
with an increased risk of extra-hepatic recurrence (Hazard Ratio 1.68; p=0.01) but not intra-
hepatic recurrence.(de Jong, Pulitano et al. 2009)   
The evidence for the effect of tumour number on outcome following resection of colorectal 
liver metastases is summarised in Table 1 below.  In light of these studies it is reasonable to 
conclude that, provided it is possible to remove all evidence of disease, the number of 
hepatic metastases per se is not a contra-indication to resection and it can allow local 
disease control to be obtained.  Nonetheless an increasing number of metastases is a 
marker of poorer tumour biology and as such this group of patients are at an overall greater 
risk of disease recurrence and are perhaps appropriate for more intense follow up in the 
early post-operative course.(Gomez, Morris-Stiff et al. 2010) 
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Study Summary of Key Findings 
Ekberg, Tranberg et al. 1986 No patients with > 4 metastases survived beyond 3 years 
Scheele, Stang et al. 1995 The presence of >4 metastases was a negative predictor of 
resectability but if a radical resection was possible it had no 
impact on disease free or overall survival 
Pawlik, Abdalla et al. 2006 Patients with >4 metastases undergoing liver resection 
achieved a 5 year overall survival of 51% 
Kornprat, Jarnagin et al. 
2007 
Resection of >4 metastases was associated with an actuarial 
overall 5 year survival of 33% 
de Jong, Pulitano et al. 2009 Resection of >4 metastases was associated with an 
increased risk of extrahepatic recurrence (HR 1.68; p=0.01) 
 
Table 1 - Summary of evidence for the effect of tumour number on outcome following 
resection of colorectal liver metastases 
It is not particularly surprising that the presence of extra-hepatic metastases is associated 
with a poorer prognosis in patients undergoing resection of liver metastases, a view upheld 
in several early case series.(Ekberg, Tranberg et al. 1986; Hughes, Simon et al. 1986) It is 
increasingly recognised that there are two groups of patients with extra-hepatic disease – 
those with diffuse multifocal disease and those with localised extra-hepatic disease that 
might be amenable to surgical resection.   
In patients with isolated lung metastases from colorectal cancer it is generally accepted that 
surgical resection, where possible, offers a good option for disease control with 5 year 
survival rates in the order of 30 – 45% being reported in the literature.(Zink, Kayser et al. 
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2001; Saito, Omiya et al. 2002; Inoue, Ohta et al. 2004; Iizasa, Suzuki et al. 2006; Rama, 
Monteiro et al. 2009; see Table 2) This has led some authors to question whether or not 
patients presenting with synchronous, but resectable, liver and lung metastases should be 
offered surgical treatment.  
Study Summary of Key Findings 
Zink, Kayser et al. 2001 In 110 patients undergoing resection of isolated lung 
metastases a 5 year overall survival of 33% was achieved 
Saito, Omiya et al. 2002 In 165 patients undergoing resection of isolated lung 
metastases a 5 year overall survival of 39.6% was achieved.  
The overall survival at 10 years was 37.2% 
Inoue, Ohta et al. 2004 In 128 patients undergoing resection of isolated lung 
metastases a 5 year overall survival of 45% was achieved.   
Iizasa, Suzuki et al. 2006 In 75 patients undergoing resection of isolated lung 
metastases a 5 year overall survival of 41% was achieved. 
Rama, Monteiro et al. 2009 In 61 patients undergoing resection of isolated lung 
metastases a 5 year overall survival of 48% was achieved.  
The overall survival at 10 years was 11%. 
 
Table 2 - Summary of outcomes from studies reporting outcome of isolated lung 
metastases from colorectal cancer 
Brouquet et al. recently published a consecutive series of 112 patients undergoing liver and 
lung resection for colorectal metastases over a 14 year period and compared their outcome 
to 1148 patients who underwent liver only resection.  Remarkably they demonstrated that 
the overall 5 year survival for patients undergoing combined liver and lung resection was 
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50% as compared to 40% in the patients undergoing liver only resection (p=0.01).  It should 
be noted however that the use of systemic chemotherapy was considerably higher in the 
former group (69% vs. 57% p=0.01).(Brouquet, Vauthey et al. 2011) In a similar series of 131 
patients undergoing resection of both liver and lung metastases from colorectal cancer 
Miller et al. reported an overall 5 year survival of 31% once both sites of disease had been 
resected.(Miller, Biernacki et al. 2007) Similar findings have been reported in other 
published series (Shah, Haddad et al. 2006; Neeff, Horth et al. 2009) suggesting that, in 
appropriately selected patients, the presence of both pulmonary and hepatic metastases 
should not be considered a barrier to surgical resection.   The key findings of these studies 
are summarised in Table 3.  It is likely that the role of surgery in the management of 
pulmonary colorectal metastases will be more clearly defined when PulMICC randomised 
control study, whereby patients with pulmonary metastases are allocated to either surgery 
or active observation, reports in due course.(Treasure, Fallowfield et al. 2012) 
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Study Summary of Key Findings 
Miller, Biernacki et al. 2007 131 patients undergoing resection of both liver and lung 
metastases achieved an overall 5 year survival of 31% 
Shah, Haddad et al. 2006 39 patients undergoing resection of both liver and lung 
metastases achieved an overall 5 year survival of 74% 
Neeff, Horth et al. 2009 44 patients undergoing resection of both liver and lung 
metastases achieved an overall 5 year survival of 42% 
Brouquet, Vauthey et al. 
2011 
112 patients undergoing resection of both liver and lung 
metastases achieved an overall 5 year survival of 50% 
 
Table 3 - Summary of key findings from studies reporting the outcome of patients 
undergoing resection of both liver and lung metastases of colorectal cancer 
In 1997 Beckurts et al. reported a series of 126 patients who had undergone resection of 
colorectal liver metastases 28% of whom were identified to have metastatic disease present 
in lymph nodes of the hepato-duodenal ligament.  In those patients with node negative 
disease the overall 3 and 5 year survival figures were 48% and 22% respectively as 
compared to 3% and 0% for those with node positive disease.(Beckurts, Holscher et al. 
1997)  Two more recent prospective series have confirmed the dismal survival in patients 
undergoing liver resection in the presence of peri-portal lymph node metastases.(Kokudo, 
Sato et al. 1999; Laurent, Sa Cunha et al. 2004)  In 2009 Carpizo et al reported a series of 
127 patients who underwent concomitant resection of liver metastases and extra hepatic 
disease, 27 of whom underwent resection of isolated lymph node metastases at the porta 
hepatis.  It is noteworthy that the 5 year survival of this subgroup of patients was 
significantly worse (12%) as compared to those who underwent resection of either lung 
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(28%), peritoneal (30%) or ovarian metastases (51%).(Carpizo, Are et al. 2009)  At the 
present time these data support the view that the presence of overt lymph node metastases 
in the hepato-duodenal ligament should be regarded as a relative contra-indication to the 
resection of liver metastases. 
Occasionally isolated adrenal metastases of colorectal cancer are encountered and when 
unilateral are potentially amenable to surgical treatment.  De Haas et al. reported a single 
centre experience of 796 resections for colorectal liver metastases. During follow of this 
patient cohort they detected adrenal metastases in 14 individuals.  Of these 14 patients all 
received chemotherapy and 10 went on to have a subsequent adrenalectomy.  The median 
overall for patients with adrenal metastases was 23 months irrespective of surgical 
status.(de Haas, Rahy Martin et al. 2009)  The reported series of patients presenting with 
isolated adrenal metastases and undergoing subsequent surgery are extremely small and 
therefore make it difficult to reach meaningful conclusions about the role of surgery in this 
cohort of patients.(Mourra, Hoeffel et al. 2008; Marangos, Kazaryan et al. 2009)  
Following on from the paper of Ekberg et al.(Ekberg, Tranberg et al. 1986) in 1986 several 
case series were published which up held the belief that a clear margin of 1cm was the 
minimum requirement when undertaking resection of colorectal liver metastases – indeed 
less than this was demonstrated to be associated with an increased risk of recurrence and 
poorer overall survival. (Hughes, Simon et al. 1986; Cady, Jenkins et al. 1998)  In a 
multicentre series of 557 patients undergoing resection of colorectal liver metastases, over 
a 14 year period, Pawlik et al. examined the effect of different resection margin widths on 
both disease recurrence and overall survival.  On univariate analysis they demonstrated that 
the presence of tumour at the resection margin (i.e. margin <1mm) was associated with an 
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increased risk of disease recurrence (51.1% vs. 38.6% p = 0.04) and poorer 5 year survival 
(63.8% vs. 17.1%; p = 0.01).  Provided tumour was greater than 1mm from the hepatic 
transection line no effect on survival or recurrence rates could be demonstrated.  It is also 
noteworthy that on multivariate analysis resection margin status was not an independent 
predictor of disease recurrence or poorer survival.(Pawlik, Scoggins et al. 2005)  
In a similar single centre series of 314 patients undergoing resection of colorectal liver 
metastases Muratore et al. compared the effect of a margin positive resection (<1mm), a 
clear margin of less than 1cm and a margin greater than 1cm on long term outcome.  Again 
in this study the width of the surgical margin was not a factor in determining the risk of 
recurrence or long term survival provided that that the line of transection was free of 
tumour.(Muratore, Ribero et al. 2010)  Other case series have confirmed the view that a less 
than 1cm resection margin is not an independent predictor of disease recurrence on 
multivariate analysis.(Bodingbauer, Tamandl et al. 2007; Figueras, Burdio et al. 2007) 
It can be seen from the discussion so far that, over the last decade, many of the 
conventional criteria for defining resectability of colorectal liver metastases have been 
challenged and, in many cases, found not to hold true.  The decision of whether or not to 
proceed with liver resection for colorectal liver metastases can no longer be based upon 
these criteria alone.  Rather one must also consider the extent of resection necessary to 
remove the disease and therefore the risks posed to the individual patient in the peri-
operative period.  
1.2.2 Safety of Liver Surgery for Colorectal Liver Metastases 
In a systematic review of studies reporting outcome for patients undergoing resection of 
colorectal liver metastases Simmonds et al. reported a median 30 day mortality of 2.8% and 
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a median hospital stay of 9.5 days.(Simmonds, Primrose et al. 2006)  Despite being 
published in 2006 the literature search for this study was performed in 2000 meaning that 
the majority of included studies were published in the 1980’s and 90’s.  A single centre 
series of 1803 consecutive liver resections over the decade 1991-2001 revealed an overall 
operative mortality of 3.1%. When the periods 1992-3 (n=259) and 2000-01 (n=392) were 
compared a significant reduction in operative mortality was demonstrated (3.5% vs. 
1.3%).(Jarnagin, Gonen et al. 2002) Other large series published within the last decade have 
confirmed a reduction in operative mortality with typical rates being less than 1%.(Imamura, 
Seyama et al. 2003; Cescon, Vetrone et al. 2009; Kamiyama, Nakanishi et al. 2010) It is 
unlikely that this improvement is attributable to any one single factor but rather represents 
a variety of factors including increased surgical expertise, technological advances and 
improved patient selection. 
Perhaps one of the most dreaded complications following liver resection is the development 
of post-hepatectomy liver failure, which was recently defined in a consensus statement 
from the International Study Group of Liver Surgery as: 
“...a postoperatively acquired deterioration in the ability of the liver to maintain its 
synthetic, excretory and detoxifying functions, which are characterised by an 
increased INR and concomitant hyperbilirubinaemia on or after postoperative day 
5.”(Rahbari, Garden et al. 2011) 
Clearly the difficulty with such a definition is that it will encompass a varied spectrum of 
disease ranging from little more than deranged blood tests to patient death.  The study 
group therefore went on to further subdivide post-hepatectomy liver failure into 3 grades 
where grade A required no changes to be made to patient management, grade B required a 
26 
 
change to patient management but no invasive treatment and grade C required invasive 
treatment.(Rahbari, Garden et al. 2011)  To validate this system it was applied 
retrospectively to a series of 835 patients of whom 65 (11%) developed post-hepatectomy 
liver failure.  Grade A liver failure was present in 8% (5 of 65) of these, grade B in 72% (47 of 
65) and grade C in 20% (13 of 65) with the peri-operative mortality in these 3 groups being 
0%, 12% and 54% respectively.(Reissfelder, Rahbari et al. 2011) A similar system was applied 
by Mullen et al. to a series of 1059 patients undergoing liver resection and they 
demonstrated on multivariate analysis that a bilirubin of 7mg/dl, on or after post-operative 
day 5, was associated with a markedly increased risk of 90 day mortality (Odds Ratio = 250; 
p<0.0001).(Mullen, Ribero et al. 2007)  
A key determinant in predicting the development of post-hepatectomy liver failure is the 
presence of underlying liver disease.  In a series of 747 patients undergoing liver resection 
over an 8 year period Belghiti et al. reported in those with histological abnormalities in the 
underlying liver (either cirrhosis or steatosis > 30%, n=253) the operative mortality was 9.5% 
as compared to only 1% in those without underlying parenchymal disease.(Belghiti, 
Hiramatsu et al. 2000)  A systematic review and meta-analysis of the published literature by 
De Meijer et al. reported that the presence of steatosis > 30% was associated with an 
increased risk of both peri-operative complications (Risk Ratio 2.01; p<0.0001) and mortality 
(Risk Ratio 2.79; p = 0.02) in patients undergoing major hepatectomy (≥3 Couinaud 
segments).(de Meijer, Kalish et al. 2010) In support of this rodent studies have 
demonstrated that liver resection in the context of steatosis is associated with increased 
hepatocellular injury and a poorer functional recovery.(Vetelainen, Bennink et al. 2007; 
Vetelainen, van Vliet et al. 2007) 
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The other key factor in determining the likelihood of post-hepatectomy liver failure is the 
volume of liver that will remain after resection (known as the future liver remnant or FLR) 
and this can normally be calculated pre-operatively using techniques such as CT 
volumetry.(Karlo, Reiner et al. 2010)  In a study of patients undergoing hepatic 
trisectionectomy for colorectal liver metastases Shoup et al. determined that, in those with 
a FLR of 25% or less, 90% developed post-hepatectomy liver failure as compared to  none of 
those with an FLR greater than 25% (p<0.0001).(Shoup, Gonen et al. 2003)  In a prospective 
study of 119 patients undergoing liver resection Ferrero et al. reported that in those 
patients with a normal hepatic parenchyma who went on to develop post-hepatectomy liver 
failure the median FLR was 26.9% as compared to 49.1% in those who did not.(Ferrero, 
Vigano et al. 2007)  It is on the basis of evidence such as this that the recommended 
minimum safe FLR, in patients with an otherwise normal liver, undergoing resection of 
colorectal metastases is 25%.(Garden, Rees et al. 2006; Pawlik, Schulick et al. 2008)  In 
patients with underlying parenchymal disease the required FLR for safe liver surgery 
increases significantly and maybe as high as 40%.(Kubota, Makuuchi et al. 1997)   
For those patients in whom it is not possible to resect all disease with an adequate FLR it is 
sometimes necessary to consider alternative strategies, such as pre-operative portal vein 
embolisation (PVE) or two-stage hepatectomy, in order to minimise the risk of surgical 
treatment.  The role of these strategies, in patients with colorectal liver metastases, is 
discussed in more detail below. 
1.2.3 Pre-Operative Portal Vein Embolisation 
Whilst the volume of the individual liver segments (Figure 1) is highly variable data from a 
series of 102 patients who underwent CT volumetry has suggested that the right lobe 
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typically constitutes 65% of the total liver volume.(Abdalla, Denys et al. 2004)  On occasion, 
in patients with colorectal liver metastases, it is necessary to perform more extensive 
procedures than a classical hemi-hepatectomy.   For example, in a patient with a tumour in 
the right lobe of the liver but in close proximity to the middle hepatic vein, it may be 
necessary to perform a right hepatectomy (segments 5 to 8) alongside resection of segment 
4.(Halazun, Al-Mukhtar et al. 2007; Karanjia, Lordan et al. 2009)  In this situation the FLR 
would consist of segments I, II and III which, according to the data of Abdalla et al., would 
comprise no more than 20% of the original liver volume thereby placing these patients at 
high risk for post-hepatectomy liver failure.(Abdalla, Denys et al. 2004) 
In situations such as these where disease could technically be removed in a single operation 
but would leave an inadequate FLR, then the technique of PVE is particularly useful.  The 
experimental basis for this technique originates from work in the 1920’s, where it was 
observed that ligation of one branch of the portal vein in a rabbit results in atrophy of the 
ipsilateral hepatic lobe with subsequent compensatory hypertrophy of the contralateral 
lobe. (Rous and Larimore 1920) In the clinical situation the portal vein is normally accessed 
by a percutaneous approach and then embolised using an appropriate material (e.g. coils, 
cyanoacrylate glue etc).(Abdalla, Hicks et al. 2001)  The safety of this approach was 
demonstrated by Makuuchi et al. in a series of 14 patients with hilar 
cholangiocarcinoma.(Makuuchi, Thai et al. 1990) In a prospective trial by Farges et al. 
patients undergoing a right hepatectomy were assigned to receive either right PVE or 
standard management.  In those patients with an otherwise normal liver parenchyma who 
underwent PVE there was a median 16% increase in the FLR (as assessed by CT Volumetry) 
as compared to 9% in those with background chronic liver disease.(Farges, Jagot et al. 2002) 
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Figure 1 - Pictoral description of hepatic anatomy with common resections labelled.  From 
Abdalla et al. 2004(Abdalla, Denys et al. 2004) 
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Wicherts et al. retrospectively compared the outcome of 67 patients who had received pre-
operative PVE with 297 who did not and subsequently underwent major hepatic resection 
(≥3 Couinaud segments).  They demonstrated that whilst there was no difference in post-
operative mortality between the two groups the overall complication rate was significantly 
higher in those who had PVE performed (55% vs. 41.1%; p=0.035).  Interpreting this data is 
difficult as 54% of patients in the PVE group underwent a right trisectionectomy as 
compared to only 28% in the control group.  Those who underwent pre-operative PVE had 
poorer 3 year overall survival than controls (44% vs. 61%; p<0.001).  It is noteworthy that in 
32 patients who underwent PVE embolisation but subsequently didn’t proceed to surgery 
there were no survivors at 3 years suggesting that the combination of PVE and surgery 
offers a significant survival advantage but is probably disadvantageous if surgery is not 
performed.(Wicherts, de Haas et al. 2010) 
In a similar study Pamecha et al. compared the outcome of 22 patients undergoing either 
right hepatectomy or right trisectionectomy after PVE with 65 who did not receive PVE.  The 
surgical mortality did not differ between groups but the morbidity was higher in those 
receiving PVE (36% vs. 20%) however again more patients in the PVE group underwent right 
trisectionectomy (22% vs. 11%).  The 3 year overall survival in the PVE group was slightly 
lower at 52% as compared to 65% in the control arm although this difference was not 
statistically significant.  Of the original cohort who underwent PVE (n=36) 12 did not 
progress to surgery and had a median survival of 14 months as compared to 42 months in 
the PVE and surgery group (p<0.0001).(Pamecha, Glantzounis et al. 2009)  
It is striking from both of these series that approximately one third of patients with 
colorectal liver metastases treated with PVE will not subsequently undergo planned surgery 
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and, in the majority of cases, this is as a result of disease progression.(Pamecha, Glantzounis 
et al. 2009; Wicherts, de Haas et al. 2010)  In a series of 18 patients undergoing PVE prior to 
resection of colorectal metastases Kokudo et al. noted there was a 21% increase in tumour 
mass at 3 weeks following the procedure as measured by CT Volumetry.  They also 
compared the Ki67-index in these patients with that of 29 controls and found this to be 
significantly increased in the PVE group (46.6% vs. 35.4%; p = 0.013).(Kokudo, Tada et al. 
2001) In a similar study Pamecha et al. also confirmed an elevated Ki-67 index and mitotic 
cell count in the tumours of patients treated by PVE.(Pamecha, Levene et al. 2009)   
Following PVE there is increased hepatic production of a variety of growth factors such as 
HGF, as well as cytokines involved in liver regeneration, and these may play a role in driving 
metastases progression.(Uemura, Miyazaki et al. 2000; Yokoyama, Nagino et al. 2007)  In 
addition post-PVE the arterial supply to the embolised lobe increases.(Denys, Abehsera et 
al. 2000)  Given that the blood supply of colorectal metastases is predominantly derived 
from the hepatic artery(Archer and Gray 1989) it is conceivable that this leads to increased 
oxygen and nutrient supply to the tumour thereby encouraging its growth. 
It can be seen from this discussion that whilst PVE is a useful technique for patients who are 
at risk for having an insufficient FLR it must be remembered that nearly one third of patients 
in whom this procedure is performed will not progress to surgery as a result of PVE induced 
tumour progression.  This group of patients appear to have a particularly poor prognosis and 
therefore PVE in patients with colorectal liver metastases must be considered very carefully. 
1.2.4 Two-Stage Hepatectomy 
In patients presenting with bilobar disease who may require, for example, an extended right 
hepatectomy and resection of a solitary metastases in segment II then a two-stage 
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hepatectomy may be preferable to PVE because of the risk of tumour progression in the 
FLR.  In the case of this scenario it would typically consist of an initial procedure to clear the 
left lateral segment of the liver with a metastatectomy with either intra-operative ligation of 
the right portal vein or post-operative percutaneous right portal vein embolisation, thereby 
encouraging hypertrophy of the remnant liver, before undertaking an extended right 
hepatectomy as a second operation several weeks later.(Jaeck, Oussoultzoglou et al. 2004)  
On occasion it may not be necessary to undertake the portal vein embolisation if it is felt 
that the hypertrophy induced by the primary procedure will be enough to give an adequate 
FLR following the second resection.(Adam, Laurent et al. 2000) 
In 2008 Wicherts et al. reported a series of 59 patients who were considered to have non 
resectable colorectal liver metastases using a single step surgical approach but were felt to 
be amenable to a two stage procedure.  All patients underwent an initial surgical procedure 
which, in the majority of cases, consisted of a minor hepatic resection (< 3 Couinaud 
segments) with the aim of clearing the left liver of tumour.  Of the 59 patients 17 were 
unable to go a second procedure because of tumour progression.  Of those patients that did 
undergo a second procedure this took place typically 3 months following the primary 
procedure and consisted of a major resection (≥3 Couinaud segments) in the majority of 
cases.  The overall 5 year survival in this series was 31% on an intention to treat basis.   It is 
noteworthy that when compared to patients undergoing a single stage procedure over the 
same time period there was no statistically significant difference in survival between the 
two groups although there was a trend towards poorer survival in the two-stage 
group.(Wicherts, Miller et al. 2008) 
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In another series Narita et al. report the outcome of 79 patients selected to undergo a two 
stage hepatectomy.  Following the primary procedure 75 patients were considered 
appropriate to undergo a second stage procedure, the majority of whom (92%) underwent 
portal vein embolisation.  Off this cohort 61 underwent a second stage procedure (78% of 
original patients).  The main reasons why patients failed to progress to a second resection 
were either tumour progression (n=10) or insufficient regeneration following PVE (n=5).  In 
those undergoing a two stage procedure 16% were found to have a de novo metastases 
present in the FLR which was dealt with at the time of operation.  The overall survival 5 year 
survival in the 61 patients who underwent a completed two-stage hepatectomy was 32%.  
In addition 11 patients went on to have a subsequent lung resection for metastatic disease 
but their survival was no different to the 50 patients who did not require this. (Narita, 
Oussoultzoglou et al. 2011) 
Two-stage hepatectomy is clearly a major undertaking for any patient and given the not in-
significant risk of failing to complete the treatment plan it is essential that, in a similar 
manner to PVE, this is only offered to a carefully selected group of patients.  Nonetheless it 
does provide a treatment option for those patients with advanced disease which has the 
potential to prolong survival. 
1.2.5 The New Surgical Paradigm 
It is clear that our understanding of the behaviour of metastatic colorectal cancer and the 
benefits offered by surgical treatment have evolved considerably over the last decade.  The 
strict stipulations set down in the 1980’s with regard to what constituted resectable disease 
have been challenged in recent years and are now of little relevance to modern surgical 
practice.  In addition the advent of techniques such as PVE and two-stage hepatectomy have 
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meant that patients can undergo more extensive hepatic resections that would previously 
have not been possible because of the unacceptable risk of post-hepatectomy liver failure.  
The result of this has been a fundamental change in the mind set of surgeons treating this 
disease with the question having changed from “Who is resectable?” to “Who is not 
resectable?”. (Pawlik, Schulick et al. 2008)  
This change in outlook was reflected in a recent international consensus conference of the 
management of colorectal liver metastases which concluded that liver resection should be 
considered whenever it is possible to achieve a margin negative resection whilst maintaining 
adequate vascular inflow and biliary/hepatic venous outflow to a liver remnant of sufficient 
volume to avoid the risk of PHLF.  In addition patients with extrahepatic metastatic disease 
should still be considered for resection provided that disease is amenable to either surgical 
resection or long term control with other adjuvant treatments. (Adams, Aloia et al. 2013) 
Within this context surgical treatment canot be viewed in isolation.  Alongside the evolution 
in thesurgical management of this diseasethere has also been significant progressing in the 
available systemic treatment options in terms of both conventional chemotherapeutics and 
biological agents targeting specific pathways implicated in tumour progression.(Robinson, 
Manas et al. 2009)  These advances have important ramifications for the management of 
this group of patients, not only for those with inoperable disease but also for those 
amenable to surgical treatment, and this will be discussed in the next section of this 
chapter.  
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1.3  Systemic Agents for the Treatment of Colorectal Cancer 
For many years the mainstay of chemotherapy for colorectal malignancies consisted solely 
of fluoropyrimidines (e.g. 5-FU) and these agents still form the backbone of modern 
chemotherapy regimens.  A major transformation in chemotherapy for this disease took 
place over the early part of the last decade with the widespread introduction of newer 
agents such as Oxaliplatin and Irinotecan.  These agents have revolutionised the treatment 
options available to patients with metastatic colorectal cancer and the evidence for their 
use is discussed in more detail below. 
1.3.1 Fluoropyrimidines 
The fluoropyrimidines are a family of compounds which include the parenterally 
administered agent 5-FU (Adrucil®, Fluouracil®, Efudex®, Fluoroplex®)  and its oral pro-drug 
Capecitabine (Xeloda®).  5-FU is an analogue of the pyrimidine nucleotide uracil in which 
one of the hydrogen atoms is replaced by fluorine.  After entry to the cell 5-FU is 
metabolised into several active compounds including: 
- Fluorodeoxyuridine monophosphate(FdUMP) 
- Fluorodeoxyuridine triphosphate (FdUTP) 
- Fluorouridine triphosphate (FUTP) 
FdUMP exerts its toxic effects through inhibition of thymidylate synthase which is a key 
enzyme involved in the generation of pyrimidine nucleotides necessary for DNA synthesis.  
In addition to this effect FUTP is able to be incorporated into RNA thereby disrupting its 
function.  The generation of these active metabolites of 5-FU is dependent on the enzyme 
thymidine phosporylase (TP) however an alternative pathway also exists in many cells in 
which 5-FU is converted into the inactive metabolite dihydrofluorouracil (DHFU) whereby it  
  
 
Figure 2 - Summary of 5-FU metabolism.  Adapted from Longley 
al. 2003) 
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is excreted, a process facilitated by the enzyme dihydropyrimidine dehydrogenase 
(DPD).(Longley, Harkin et al. 2003)   The metabolism of 5-FU is summarised in Figure 2.   
It is standard practice to administer Folinic acid (Leucovorin, LV) alongside fluoropyrimidines 
as this has been demonstrated to improve response rates when compared to 5-FU 
administered alone.(Poon, O'Connell et al. 1989)Administration of Folinic acid increases the 
intracellular levels of reduced folate which is essential for the irreversible binding of FdUMP 
to TS.(Longley, Harkin et al. 2003) The Mayo regimen consists of bolus injections of 5-FU/LV 
daily for 5 days in repeated cycles.  When compared to 5-FU alone, in patients with 
advanced colorectal cancer, the addition of LV was found to improve overall median survival 
by almost 5 months (7.7 months vs. 12.2 months; p = 0.037).(Poon, O'Connell et al. 1989) 
The efficacy of the Mayo regimen has been questioned since 5-FU has a very short half life 
in the plasma.  Furthermore it is only active on cells that are in S phase and therefore in 
theory a more prolonged exposure of tumours to 5-FU would increase response rates.   
Awareness of this led to the development of the De Gramont regimen in which bolus 5-FU 
was substituted for a 24 hour infusion.(De Gramont, Krulik et al. 1988) A meta-analysis of 6 
randomised controlled trials comparing bolus or continuous infusion of 5-FU, in a total of 
1219 patients with metastatic colorectal cancer demonstrated that infusion of 5-FU was 
associated with an improvement in tumour response rate (22% vs. 14%; p = 0.0002) and a 
modest improvement in median survival (12.1 months vs. 11.3 months; p = 0.039).(Meta-
analysis Group In Cancer 1998) Chronomodulated infusion of 5-FU, whereby the drug 
infusion is adjusted to match changes in circadian rhythm, has been proposed as a means of 
improving tumour response rates and minimising toxicity.(Cure, Chevalier et al. 2002) 
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Clearly the use of a self administered oral chemotherapeutic has many potential advantages 
to offer, in terms of quality of life for patients with advanced malignancy.  In a randomised 
controlled trial of oral Capecitabine (n = 301) versus the Mayo regimen (n=301) in patients 
with advanced colorectal cancer the investigators assessed tumour response rates which 
were significantly greater in patients treated in the Capecitabine arm (26.6% vs. 17.9%; p = 
0.013).  There was no difference in median survival between the two groups (13.2 months 
vs. 12.1 months).  The incidence of haematological toxicity was lower in those treated with 
Capecitabine whereas the incidence of cutaneous toxicity was higher.(Van Cutsem, Twelves 
et al. 2001) These results have been confirmed in a second similarly sized randomised phase 
III study.(Hoff, Ansari et al. 2001) 
1.3.2 Oxaliplatin 
 Oxaliplatin is a third generation platinum (Pt) compound the structure of which consists of a 
platinum atom conjugated to diaminocyclohexane and oxalate groups.  Following cellular 
uptake Oxaliplatin undergoes non-enzymatic hydrolysis to form the active drug which 
results in the generation of DNA-Pt adducts.  These adducts cause DNA double strand breaks 
to occur with subsequent activation of cellular DNA repair mechanisms or, if sufficient DNA 
damage occurs, the activation of programmed cell death pathways.  The active forms of 
Oxaliplatin are excreted from the cell by conjugation to glutathione and undergo 
subsequent renal clearance.(Kweekel, Gelderblom et al. 2005) 
In 1996 Machover et al. reported two single arm Phase II studies which included a total of 
106 patients with advanced colorectal cancer treated with Oxaliplatin, all of whom had 
experienced disease progression during treatment with a fluoropyrimidine based regimen.  
The overall tumour response rate for patients in both studies was 10% and the major dose 
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limiting toxicity was peripheral neuropathy.(Machover, Diaz-Rubio et al. 1996) A second 
phase II trial, this time using chronomodulated Oxaliplatin, by Levi et al. similarly 
demonstrated a 10% tumour response rate in patients who had experienced disease 
progression on fluoropyrimidine therapy.(Levi, Perpoint et al. 1993) 
In vitro experiments on cancer cell lines and in vivo xenograft tumour models have 
demonstrated that the combination of Oxaliplatin and 5-FU are synergistic.(Raymond, 
Buquet-Fagot et al. 1997) This experimental data was confirmed in subsequent phase II 
trials which demonstrated tumour response rates anywhere between 20 and 50% when the 
two drugs were used in combination.(Levi, Zidani et al. 1994; Andre, Louvet et al. 1998) In a 
phase III trial Giacchetti et al. randomised 200 patients with metastatic colorectal cancer to 
receive chronomodulated 5-FU/LV either alone or in combination with Oxaliplatin.  This 
study demonstrated a dramatic improvement in objective tumour response in the group 
receiving Oxaliplatin (53% vs. 16%; p<0.01) although there was no difference in median 
survival between the two groups (19.9 months vs. 19.4 months).(Giacchetti, Perpoint et al. 
2000)  In a second randomised control trial 420 patients, again with metastatic colorectal 
cancer, were randomised to receive 5-FU/LV either alone or in conjunction with Oxaliplatin.  
In this study the patients receiving the combined therapy demonstrated again a markedly 
improved objective response rate (50.7% vs. 22.3%; p<0.0001) but with no improvement in 
overall survival.(de Gramont, Figer et al. 2000) 
Despite the lack of improvement in overall survival in these studies the dramatic 
improvement in objective tumour response suggested that there may be a role for the 5-
FU/LV and Oxaliplatin regimen in down staging patients with inoperable metastatic disease 
and this will be discussed in more detail below.  The combination of 5-FU/LV with 
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Oxaliplatin is now widely known by the acronym FOLFOX and this will be used throughout 
the rest of this discussion.  A variety of different FOLFOX regimes have been reported in the 
literature e.g. FOLFOX4, FOLFOX 6 etc which all differ slightly in drug dosing regimen and 
scheduling.  There is no direct evidence that one regimen is superior to any other and 
therefore no distinction is made in this text.  In some studies Capecitabine is substituted for 
5-FU and in this instance the regimen is referred to by the acronym CAPOX. 
1.3.3 Irinotecan 
Irinotecan (Campto®), a derivative of Camptothecin, is a pro-drug which upon entry into the 
cell undergoes metabolism by the enzyme carboxylesterase into its active form SN-38 or 
alternatively is inactivated by cytochrome CYP3A4.  SN-38 binds to DNA/topoisomerase I 
complexes leading to an inability of the cell to repair DNA single strand breaks and thereby 
ultimately results in cell death.  SN-38 is inactivated by glucurodination, a process facilitated 
by the enzyme UGT1A1.  Polymorphisms in the gene encoding this enzyme lead to excessive 
accumulation of the active form of SN-38 and consequentially increased drug 
toxicity.(Kweekel, Guchelaar et al. 2008; Marsh and Hoskins 2010) 
In 1998 Rougier et al. randomised 267 patients with advanced colorectal cancer, who had 
experienced disease progression on a 5-FU based regimen, to either Irinotecan or further 
infusional 5-FU.  The patients in the Irinotecan arm demonstrated an improvement in 
median progression free survival (4.2months vs. 2.9 months; p = 0.03) and overall 1 year 
survival (45% vs. 32%; p = 0.035) as compared to those receiving 5-FU.(Rougier, Van Cutsem 
et al. 1998)  A second randomised trial, published in the same edition of the Lancet, 
allocated 279 patients with metastatic colorectal cancer and disease progression on 5-FU to 
receive either Irinotecan or best supportive care.  Those in the Irinotecan group 
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demonstrated a significant improvement in overall 1 year survival as compared to those in 
the supportive care alone arm (36% vs. 13%; p=0.0001).(Cunningham, Pyrhonen et al. 1998) 
It is on the basis of these two trials that Irinotecan became established as a treatment 
option for advanced colorectal cancer. 
 In subsequent trials Irinotecan was combined with 5-FU/LV in an attempt to improve 
efficacy (known by the acronym FOLFIRI).  Saltz et al. randomised 683 patients with 
metastatic colorectal cancer, who had not received systemic treatment within the last year, 
to receive either 5-FU/LV alone, Irinotecan alone or FOLFIRI.  They were able to 
demonstrate that those allocated to the FOLFIRI arm had a superior objective response rate 
(50% vs. 28%; p<0.001) and longer median survival (14.8 months vs. 12.6 months; p = 0.04) 
as compared to those receiving 5-FU/LV.  There was no difference in either objective 
response (28% vs. 29%) or median survival (12.6 months vs. 12.0 months) in those receiving 
either 5-FU/LV or Irinotecan alone.(Saltz, Cox et al. 2000)  In a smaller study Maiello et al. 
randomised 102 patients with either locally advanced or metastatic colorectal cancer to 
FOLFIRI or 5-FU/LV.  Again patients had not received adjuvant systemic therapy within the 
year prior to study entry.  Patients in the FOLFIRI arm demonstrated a significantly improved 
objective tumour response rate (40% vs. 18%; p = 0.014) although there was no significant 
difference in median survival (15 months vs. 14 months) between the two groups.   
From these trials it seems, in a similar manner to Oxaliplatin, that whilst the addition of 
Irinotecan to conventional 5-FU may offer, at best, a modest increase in overall patient 
survival its major advantage is improving the tumour response rate.   
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1.3.4 Biological Agents 
In parallel with the development of conventional chemotherapy biological agents, i.e. 
antibody based therapies, have emerged which target specific pathways involved in the 
maintenance of tumour growth and development.  In particular agents targeting tumour 
angiogenesis and tumour proliferation have been the subject of much investigation and are 
now finding their place in routine clinical practice. 
1.3.4.1 Tumour Angiogenesis 
For both primary and malignant tumours development there must be an independent blood 
supply which enables delivery of nutrients and oxygen.  The process through which this 
blood supply evolves, known as angiogenesis, is driven by production of a large number of 
pro-angiogenic factors by tumour cells.(Carmeliet and Jain 2000; Garcea, Lloyd et al. 2004)  
One such factor is Vascular Endothelial Growth Factor-A (VEGF-A) which is a member of the 
VEGF family of growth factors.  VEGF-A acts through the VEGF receptors VEGFR-1 and 
VEGFR-2, expressed on endothelial cells, whereby it stimulates the proliferation, migration 
and invasion of endothelial cells into the tumour resulting in new blood vessel 
formation.(Ellis and Hicklin 2008)  Bevacizumab is a humanised monoclonal antibody which 
specifically targets soluble VEGF-A.  By binding to VEGF-A Bevacizumab prevents the 
interaction of the ligand with its receptor and therefore aims to reduce tumour 
angiogenesis.(Ellis and Hicklin 2008; Geva, Prenen et al. 2010) 
In 2003 Kabbinavar et al. published a phase II randomised trial which allocated patients with 
metastatic colorectal cancer to receive either 5-FU/LV alone or in combination with either 
5mg/kg or 10mg/kg Bevacizumab.  The key finding from this study was that, when both 
Bevacizumab arms were pooled, its addition resulted in a 55% reduction in the hazard of 
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disease progression as compared to 5-FU/LV alone (p=0.02). (Kabbinavar F 2003) In a key 
phase III trial Hurwitz et al. randomised patients with metastatic colorectal cancer to receive 
either FOLFIRI alone (n=411) or FOLFIRI & Bevacizumab (n=402).  In those allocated to 
receive Bevacizumab there were significant improvements in median survival (20.3 months 
vs. 15.6 months; p<0.001), progression free survival (10.6 months vs. 6.2 months; p<0.001) 
and the measured overall response rate (44.8% vs. 34.8%; p = 0.004).(Hurwitz, 
Fehrenbacher et al. 2004)  Similar results were also demonstrated when Bevacizumab was 
added to FOLFOX based chemotherapy in the Tree-1 and Tree-2 studies with an 11% 
improvement in tumour response rates.(Hochster, Hart et al. 2008) 
1.3.4.2 Tumour Proliferation  
 One of the key features of tumour cells is disordered proliferation.  Numerous pathways 
exist to regulate cellular proliferation and the activity of many of these is regulated by a 
variety of growth factors and their associated receptors.  One such pathway is regulated by 
the epidermal growth factor (EGF) which on binding to its receptor (EGFR) activates a 
signalling cascade which ultimately results in up regulation of a variety of genes involved in 
cellular growth, migration, differentiation and adhesion of cells to the extracellular 
matrix.(Yarden 2001)  Over-expression of EGFR is well documented in colorectal cancers and 
is considered to be a poor prognostic marker.(Lockhart and Berlin 2005; Theodoropoulos, 
Karafoka et al. 2009; Ljuslinder, Melin et al. 2011)  Awareness of this has led to the 
development of the anti-EGFR antibodies Cetuximab (chimeric IgG1) and Panitumumab 
(fully humanised IgG2) for use as adjuncts in the management of colorectal cancer.(Geva, 
Prenen et al. 2010) 
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The Bond study randomised patients with EGFR expressing metastatic colorectal cancer, 
who had experienced disease progression on Irinotecan based chemotherapy, to receive 
either Cetuximab monotherapy (n= 111) or Cetuximab and further Irinotecan (n=218).  In 
this study those receiving the combination of Irinotecan and Cetuximab experienced a 
higher overall response rate (22.9% vs. 10.8%; p = 0.0007) but no statistically significant 
difference in overall median survival (8.6% vs. 6.9%; p = 0.48).(Cunningham, Humblet et al. 
2004)   In the EPIC trial patients with EGFR expressing metastatic colorectal cancer who 
experienced treatment failure with FOLFOX chemotherapy were randomised to either 
Irinotecan alone (n=650) or Irinotecan and Cetuximab (n=650).  Again the addition of 
Cetuximab was associated with an improvement in overall response rates (16.4% vs. 4.2%; p 
= 0.0001) but no effect was seen on median survival (10.7 months vs. 10.0 months; p = 
0.71).(Sobrero, Maurel et al. 2008) 
A key intermediary in the EGFR signalling pathway is the protein RAS which is encoded by 
the Kirsten-RAS (K-RAS) oncogene.  Mutations in this gene are present in about one third of 
patients with colorectal cancer and are associated with poorer disease specific and overall 
survival.(Andreyev, Norman et al. 1998; Esteller, Gonzalez et al. 2001)  K-RAS mutations lead 
to constitutive activation of the signalling pathways downstream of EGFR thereby negating 
the effect of agents targeting the receptor itself. (Ramos and Tabernero 2008)  
Consequently this has resulted in the retrospective analysis of K-RAS mutation status in the 
major randomised trials utilising Cetuximab.  The OPUS trial patients randomised patients 
with EGFR expressing metastatic colorectal cancer to receive either FOLFOX (n=168) or 
FOLFOX & Cetuximab (n=170).  The addition of Cetuximab was associated with a trend 
towards improved overall tumour response (46% vs. 36%; p = 0.064) although this did not 
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reach statistical significance.  When the analysis was limited to patients  with only wild type 
K-RAS the difference in overall response rate was markedly higher in the Cetuximab group 
and statistical significance was achieved (61% vs. 37%; p = 0.011).(Bokemeyer, Bondarenko 
et al. 2009) 
In the CRYSTAL study patients with EGFR expressing metastatic colorectal cancer were 
randomised to receive either FOLFIRI alone (n=599) or FOLFIRI and Cetuximab (n=599).  
When considering the overall study population the addition of Cetuximab was associated 
with an improved overall tumour response rate (46.9% vs.. 38.7%; p = 0.0004) but no overall 
difference in median survival (19.9 months vs. 18.6 months; p=0.31).  Wild type K-RAS in 
particular was associated with an improved tumour response rate when Cetuximab was 
added (59.3% vs. 43.2%; p = 0.03) whereas mutant K-RAS was associated with a poorer 
tumour response (36.2% vs. 40.2%).(Van Cutsem, Kohne et al. 2009) 
Mutations in oncogenes other than K-RAS have also been linked with tumour 
responsiveness too Cetuximab.  One of these is BRAF which encodes the RAF protein, 
another downstream intermediary in the EGFR signalling pathway.  Mutations in BRAF, 
which again lead to constitutive activation of this pathway, are independent of K-RAS status 
and have been reported as predictors of poorer overall and progression free survival in 
patients treated with both Oxaliplatin and Irinotecan based regimens, as well as with 
Bevacizumab.(Siena, Sartore-Bianchi et al. 2009; Souglakos, Philips et al. 2009)  In addition 
patients with wild type K-RAS but mutant BRAF have been demonstrated to be unresponsive 
to either Cetuximab or Panitumumab.(Di Nicolantonio, Martini et al. 2008; Loupakis, Ruzzo 
et al. 2009) 
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The MRC Coin trial randomised patients with inoperable advanced colorectal cancer, 
irrespective of EGFR status, to receive either Oxaliplatin based chemotherapy (CAPOX or 
FOLFOX; n = 815) or the same regimen with the addition of Cetuximab (n=815).  The 
investigators also performed mutation analysis for K-RAS and BRAF and subgroup analysis 
was performed based on this.  Overall the addition of Cetuximab was associated with a 
modest increase in overall tumour response rate in patients with wild-type K-RAS only (64% 
vs. 57%; p = 0.049).  No benefit in terms of overall survival was seen with the addition of 
Cetuximab in any of the three groups.(Maughan, Adams et al. 2011) 
Whilst much of the data describing the efficacy of anti-EGFR antibodies in patients with 
colorectal cancer relates to Cetuximab the reported outcomes for Panitumumab are similar.  
For example in one trial patients with metastatic colorectal cancer were randomised to 
receive either FOLFIRI alone (n=595) of FOLFIRI and Panitumumab (n=591).  Whilst there 
was no effect on overall survival the addition of Panitumumab was associated with an 
improved overall response rate (35% vs. 10%; p < 0.001) an effect which was lost in patients 
with mutant K-RAS.(Peeters, Price et al. 2010) Similar results were also reported when 
Panitumumab was combined with FOLFOX in a separate randomised trial.(Douillard, Siena 
et al. 2010) 
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1.4  Systemic Therapy for Inoperable Colorectal Liver Metastases 
 It can be seen from the discussion thus far that one of the key attributes of systemic 
therapy are tumour response rates allowing down-staging of disease.  In patients who 
present with inoperable metastatic disease one of the key goals of therapy is to down-stage 
in a manner which may enable subsequent surgical resection – an approach which has been 
labelled “conversion chemotherapy”.(Khatri, Chee et al. 2007)   
As early as 1996 Bismuth reported a series of 434 patients presenting with colorectal liver 
metastases, of whom 330 were considered to have inoperable disease and were thus 
treated with Oxaliplatin based chemotherapy.  Of these 330 patients 16% (n=53) were 
subsequently down-staged in such a manner that they were able to undergo surgery with 
curative intent.  In 46 of these patients all evidence of disease was removed following a 
primary liver resection however in 7 patients there was residual disease present after the 
primary procedure.  These patients underwent a second course of chemotherapy and all 
had any remaining disease removed during a second surgical procedure (either with a 
further liver resection or pulmonary resection).  The overall 5 year survival in this series of 
patients was 40% which the authors state compared favourably to that being obtained in 
patients with initially operable disease during the same period.(Bismuth, Adam et al. 1996)  
A updated report from the same unit in 2001 which included 701 patients with initially 
inoperable disease showed the overall conversion rate to operable disease to be 13.6% with 
a 5 year actuarial survival of 34%.(Adam, Avisar et al. 2001) 
In a non-randomised phase II trial Alberts et al. reported the outcome of 42 patients with 
initially inoperable colorectal liver metastases who were treated with FOLFOX 
chemotherapy.  25 (60%) of these patients experienced some degree of tumour response to 
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chemotherapy and 17 (40%) were deemed to have potentially operable disease and 
underwent exploratory laparotomy.  From this group of patients 14 (33% of the original 
cohort) were deemed to have had complete resection of their disease.  For those patients 
undergoing a complete resection an overall 3 year survival of 67% was reported compared 
to a median survival of only 26months for the others. Taken together these findings confirm 
there is a significant survival advantage for those patients who are able to undergo a 
complete surgical resection after down-staging chemotherapy despite initially having 
inoperable disease.(Alberts, Horvath et al. 2005)  
Nuzzo et al. reported the outcome of 42 patients with initially inoperable colorectal liver 
metastases who were treated with FOLFIRI chemotherapy.  From this group 18 patients 
were considered to have been down-staged sufficiently to warrant exploratory laparotomy 
with 15 patients (35.7%) undergoing curative intent surgery.  The outcomes of these 15 
patients were compared to a cohort of 60 patients who had undergone primary surgical 
treatment of operable liver metastases.  The median overall survival did not differ between 
the two groups (46 months vs. 47 months) however those who had received down-staging 
chemotherapy had a poorer 3 year recurrence free survival (31% vs. 58%; p = 0.04).(Nuzzo, 
Giuliante et al. 2007) 
Whilst these studies demonstrate that the concept of down-staging inoperable disease is 
worthy of pursuit they do not provide any insight into the optimal chemotherapy strategy 
for obtaining this.  In an attempt to address this question the GOIM No 9901 trial 
randomised patients with either locally advanced or inoperable metastastic disease to 
receive treatment with either FOLFOX (n=182) or FOLFIRI (n=178).  This trial did not detect 
any difference in objective response rates between either regimen (36% vs. 34%) or in 
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median overall survival (15 months vs. 14 months).  Unfortunately however the study did 
not report how many patients, if any, were able to progress to surgical treatment.(Colucci, 
Gebbia et al. 2005) 
The GERCOR trial randomised patients with inoperable metastatic colorectal cancer to 
receive either FOLFIRI until disease progression or unacceptable toxicity and then FOLFOX or 
the reverse sequence (n=113 per arm).  When used as first line therapy there was no 
difference in progression free survival with FOLFIRI or FOLFOX (8.5 months vs. 8 months).  
As second line therapy FOLFOX demonstrated an improved progression free survival as 
compared to FOLFIRI (4.2 months vs. 2.5 months; p = 0.003).  There was no difference in 
overall survival in either arm of the study.  In the first line setting FOLFOX demonstrated 
superiority in down-staging with 24 patients (22%) in this arm undergoing subsequent 
curative intent surgery as compared to 10 patients (9%) in the first line FOLFIRI arm 
(p=0.02).(Tournigand, Andre et al. 2004) 
More recently the combination of 5-FU/LV, Oxaliplatin and Irinotecan (FOLFOXIRI) has been 
proposed as a therapeutic strategy in patients with inoperable metastatic colorectal cancer.  
The GONO group randomised patients with inoperable metastatic colorectal cancer to 
receive either FOLFIRI or FOLFOXIRI (n=122 per arm).  Those in the FOLFOXIRI arm 
demonstrated an improvement in overall tumour response (66% vs. 41%; p = 0.0002) with a 
higher proportion of patients going on to have complete resection of their metastatic 
disease (18% vs. 6%; p = 0.033).  If the analysis is limited to patients with liver only 
metastases then an even greater proportion were able to undergo curative intent surgery 
after FOLFOXIRI (36% vs. 12%; p = 0.017).(Falcone, Ricci et al. 2007) In a pooled analysis of 
patients in this and 2 smaller phase II studies who underwent complete resection of their 
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disease after FOLFOXIRI treatment (37/196; 19%)a 5 year survival of 42% was 
achieved.(Masi, Loupakis et al. 2009) 
In addition to conventional chemotherapy the role of biological agents as adjuncts in 
disease down-staging has also been explored.  The first BEAT trial, an uncontrolled phase IV 
study, assessed the addition of Bevacizumab to fluoropyrimidine based chemotherapy, 
given according to the treating physicians’ choice, in patients with inoperable metastatic 
colorectal cancer.   Only 16% of patients received a fluoropyrimidine alone whereas 50% of 
patients received additional Oxaliplatin and 34% of patients received additional Irinotecan.  
Of the 1965 patients in this study 145 (7.6%) underwent a liver resection with curative 
intent after treatment with a Bevacizumab containing regimen.  In those treated with 
regimens containing Oxaliplatin the resection rate was 10.4% whereas in those containing 
Irinotecan the rate was 6.5%.  If the analysis was limited to those with inoperable liver only 
disease at the time of study entry 15.2% of patients overall were able to undergo 
subsequent liver surgery with curative intent but the individual rate in those receiving 
Oxaliplatin being 20.3% and for Irinotecan 14.3%.  In this study the 2 year overall survival in 
patients with inoperable liver only disease at the time of study entry was 54% whereas for 
those who underwent liver resection with curative intent this increased to 89% (p<0.0001) 
again confirming the necessity of surgical intervention in those who are down-staged by 
systemic treatment regimens.(Okines, Puerto et al. 2009; Van Cutsem, Rivera et al. 2009) 
The NO16966 study initially commenced as a randomised trial which allocated patients with 
inoperable metastatic colorectal cancer to receive either FOLFOX or XELOX.  On the basis of 
the study by Hurwitz et al. (Hurwitz, Fehrenbacher et al. 2004) this was subsequently 
modified to a 2 x 2 design whereby patients received these regimens either with or without 
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the addition of Bevacizumab.  A total of 1401 patients were randomised on a 1:1 basis.  In 
those patients who received Bevacizumab alongside either FOLOX or XELOX there was an 
improvement in progression free survival (10.4 months vs. 7.9 months; p<0.0001) but not in 
overall tumour response rates (49% vs. 47%; p = 0.31).  In light of this it is not overly 
surprising that this study also failed to demonstrate an improvement in the number of 
patients who underwent potentially curative surgical resection with the addition of 
Bevacizumab either overall (8.4% vs. 6.1%; p=0.24) or amongst those with liver only disease 
at the time of study entry (12.3% vs. 11.6%; p = 0.81).(Okines, Puerto et al. 2009) 
The BOXER trial was a phase II uncontrolled study which examined the effect of XELOX and 
Bevacizumab in combination for patients with colorectal liver metastases deemed not 
suitable for liver resection (n=46).  Of those entered into the study an objective response 
was obtained in 35 patients (78%).  18 patients (40%) proceeded to undergo a liver 
resection with curative intent and a further 5 patients (11%) had a complete radiological 
response to treatment and therefore were not offered surgery.  One criticism of this study is 
that the definition of resectability applied was somewhat conservative and excluded 
patients with >4 metastases and patients with a maximum tumour size of >5cm as well as 
those in whom it was not thought possible to obtain a clear resection margin or who would 
have had an insufficient FLR. (Wong, Cunningham et al. 2011) 
The CELIM study was a randomised phase II study which allocated patients with inoperable 
colorectal liver metastases to receive either FOLOX (n=53) or FOLFIRI (n=53) in combination 
with Cetuximab.  Overall an objective tumour response was seen in 66 patients (62%) but 
there was no statistically significant difference between the two groups.  36 patients (34%) 
in this study were able to undergo a complete resection of metastatic disease following 
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treatment.  The proportion of patients undergoing resection in the FOLFOX group was 
marginally higher but this difference did not reach statistical significance (20% vs. 
16%).(Folprecht, Gruenberger et al. 2010)   
In the previously discussed CRYSTAL trial, which randomised patients with inoperable 
metastatic colorectal cancer to receive either FOLFIRI alone or in conjunction with 
Cetuximab, those patients who received Cetuximab and were K-RAS wild type were more 
likely to be able to undergo complete resection of metastatic disease when compared to 
those receiving FOLFIRI alone (5.1% vs. 2.0%; p = 0.03).(Van Cutsem, Kohne et al. 2009; Van 
Cutsem, Kohne et al. 2011) Similarly in a retrospective analysis of the OPUS trial according 
to K-RAS status, whereby patients were randomised to either FOLFOX or FOLFOX and 
Cetuximab, it was reported that, for K-RAS wild type patients, those who received pre-
operative Cetuximab were more likely to undergo curative intent surgery of metastatic 
disease (12% vs. 3%; p = 0.02).(Bokemeyer, Bondarenko et al. 2011) 
When discussing the merits of aggressive systemic therapy in patients with initially 
inoperable disease it is important to be aware of what the long term outcome is for those 
who achieve the goal of subsequent surgical resection. In an attempt to address this Adam 
et al. reported a series of 184 patients with initially inoperable colorectal liver metastases 
who underwent hepatectomy with curative intent after down-staging chemotherapy.  In this 
cohort of patients an overall 5 year survival of 33% was obtained and a recurrence free 5 
year survival of 19%.  148 patients in this series had complete 5 year follow-up data 
available and of these patients 24 were considered to have been ‘cured’ i.e. free of 
recurrent disease for 5 years following the last surgical resection.  It is noteworthy that of 
these patients 16 remained disease free after the initial hepatic resection whereas a further 
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8 required surgery to remove either residual, or recurrent, metastatic disease before ‘cure’ 
was obtained.(Adam, Wicherts et al. 2009)  This observation serves to highlight that, at least 
for a subgroup of patients, two or more surgical procedures often interspersed with 
chemotherapy are required to achieve long lasting disease control.  
It is undoubtedly true that systemic treatment of inoperable metastatic colorectal cancer 
can, in a proportion of patients, result in down-staging such that a potentially curative 
resection can be offered and the likelihood of long term survival increased.  There appears 
to be little real difference in terms of conventional chemotherapy regimens to achieve 
effective down-staging, although on the basis of the GERCOR trial it is more common to use 
FOLFOX as first line.(Tournigand, Andre et al. 2004; Kelly and Cassidy 2007; Hind, Tappenden 
et al. 2008)  Whilst there is good evidence that Cetuximab, in K-RAS wild type patients, can 
undoubtedly offer an advantage in terms of down-staging when combined with 
conventional chemotherapy the evidence for Bevacizumab is less clear.  In light of this, and 
the expensive nature of these agents, at the present time the UK National Institute for 
Health and Clinical Excellence only permits the use of Cetuximab in patients with inoperable 
colorectal liver metastases.(National Institute for Health and Clinical Excellence 2009) 
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1.5  Systemic Therapy for Operable Colorectal Liver Metastases 
In those who present with operable disease from the outset the goal of systemic 
chemotherapy is to improve overall long term outcome and should be distinguished from 
down-staging chemotherapy.  Two chemotherapy strategies are available in this setting i.e. 
either neoadjuvant or adjuvant although it is not particularly clear from the current 
evidence which, if any, is superior. 
One difficulty in interpreting the evidence relating to neoadjuvant chemotherapy for 
patients with operable disease is that it has, in many cases, been combined with adjuvant 
chemotherapy making it extremely difficult to discern which of the two components is of 
most benefit.  Bathe et al. conducted a phase II uncontrolled study to examine the safety 
and efficacy of peri-operative FOLFIRI in 35 patients with operable liver metastases.  
Patients were treated with chemotherapy for 12 weeks and then underwent re-staging prior 
to surgery.  Of this cohort 14 (40%) had some degree of response to chemotherapy, 12 had 
stable disease (36%) and 7 (18%) had evidence of disease progression.  31 patients 
progressed to surgery and 30 had successful resection of all disease. Of these 22 were then 
treated with adjuvant chemotherapy with 2 patients refusing, 2 being ineligible because of 
peri-operative complications and the remainder refused because of disease progression on 
neoadjuvant chemotherapy.  The overall survival for those patients who experienced 
disease progression on chemotherapy was a median of 39 months whereas the median 
survival was not reached during the follow-up period for those with responsive disease. 
(Bathe, Ernst et al. 2009) 
The EPOC trial was the first prospective randomised controlled trial to examine the role of 
peri-operative chemotherapy in patients with resectable liver metastases.  Patients were 
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allocated to receive either surgery alone or peri-operative FOLFOX consisting of 6 cycles 
prior to surgery and 6 cycles after surgery (n=182 per arm).  Of those assigned to peri-
operative FOLFOX 143 patients (79%) were able to complete all 6 cycles of whom 67 had 
some degree of tumour response, 60 had stable disease and 11 had disease progression.  In 
the surgery alone arm 170 patients ultimately underwent exploratory laparotomy with 152 
(84%) being resected.  Whilst the number proceeding to surgery in the peri-operative 
chemotherapy arm was smaller (n=159; 87%) a similar proportion underwent a curative 
intent resection (n=151; 83%).  It is noteworthy that only 50% of patients in the peri-
operative chemotherapy arm were able to complete all 6 cycles of adjuvant chemotherapy 
(n=80) suggesting that it was poorly tolerated. On an intention to treat basis there was a 
trend towards  improved 3 year progression free survival in the chemotherapy arm although 
this did not reach statistical significance (35.4% vs. 28.1%; p = 0.058).  If the analysis was 
limited to those who underwent resection however then statistical significance was reached 
(42.4% vs. 33.2%; p = 0.025).(Nordlinger, Sorbye et al. 2008) 
In an attempt to understand whether all patients with operable disease benefit from peri-
operative chemotherapy the LiverMet database was analysed to identify patients who 
underwent liver resection for solitary, liver only, metachronous metastases.  Two groups of 
patients were analysed, those who underwent surgery alone (n=1302) or those who 
received at least 3 courses of neoadjuvant chemotherapy which contained either Irinotecan 
or Oxaliplatin.  In this group of select patients there appeared to be no advantage in terms 
of either overall survival (60% vs. 60%; p = 0.57) or disease free survival (42% vs. 46%; p = 
0.09) at 5 years in those receiving neoadjuvant chemotherapy.  Multivariate analysis on the 
entire cohort however identified the use of adjuvant chemotherapy as being associated with 
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better overall (Relative Risk 1.64; p<0.01) and disease specific survival (Relative Risk 1.46; 
p<0.01) than surgery alone.(Adam, Bhangui et al. 2010) 
The proponents of neoadjuvant chemotherapy argue that it allows an assessment of disease 
biology prior to resection, with patients being classified as either responders, having stable 
disease or those experiencing disease progression.  Adam et al. performed a retrospective 
analysis of 131 patients with more than 4 colorectal liver metastases undergoing 
hepatectomy after systemic chemotherapy and stratified outcome according to tumour 
response.  They noted that in those who had experienced disease progression whilst on 
chemotherapy the overall 5 year survival was only 8% as compared to 37% in responders 
and 30% in those with stable disease (p<0.0001).(Adam, Pascal et al. 2004)  One criticism of 
this study however is that the 44% of patients who experienced disease progression were 
treated with 5-FU/LV alone as compared to only 19% who experienced disease response.  
Whilst treatment with regimens containing Oxaliplatin or Irinotecan may have changed the 
response of those with progressive disease it is impossible to know how this might have 
impacted on their overall long term outcome.  
In an attempt to assess the benefit of adjuvant systemic therapy Figueras et al. 
retrospectively compared the outcome of 99 patients who had undergone complete 
resection of colorectal liver metastases and received adjuvant chemotherapy 
(predominantly 5-FU/LV) to that of 81 patients who were treated with surgery alone.  They 
demonstrated that the 5 year actuarial survival of those receiving adjuvant chemotherapy 
was 53% as compared to 25% in the surgery alone group (p = 0.0008).(Figueras, Valls et al. 
2001)   
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The retrospective nature of this study means it is hard to make any definitive statements 
regarding the utility of adjuvant chemotherapy.  In order to address this two prospective 
randomised trials were set up however both were underpowered as a result of slow patient 
accrual and as such were unable to demonstrate any statistically significant difference in 
survival.(Langer, Bleiberg et al. 2002; Portier, Elias et al. 2006) In an attempt to overcome 
this the results of these two trials were pooled.  It should be noted that this pooled analysis 
was not limited to patients with liver only metastases but also included a subset of patients 
who underwent curative resection of lung only metastases who had been included in the 
study by Langer et al..(Langer, Bleiberg et al. 2002)  Nonetheless those treated with surgery 
alone were found to be at higher risk of early disease recurrence than those who had 
received adjuvant 5-FU/LV (HR 1.39; p = 0.026) which was reflected in a longer median 
progression free survival in the adjuvant therapy arm (27.9% vs. 18.8%).  Despite this 
apparent benefit there was no statistically significant difference in overall survival for those 
receiving adjuvant chemotherapy, although the trend was very much in favour of this 
(62.2% vs. 47.3%).(Mitry, Fields et al. 2008)  One might expect that the results of these trials 
would be improved by addition of either Oxaliplatin or Irinotecan to the 5-FU/LV regimen 
however there is, at the present time, no prospective experimental data to support this 
assertion. 
In summary the role of peri-operative chemotherapy in patients with operable colorectal 
liver metastases is less than clear cut.  The EPOC trial certainly demonstrated a survival 
advantage to patients treated with peri-operative chemotherapy but it is impossible to 
dissect out whether it is the neoadjuvant or adjuvant components of the regimen that are 
important.  Proponents of neo-adjuvant chemotherapy would argue that its use allows one 
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to make an assessment of tumour biology but high quality prospective data to back this 
assertion is lacking.  The evidence to date does however seem to suggest that adjuvant 
chemotherapy is poorly tolerated and this may mean there is a practical advantage in 
utilising a neoadjuvant strategy.  The role of biological agents in this setting has not been 
evaluated as yet, although it is the subject of investigation in an ongoing EPOC trial (peri-
operative FOLFOX vs. peri-operative FOLFOX and Cetuximab). 
From the data of Adam et al. it would seem that not all patients with operable disease 
would necessarily benefit from peri-operative chemotherapy but rather it might be better 
targeted at those with poor prognostic features such as large number of metastatic deposits 
or large tumour size.(Fong, Fortner et al. 1999; Adam, Bhangui et al. 2010)  In any case it is 
likely that, as clarity emerges around the optimal target patient group, an ever increasing 
number of patients with operable metastatic disease will be treated using a combined 
approach of surgery and peri-operative systemic therapy. 
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Chapter  2  
Chemotherapy Associated Liver Injury – A Systematic Review and 
Meta-Analysis  
 
2.1  Background 
Data from 7764 patients entered into the LiverMet survey over a 22 year period suggests 
that 32% of patients receive chemotherapy prior to surgery, although it is likely that this 
proportion has increased significantly in recent years as our understanding of the use of 
chemotherapy in these patients has become clearer.(Adam, Frilling et al. 2010)  As 
experience of patients receiving pre-operative chemotherapy has grown there has been an 
increasing recognition that chemotherapy use can be associated with injury to the hepatic 
parenchyma (chemotherapy associated liver injury, CALI).  Two distinctive patterns of 
chemotherapy associated liver injury have been described i.e. steatosis/steatohepatitis and 
sinusoidal obstruction syndrome, each of which is discussed in more detail 
below.(Nordlinger and Benoist 2006) 
2.1.1 Hepatic Steatosis/Steatohepatitis 
Non-alcoholic fatty liver disease (NAFLD) is increasingly common in the general adult 
population with the UK prevalence thought to be in the order of 25%.(Anstee, McPherson et 
al. 2011)  It is most commonly associated with the so called metabolic syndrome which is 
characterised by obesity and insulin resistance.  NAFLD does not represent a single entity 
but rather characterises a spectrum of disease that ranges from simple steatosis through to 
steatohepatitis (non-alcoholic steatohepatitis, NASH) and at the extreme end of the 
spectrum cirrhosis.(Anstee, McPherson et al. 2011)  The key features that distinguish NASH 
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from simple steatosis are the presence of lobular inflammation and hepatocellular 
degeneration characterised by ballooning of hepatocytes.(Kleiner, Brunt et al. 2005) 
In an attempt to make a definitive statement on the risk of steatosis in patients undergoing 
hepatic surgery de Meijer et al. performed a systematic review and meta-analysis of the 
published data.  In this study patients with steatosis were classified as either having <30% 
steatosis or ≥30% steatosis and a major resection was considered as being resection of at 
least 3 Couinaud segments.  Those patients with steatosis <30% undergoing major 
hepatectomy were at a moderately increased risk of overall complications (Relative Risk 
1.53; p < 0.001) but at no greater risk of overall post-operative mortality when compared to 
those without steatosis.  In those with ≥30% steatosis undergoing major hepatectomy there 
was again an increased risk of overall complications (Relative Risk 2.01; p<0.001) but also of 
peri-operative mortality (Relative Risk 2.79; p = 0.02) as compared to those without 
steatosis.(de Meijer, Kalish et al. 2010)   
The association between chemotherapy use and hepatic steatosis has been recognised for 
almost 15 years.  In 1998 Peppercorn et al. reported a series of 21 patients with colorectal 
liver metastases who were treated with systemic 5-FU/LV.  On baseline CT none of these 
patients had evidence of hepatic steatosis whereas, after 12 cycles of chemotherapy, 
radiological changes of hepatic steatosis were present in 48% of patients 
(n=10).(Peppercorn, Reznek et al. 1998) Pawlik et al. reported a series of 212 patients who 
underwent resection of colorectal liver metastases of whom 153 had received pre-operative 
chemotherapy.  Overall the use of chemotherapy was associated with an increased risk of 
steatosis ≥ 30% (18.3% vs. 3.4%; p = 0.004).  When chemotherapy was stratified according 
to regimen those who received Irinotecan were found to be at highest risk of steatosis ≥ 
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30% as compared to chemotherapy naive controls (27.3% vs. 3.4%; p<0.001) followed by 
those receiving fluoropyrimidine monotherapy (14.9% vs. 3.4%; p = 0.03) and finally those 
receiving Oxaliplatin based regimens (9.6% vs. 3.4%; p = 0.04).  There was no statistically 
significant association between chemotherapy use and the development of 
steatohepatitis.(Pawlik, Olino et al. 2007) 
In a separate series of 406 patients undergoing resection of colorectal liver metastases no 
association could be demonstrated between pre-operative chemotherapy and the 
development of hepatic steatosis ≥ 30% either overall or when patients were stratified 
according to the regimens received.  In the 94 patients who received Irinotecan based 
regimens however there was an increased incidence of steatohepatitis when compared to 
those who were chemotherapy naive (20.2% vs. 4.4%; p = 0.001).  Importantly in those 
patients with steatohepatitis in this series there was an increase in all cause 90 day 
mortality (14.7% vs. 1.6%; p = 0.001) and specifically death from post-hepatectomy liver 
failure (5.8% vs. 0.8%; p = 0.01).(Vauthey, Pawlik et al. 2006)  In a small study of 37 patients 
undergoing resection of colorectal liver metastases Fernandez et al. demonstrated that, on 
multivariate analysis, the use of either Irinotecan or Oxaliplatin based chemotherapy and 
the presence of a high BMI were independent risk factors for the development of 
steatohepatitis.(Fernandez, Ritter et al. 2005) 
2.1.2 Sinusoidal Obstruction Syndrome 
Prior to the development of modern chemotherapeutic agents Sinusoidal Obstruction 
Syndrome (SOS), previously known as hepatic veno-occlusive disease, was considered to be 
a rare phenomenon that was primarily related to the ingestion of a group of compounds 
known as pyrrolizidine alkaloids which are commonly found in plants used in traditional 
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African herbal remedies.(Willmot and Robertson 1920; DeLeve, Shulman et al. 2002)  
Latterly SOS has been described in patients receiving myeloablative chemotherapy prior to 
bone marrow transplantation where the reported incidence is in the order of 27 – 
54%.(McDonald, Hinds et al. 1993; Hasegawa, Horibe et al. 1998)  Early histological features 
of SOS are the development of dilatation of the hepatic sinusoids with associated 
hepatocyte atrophy.  In later stage disease these features are accompanied by the 
development of peri-sinusoidal fibrosis and nodular regenerative hyperplasia.  The severity 
of sinusoidal dilatation is commonly graded according to the method of Rubbia-Brandt (0 = 
absent; 1 = mild; 2 = moderate; 3 = severe) where an increasing score reflects a more severe 
sinusoidal injury.(Rubbia-Brandt, Audard et al. 2004) 
In 2004 Rubbia-Brandt et al. published a retrospective analysis of histological changes in the 
non tumour bearing liver of 153 patients who had undergone resection of colorectal liver 
metastases.  In 44 out of 87 patients (51%) who had received pre-operative chemotherapy 
there were marked centrilobular changes characterised by sinusoidal dilatation and peri-
sinusoidal fibrosis in keeping with a diagnosis of SOS.  In contrast none of the patients who 
had undergone surgery alone had these changes.  When the patients who had received 
chemotherapy were stratified according to regimen it was found that SOS was much more 
common in those who had received Oxaliplatin based treatment as compared to those who 
had not (79% vs. 23%; p < 0.001).(Rubbia-Brandt, Audard et al. 2004) 
In the previously described series by Vauthey et al. those patients who had received 
treatment with Oxaliplatin based regimens were more likely to develop SOS than those 
patients who were chemotherapy naive (18.9% vs. 1.9%; p < 0.001).  Those treated with 
other chemotherapy regimens were not demonstrated to be at increased risk of developing 
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SOS as compared to those treated with surgery alone. (Vauthey, Pawlik et al. 2006)  Aloia et 
al. reported the effect of chemotherapy on liver histology in 75 patients treated with either 
pre-operative 5-FU/LV or FOLFOX as compared to 17 patients who underwent surgery 
alone.  It was also demonstrated that those receiving pre-operative chemotherapy were at 
higher risk of developing vascular lesions in keeping with SOS (52% vs. 18%; p = 0.01) but 
were at no greater risk of developing hepatic steatosis than controls (12% vs. 13%).(Aloia, 
Sebagh et al. 2006)  In those patients in the EPOC trial who progressed to surgery 48% of 
those who received pre-operative FOLFOX had changes consistent with SOS as compared to 
only 11% of controls who received surgery alone.(Julie, Lutz et al. 2007) 
The effect of SOS on peri-operative outcomes has been a source of debate in the literature.  
In the studies by Vauthey et al. and Aloia et al. there was no demonstrable effect on surgical 
morbidity or mortality although those with SOS had an increased requirement for blood 
transfusion.(Aloia, Sebagh et al. 2006; Vauthey, Pawlik et al. 2006) In a series of 51 patients 
undergoing major hepatectomy (3 or more Couinaud segments) after neoadjuvant 
Oxaliplatin based chemotherapy 75% (n=38) developed SOS as characterised by grade 2 or 
greater sinusoidal dilatation.  The presence of histological changes associated with SOS was 
associated with an increased incidence of post hepatectomy liver failure (68% vs. 23%; p = 
0.004).(Soubrane, Brouquet et al. 2010)  In a similar manner Nakano et al. compared the 
outcome of 20 patients with SOS undergoing major hepatectomy (>3 Couinaud segments) to 
16 patients without SOS.  The presence of SOS was associated with an increased risk of peri-
operative complications (40% vs. 6.3%; p = 0.026) and a prolonged mean hospital stay (17 
days vs. 11 days; p = 0.006).(Nakano, Oussoultzoglou et al. 2008) 
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In addition to the short term effects of SOS on patient outcome a more recent paper by 
Tamandl et al. has raised concerns about its implications on long term patient survival.  In 
this paper they compared the outcome of 20 patients with SOS to 154 patients without SOS 
all of whom had undergone curative intent surgery for colorectal liver metastases.  Those 
patients with SOS were found to have a much poorer 3 year progression free as compared 
to those without (6.7% vs. 22.7%; p = 0.006) and indeed this increased risk for early 
recurrence was upheld on multivariate analysis (Hazard Ratio 2.20; p = 0.006).  In particular 
patients with SOS seemed to be at higher risk of intra-hepatic recurrence (66.7% vs. 30.5%; 
p = 0.003).  In light of this it is not surprising that the presence of SOS was also associated 
with an overall increased risk of early death (Hazard Ratio 2.90; p<0.001).(Tamandl, Klinger 
et al. 2011) 
2.1.3 Summary 
 As can be seen from the discussion thus far the literature with regard to chemotherapy 
associated liver injury is less than clear with a variety of conflicting reports published.  For 
example  whilst the studies or Ryan et al. and Vauthey et al. report a strong association 
between Irinotecan usage and the development of hepatic steatosis that of Pawlik et al. 
failed to demonstrate any such association.(Vauthey, Pawlik et al. 2006; Pawlik, Olino et al. 
2007; Ryan, Nanji et al. 2010)  Similarly whilst Vauthey et al. and Tamandl et al. report a 
strong link between Oxaliplatin usage and SOS only a very modest association, if any at all, is 
reported by Makowiec et al. and Ryan et al..(Vauthey, Pawlik et al. 2006; Ryan, Nanji et al. 
2010; Makowiec, Mohrle et al. 2011; Tamandl, Klinger et al. 2011)  To address this issue of 
heterogeneity in the literature I elected to perform a systematic review and meta-analysis of 
published studies in order that the nature and extent of clinical problem can be properly 
defined.  
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2.2  Method 
I undertook a systematic search for reports of studies published between the dates 1
st
 
January 1996 and 31
st
 June 2011 using the online databases Medline, Embase and the 
Cochrane library.  These searches included the key words “liver resection”; “hepatectomy”; 
“chemotherapy”; “steatosis”; “steatohepatitis”; “sinusoidal obstruction syndrome”.  In 
addition I utilised the medical subject headings (MeSH terms) “Surgical Procedures, 
Operative”; “Colorectal Neoplasms”; “Hepatectomy”; “Drug-Induced Liver Injury” and “Fatty 
Liver”.  In order to further ensure all applicable reports were included I hand searched the 
reference lists of relevant review papers on the subject. 
In order to screen out irrelevant studies I initially reviewed the titles of reports identified 
during the search process and rejected case reports, commentaries/editorials, reviews, 
animal studies, in vitro studies and non-English reports.  Following this the abstracts of all 
the remaining studies were retrieved and reviewed for potential relevance, applying the 
same criteria used for screening the titles.  For abstracts identified as being of potential 
relevance the full text reports were retrieved and selected for inclusion in the review if they 
met the following criteria: 
- Included patients undergoing treatment of colorectal liver metastases only  
- Histological data was provided in relation to the non tumour bearing liver 
parenchyma 
- Included a minimum of 10 patients per group 
Reports that did not include a control group, that also met the above criteria, were 
excluded.  Studies in the form of a published abstract only were excluded.  The process of 
study selection is summarised in Figure 3. 
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In order to facilitate the process of data extraction from the identified original reports I 
designed a standardised proforma and for each study recorded the following details : 
- Study design characteristics 
- Histological scoring of the liver parenchyma 
In addition close attention was paid to the kin relationship of studies, i.e. multiple 
publications using the same patient cohorts.  Where the potential for duplicate publication 
was identified only that study which provided the largest amount of data to assess a given 
outcome was utilised.   
In order to assess the quality of included studies each was scored according to the 
Newcastle-Ottawa scoring system.  This is a validated tool which aims to assess the quality 
of non-randomised trials included in systematic reviews.  Studies are scored a maximum of 8 
points according to the method of patient selection, the comparability of patient cohorts 
and the quality of outcome measures.(Wells, Shea et al. 2011)  The level of evidence 
provided by each of the included studies was graded using the Oxford Centre for Evidence-
based Medicine scale.(OCEBM Levels of Evidence Working Group 2011)  All data extraction 
was performed on two separate occasions and cross referenced to ensure accuracy. 
In order to gain an accurate picture of the effect of pre-operative chemotherapy on the 
hepatic parenchyma, as well as on post-operative morbidity and mortality, a meta-analysis 
was performed according to the Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines.(Stroup, Berlin et al. 2000)  The effects of pre-operative chemotherapy 
on histological scores of liver injury were estimated using a pooled relative risk along with 
95% confidence interval using a random-effects model.(DerSimonian and Laird 1986)  This 
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approach was chosen as it was felt it would better accommodate the inherent 
heterogeneity in outcome measures that exists in non-randomised trials and therefore 
would avoid the risk of over-estimating effect which might be seen with a fixed-effects 
model.(Higgins and Green 2011)  Studies were weighted according to population size and 
the overall effect was determined with the Z statistic.  Statistical significance was set at a 
level of p = 0.05.  Heterogeneity across studies was assessed by inspection of forest plots 
and utilisation of the I
2
 statistic.  All analysis was performed using Review Manager 
(RevMan) software (Version 5.1, The Nordic Cochrane Collaboration, Copenhagen).  Data 
from observational and randomised controlled studies were not included in the same 
analysis. 
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Figure 3 – Flow diagram summarising the process of study selection for the systematic 
review 
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2.3  Results 
A total of 14,619 studies were identified from the search process of which 37 were 
eventually considered appropriate for inclusion in the systematic review.  The majority of 
studies were considered to be of evidence level 2b (i.e. retrospective cohort studies) or 
greater (n=33; 89%).  All studies apart from 2 were observational in character.  The potential 
for overlap of patient cohorts in the identified studies was high, existing in 18 out of the 37 
studies (49%).  The full details of the included studies along with the NOS score, the 
evidence level and a summary of key findings can be found in Appendix 1 of this thesis. 
 The effect of pre-operative chemotherapy (all regimens) on the development of hepatic 
steatosis was assessed in a total of 13 studies which included 799 patients who had received 
chemotherapy and 709 patients treated with surgery alone.  There was no demonstrable 
association between pre-operative chemotherapy and the presence of hepatic steatosis of 
all grades (Relative Risk 1.25; 95% Confidence Interval 0.99 – 1.57; p = 0.06).  Data regarding 
the incidence of hepatic steatosis affecting at least 30% of hepatocytes was available for 
2040 patients but again no association could be demonstrated (Relative Risk 1.25; 95% 
Confidence Interval 0.92 – 1.68; p = 0.15; Figure 4A).  In order to assess whether the 
development of hepatic steatosis following chemotherapy was regimen specific analysis was 
performed for those patients receiving either Oxaliplatin or Irinotecan based regimens.   
In the case of Oxaliplatin there was no association with the development of hepatic 
steatosis which affected at least 30% of hepatocytes (Relative Risk 0.98; 95% Confidence 
Interval 0.59 – 1.63; p = 0.95; Figure 4B). For Irinotecan again there was no significant 
association with hepatic steatosis ≥ 30% (Relative Risk 2.51; 95% Confidence Interval 0.59 – 
1.63; p = 0.95; Figure 4C) however it can be seen from the funnel plot that there is 
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significant heterogeneity amongst the included studies (I
2
 = 74%; p = 0.01).  This arises from 
the two smaller studies, which contribute only 144 patients between them, demonstrating a 
positive association (Pawlik, Olino et al. 2007; Gomez-Ramirez, Martin-Perez et al. 2010) 
whereas the two larger studies, which contribute 504 patients, failed to show this.(Vauthey, 
Pawlik et al. 2006; Ryan, Nanji et al. 2010) 
 
Figure 4 – Pre-operative chemotherapy is not associated with the development of hepatic 
steatosis either when all regimens are considered together (A).  Neither is there evidence 
of a specific association between Oxaliplatin (B) or Irinotecan (C) and the development of 
hepatic steatosis. 
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As already described steatohepatitis represents a more severe form of the NAFLD spectrum 
and its presence has been linked to an increased risk of post hepatectomy liver failure and 
subsequent surgical mortality.(Vauthey, Pawlik et al. 2006)  Overall the use of pre-operative 
chemotherapy was associated with a borderline statistically significant trend towards an 
increased risk of steatohepatitis (Relative Risk 1.89; 95% Confidence Interval 0.99 – 3.63; p = 
0.05).  When individual regimens were considered there was no demonstrable association 
between Oxaliplatin usage and steatohepatitis (Relative Risk 1.17; 95% Confidence Interval 
0.45 – 3.04; p = 0.75).  On the other hand those patients treated with Irinotecan based 
regimens had a 3.45 fold increased risk of steatohepatitis as compared  to those treated by 
surgery alone (95% Confidence Interval 1.12 – 10.62; p = 0.03; Figure 5).  Analysis of the 
funnel plot reveals a moderate degree of heterogeneity in this analysis (I
2
 = 29%; p=0.24) 
which arises because the study of Ryan et al. which failed to show any association.(Ryan, 
Nanji et al. 2010)  If this study were to be removed from the analysis then the risk of 
steatohepatitis in patients receiving Irinotecan based regimens would be 5 fold that of 
patients undergoing surgery alone (95% Confidence Interval 2.31 – 10.79; p < 0.0001). 
 
 
Figure 5 – Irinotecan based pre-operative chemotherapy is associated with a 3.45 fold 
increased risk of steatohepatitis as compared to surgery alone 
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The incidence of all grades of sinusoidal dilatation was reported in 633 patients receiving 
pre-operative chemotherapy (all regimens) as compared to 238 patients who underwent 
surgery alone.  Overall chemotherapy administration was associated with a 1.95 fold 
increased risk of sinusoidal dilatation (95% Confidence Interval 1.46 – 2.61; p < 0.00001).  It 
is broadly accepted that grade 2 or greater sinusoidal dilatation is more representative of 
SOS.(Rubbia-Brandt, Audard et al. 2004; Rubbia-Brandt 2010) Overall the use of pre-
operative chemotherapy was associated with a 2.78 fold increase in the risk of grade 2 or 
greater sinusoidal dilatation (95% Confidence Interval 1.35 – 5.69; p = 0.0007; Figure 6A) 
although there was significant heterogeneity amongst the included studies (I
2
 = 66%; p = 
0.0007).   
In those receiving Oxaliplatin based regimens the risk of grade 2 or greater sinusoidal 
dilatation was 4.36 fold that of surgery only controls (95% Confidence Interval 1.36 – 13.97; 
p = 0.01; Figure 6B).  There is a significant amount of heterogeneity in this analysis (I
2
 = 69%; 
p = 0.01) which arises from the small study of Makowiec et al. which appears to be at odds 
with the rest of the included data.(Makowiec, Mohrle et al. 2011)  If this study is excluded 
from the analysis then the heterogeneity is resolved (I
2
 = 0; p = 0.48) and the risk of grade 2 
or greater sinusoidal dilatation increases to 6.19 fold (95% Confidence 3.14 – 12.22; 
p<0.00001).  Irinotecan based regimens were not found to be associated with the 
development of grade 2 or greater sinusoidal dilatation (Relative Risk 1.11; 95% Confidence 
Interval 0.65 – 1.90; p = 0.70; Figure 6C) strongly suggesting that this is a regimen specific 
phenomenon. 
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Figure 6 – Overall pre-operative chemotherapy is associated with an increased risk of 
grade 2 or greater sinusoidal dilatation (A).  When broken down by regimen however this 
seems to be predominantly a feature of Oxaliplatin based regimens (B) whereas Irinotecan 
based regimens are not associated with sinusoidal dilatation (C). 
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2.4  Conclusion 
In performing this systematic review and meta-analysis of the published literature I have 
been able to bring a degree of clarity to the discussion surrounding the nature of 
chemotherapy associated liver injury.  Despite commonly held beliefs to the contrary there 
is insufficient evidence to demonstrate an association between the administration of pre-
operative chemotherapy and the development of hepatic steatosis.  Furthermore the nature 
of the liver injury induced by chemotherapy appears to be regimen specific with Irinotecan 
based regimens being associated with steatohepatitis and Oxaliplatin based regimens being 
associated with sinusoidal obstruction syndrome.  
Using the data presented it is possible to calculate the number needed to treat with pre-
operative chemotherapy to cause one case of parenchymal injury.  In the case of Irinotecan 
for every 12 patients treated with this agent pre-operatively 1 would be expected to 
develop steatohepatitis.  In the case of Oxaliplatin however 1 in every 9 patients would be 
expected to develop grade 2 or greater sinusoidal obstruction.  In other words, although the 
patterns of liver injury with the two regimens are different, liver parenchymal injury as a 
result of chemotherapy is more likely to occur in those treated with Oxaliplatin based 
chemotherapy regimens. 
Locally the majority of patients with colorectal liver metastases are treated, as first line, 
with Oxaliplatin based regimens.  Taken together with the findings of the meta-analysis that 
this regimen is more commonly associated with parenchymal injury the remainder of this 
thesis will concentrate on Oxaliplatin induced liver injury. 
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Chapter 3 
Current Knowledge Regarding the Pathogenesis of Chemotherapy 
induced Sinusoidal Obstruction Syndrome 
 
At the present time there is no firm understanding of how or why patients with colorectal 
liver metastases treated with Oxaliplatin containing chemotherapy regimens develop SOS 
and as such no treatment options exist to either prevent the development of these 
pathological changes or indeed to reverse them once they have developed.  This knowledge 
is vitally important if we are to try and reduce the morbidity and mortality associated with 
liver resection in this group of patients. 
It is however possible to gain some insight into potential risk factors associated with the 
development of SOS from published case series.  In addition some researchers have 
explored the pathogenesis of this condition at the molecular level using a rodent model of 
Monocrotaline induced SOS although the relevance of this to Oxaliplatin induced SOS may 
be somewhat limited.  In this chapter I explore the current literature regarding SOS before 
setting out the aims and objectives for the experimental work contained within this thesis. 
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3.1  Risk Factors Associated with the Development of SOS 
Intuitively one might expect that the prolonged exposure to Oxaliplatin based 
chemotherapy would be a risk factor for the development of SOS.  In a study of 219 patients 
undergoing liver resection after pre-operative treatment with FOLFOX Kishi et al. reported 
that sinusoidal injury (grade 2 or greater) was present in 26% of those who had received 1 
to 8 cycles of chemotherapy and in 42% of those who had received 9 or more cycles 
(p=0.017).(Kishi, Zorzi et al. 2010) Similarly Aloia et al. noted that 50 % of those who 
received 12 or more cycles of FOLFOX chemotherapy developed hepatic vascular injury as 
compared to 25% of those receiving 6 – 12 cycles and only 10% of those receiving less than 
6 cycles (p=0.01)(Aloia, Sebagh et al. 2006) Nakano et al. performed a multivariate analysis 
to identify factors associated with development of sinusoidal injury and identified that more 
than 6 cycles of Oxaliplatin based chemotherapy placed patients at greater risk of 
developing SOS(Relative Risk 3.198; 95% Confidence Interval 1.01 – 10.12; p = 
0.048).(Nakano, Oussoultzoglou et al. 2008)  In contrast to this multivariate analysis at least 
3 other studies has failed to identify duration of chemotherapy as an independent risk 
factor for the development of SOS.(Overman, Maru et al. 2010; Soubrane, Brouquet et al. 
2010; Tamandl, Klinger et al. 2011) 
It has been proposed that tumour related factors might contribute to the development of 
SOS.  Soubrane et al. performed a univariate analysis to identify potential risk factors for the 
development of SOS in 78 patients who had received pre-operative Oxaliplatin based 
chemotherapy and found that those with grade 2 or greater sinusoidal dilatation tended to 
have a larger tumour size (7.8cm vs. 5.2cm; p < 0.004) although this was not found to be an 
independent risk factor on multivariate analysis.(Soubrane, Brouquet et al. 2010)  In 
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contrast to this Tamandl et al. reported that a tumour diameter >5cm was independently 
associated with an increased risk of SOS on multivariate analysis (Hazard Ratio 4.42; 95% 
Confidence Interval 1.38 – 13.18; p = 0.012).(Tamandl, Klinger et al. 2011) 
Several groups have examined the ability of pre-operative blood tests to predict the 
presence of SOS.  On univariate analysis Soubrane et al. found that those with SOS tended 
to have a higher AST (53 U/L vs. 37 U/L; p = 0.0009) and ALT (49.8 U/L vs. 32.7 U/L; p = 0.02) 
but a lower platelet count (167 x 10
3
 vs. 244 x 10
3
; p < 0.0001). They also demonstrated on 
multivariate analysis that a higher ratio of AST to platelet count (APRI score) was strongly 
predictive of the presence of SOS (Odds Ratio 5; 95% Confidence Interval 4 – 1532; p < 
0.005).(Soubrane, Brouquet et al. 2010)  Nakano et al. also demonstrated, on multivariate 
analysis, that an AST of greater than 36 U/L was associated with an increased risk of SOS 
(Relative Risk 3.68; 95% Confidence Interval 1.034 – 13.162; p = 0.044).(Nakano, 
Oussoultzoglou et al. 2008)  Tamandl et al., on the other hand, did not find any association 
between pre-operative AST or ALT and the development of SOS.  They did however 
demonstrate, on multivariate analysis, that an elevated ALP or γGT were associated with an 
increased risk of SOS (Hazard Ratio 4; 95% Confidence Interval 1.08 – 14.73; p = 
0.038).(Tamandl, Klinger et al. 2011) 
In a study of patients receiving either adjuvant FOLFOX (n=96) or fluoropyrimidine alone 
(n=40) following resection of primary colon cancer (non-metastatic) Overman et al. 
compared spleen size prior to starting chemotherapy with that 6 weeks after the final cycle.  
They demonstrated that in those receiving FOLFOX there was a median increase in spleen 
size of 22% as compared to -3% for those receiving fluoropyrimidine therapy alone 
(p<0.001) which was also associated with the presence of thrombocytopenia (p<0.003).  The 
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group then performed a multivariate analysis of 63 patients who had received FOLFOX prior 
to liver resection and demonstrated that a greater than 50% increase in spleen size was an 
independent risk factor for the presence of SOS (p<0.003).(Overman, Maru et al. 2010) 
Table 4 presents a summary of the potential risk factors identified on multivariate analysis 
as being associated with the presence of SOS following Oxaliplatin based chemotherapy 
however it should be noted that most of these variables are likely to be altered as a 
consequence of SOS rather than truly causative.  From the discussion it can be seen that 
much of the evidence relating to risk factors is contradictory and this likely reflects both the 
small numbers of patients in most of these studies and also the different variables entered 
into the multivariate analyses.   
Risk Factors for SOS Supporting Studies 
Prolonged Chemotherapy Exposure Nakano et al. 2008
(Nakano, Oussoultzoglou et al. 2008)
 
Elevated AST Nakano et al. 2008
(Nakano, Oussoultzoglou et al. 2008)
 
Elevated ALP/γGT Tamandl et al. 2011
(Tamandl, Klinger et al. 2011)
 
Elevated AST to Platelet Ratio (APRI) Soubrane et al. 2010
(Soubrane, Brouquet et al. 2010)
 
Larger tumour size  Tamandl et al. 2011
(Tamandl, Klinger et al. 2011)
 
Splenomegaly > 50% Overman et al. 2010
(Overman, Maru et al. 2010)
 
Female Gender Nakano et al. 2008
(Nakano, Oussoultzoglou et al. 2008)
 
 
Table 4 – Summary of risk factors for the presence of SOS identified on multivariate 
analysis 
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3.2  The Monocrotaline Model of SOS 
Monocrotaline is a pyrrolizidine alkaloid which when administered to rats results in the 
rapid appearance of SOS like histological changes in the liver (although there is no effect on 
the liver following administration to mice).  The nature of these changes has been well 
characterised using both light and electron microscopy.  Within 24 hours of administration 
there is evidence of injury to endothelial cells, in the region of the central veins, which on 
electron microscopy is characterised by a reduced number of endothelial fenestrae and the 
rounding up of endothelial cells.  This rounding up results in the appearance of large gaps 
between adjacent endothelial cells which, by day 3, is sufficient to allow extravasation of 
red blood cells into the space of Disse.  This process results in dissection of the endothelial 
lining of the sinusoid which subsequently embolises and obstructs the microcirculation with 
resultant dilatation of the hepatic sinusoid.(DeLeve, McCuskey et al. 1999; DeLeve, Ito et al. 
2003) 
 At the same time as this process of microvascular obstruction by embolised endothelial 
cells reaches a peak, on days 3 to 4 post administration, coagulative necrosis of the hepatic 
parenchymal cells is seen, predominantly in centrilobular regions.  These changes persist up 
until day 6 when there is evidence of the gaps between endothelial cells reducing and 
resolution of coagulative necrosis.(DeLeve, McCuskey et al. 1999)  It is clear that the speed 
at which the histological changes following Monocrotaline occur is extremely rapid whereas 
SOS following Oxaliplatin administration seems to occur as a consequence of prolonged 
repeated drug exposure.   
The evolution of these changes seen in animals suggests that the primary insult, following 
administration of Monocrotaline, is to the sinusoidal endothelium with hepatocyte injury 
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occurring secondary to this.  In vitro studies appear to confirm these findings with 
Monocrotaline being much more toxic, at like for like doses, to cultured sinusoidal 
endothelial cells than it is to hepatocytes.(DeLeve, Wang et al. 1996)  The toxic effects of 
Monocrotaline on cultured sinusoidal endothelial cells are exacerbated when intracellular 
glutathione levels are depleted whereas endothelium treated with Monocrotaline in the 
presence of exogenous glutathione appears to be protected from Monocrotaline toxicity 
suggesting that oxidative stress may play a role in SOS development.(DeLeve, Wang et al. 
1996)  Rats treated with Monocrotaline whilst receiving an intra-portal infusion of 
glutathione do not develop SOS thereby confirming the relevance of this mechanism in 
vivo.(Wang, Kanel et al. 2000) 
This mechanism could theoretically have potential relevance for Oxaliplatin induced SOS.  As 
already discussed one of the key mechanisms through which cells are able to remove 
platinum is through conjugation to glutathione.(Zhang, Mack et al. 1998)  One of the major 
side effects of platinum agents is the development of peripheral neuropathy and it has been 
demonstrated that variations in intracellular glutathione levels alter the sensitivity of human 
neural cell lines to platinum induced cytotoxicity.(Iida, Doi et al. 1999) In a randomised 
controlled trial the neurotoxicity of Oxaliplatin was diminished when co-administered with 
glutathione.(Cascinu, Catalano et al. 2002)  It has been observed that in patients who 
develop grade 2 – 4 neuropathy there is an increased incidence of sinusoidal injury (86% vs. 
23%; p = 0.002) suggesting that glutathione depletion may be a common link between these 
two pathologies.(Julie, Lutz et al. 2007)   
In the Monocrotaline model it has been suggested that matrix metalloproteinases such as 
MMP2 and MMP9 play key roles in the development of SOS.  Initial observations regarding 
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the role of MMPs in microcirculatory liver disturbances were made in allografts subjected to 
cold preservation.  When organs had been stored at 4
o
C for greater than 4 hours it was 
noted that sinusoidal endothelial cells became swollen and by 8 hours had sloughed off into 
the lumen of the sinusoid.(McKeown, Edwards et al. 1988)  It was demonstrated that this 
process was driven predominantly by MMP2 and 9 which digested the fibronectin tethering 
the cells to the extracellular matrix.(Upadhya, Harvey et al. 1997)  Whole liver extracts of 
rats treated with Monocrotaline 48 hours previously demonstrate a 50-fold increase in 
MMP9 protein levels and a 5-7 fold increase in MMP2 protein levels which appears to be 
driven at a transcriptional level.(Deleve, Wang et al. 2003)  De Leve et al. demonstrated 
unequivocally that the increase in MMP9 transcript arises specifically in the sinusoidal 
endothelium and does not occur in Kupffer cells, hepatocytes or stellate cells of 
Monocrotaline treated rats.  Co-administration of the MMP2 and 9 inhibitor doxycyline 
alongside Monocrotaline prevented the development of an SOS phenotype.(Deleve, Wang 
et al. 2003) 
Whilst Monocrotaline might replicate some of the changes seen in SOS at a histological level 
it is not clear how faithfully this truly reflects the pathogenesis of the disease in patients 
with colorectal liver metastases who are treated with Oxaliplatin based chemotherapy.  For 
example a key feature of severe SOS is the development of nodular regenerative 
hyperplasia which is not described in reports relating to the Monocrotaline model 
suggesting that it does not occur in this context.(Rubbia-Brandt, Audard et al. 2004) 
Likewise a prominent feature of Monocrotaline induced SOS is the development of a lobular 
inflammatory infiltrate, consisting predominantly of neutrophils, which is not described in 
patients who develop SOS.(Coppell, Brown et al. 2003; Rubbia-Brandt, Audard et al. 2004)  
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Furthermore the administration of Monocrotaline to rats was initially carried out to 
generate a model of pulmonary hypertension.(Roth and Reindel 1991; Schultze and Roth 
1998)  The presence of pathology such as this which can have a profound effect on multi-
organ physiology really serves to limit the translational value of the Monocrotaline model 
for patients with chemotherapy induced SOS. 
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3.3  Project Aims 
The aims of this project are three fold: 
1) To develop a reproducible in vivo experimental model which accurately reflects 
the development of SOS in patients treated with Oxaliplatin based chemotherapy 
regimens 
2) To interrogate this model to identify the key pathophysiological processes that 
underpin the development of SOS in these patients  
3) To identify potential therapeutic strategies to ameliorate the development of 
SOS in patients with colorectal liver metastases  
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Chapter 4  
Materials & Methods 
 
4.1  Animal Models 
All animal studies were carried out using the male C57BL/6J mice purchased from a licensed 
supplier (Harlan Laboratories Ltd, UK).   Animals were maintained under standard animal 
house conditions in filtered cages with 12 hour light/dark cycles.  Access to standard chow 
diet (Special Diets Service, UK; see Appendix 2) and water was provided ad libitum unless 
otherwise stated. 
After shipment animals were allowed to acclimatise for 1 week prior to commencing 
experimental protocols. 
All animal studies were approved by the local research ethics committee and the UK home 
office. 
4.1.1 FOLFOX Administration 
All drugs for use in vivo studies were prepared using aseptic technique and filter sterilised 
solutions.  Oxaliplatin (Sigma-Aldrich, Dorset, UK) was dissolved in PBS (Lonza, Basel, 
Switzerland) to a final concentration of 1mg/ml.  100mg of 5-FU was dissolved in 1ml of 
DMSO (Sigma-Aldrich, Dorset, UK) before making up to a final volume of 10ml in PBS to give 
a concentration of 10mg/ml.  Folinic Acid (Sigma-Aldrich, Dorset, UK) was dissolved in water 
to a final concentration of 12.5mg/ml.  Once prepared drug solutions were aliquoted and 
stored at -80
o
C until use.  Freeze-thaw cycles were avoided. 
The FOLFOX chemotherapy used in this study consisted of 6mg/kg of Oxaliplatin 
intraperitoneally followed two hours later by 50mg/kg of 5-FU and 90mg/kg of Folinic Acid.  
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The manner by which this dosing schedule was determined is described in detail in Chapter 
5.  Prior to chemotherapy administration mice were weighed and drugs administered as per 
the tables in Appendix 3.  Control animals received the equivalent amount of vehicle for 
each drug according to body weight.  Drug administration was repeated weekly for 5 weeks 
unless stated otherwise.  Animals were culled 1 week after the final dose of chemotherapy 
and organs harvested for subsequent analysis. 
4.1.2 Hepatic Tumour Implantation 
MCA38 colorectal cancer cells were stably transfected with the pGL4.51 luciferase reporting 
vector (see section 2.2.2) and harvested using Trypsin EDTA (Life Technologies Ltd, Paisley, 
UK) prior to centrifugation at 400G for 4 minutes to pellet.  The cells were resuspended in 
HBSS (Life Technologies Ltd, Paisley, UK) and counted using a haemocytometer.  After 
centrifugation a second time the cells were resuspended in HBSS to give a final 
concentration of 10
7
 cells per ml.  Cells were then placed on ice until the time of 
implantation. 
10 week old C57BL/6J mice were subjected to a short upper midline laparotomy under 
isoflurane anaesthesia and buprenorphine analgesia.  The falciform ligament was divided 
and the left lobe of the liver delivered into the wound.  A gauze swab was placed between 
the delivered lobe and the wound edges to minimise the risk of wound contamination from 
spilt cells.  10µL of the cell solution (i.e. 10
5
 cells was then injected under the capsule of the 
delivered lobe using a 30G needle.  After withdrawing the needle manual compression was 
then applied to the injection site using a cotton bud until haemostasis was achieved.  The 
injection track was then sealed by application of butylcyanoacrylate glue (Indermil, Henkel 
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Ireland Ltd).  The liver was returned to the abdominal cavity and the wound closed in two 
layers with interrupted 3/0 vicryl sutures. 
On the 5
th
 post-operative day the presence of tumour within the liver was confirmed using 
the IVIS in vivo imaging system (Caliper Life Sciences, Hopkinton, USA).  Ten minutes prior to 
imaging mice were injected intraperitoneally with XenoLight D-Luciferin (Caliper Life 
Sciences, Hopkinton, USA) at a dose of 150mg/kg body weight.  Imaging was performed 
under isoflurane anaesthesia. 
If the presence of tumour was confirmed then mice went on to receive chemotherapy as 
described above. 
4.1.3 Dietary Manipulation 
To establish hepatic steatosis 4 week old C57BL/6J mice were maintained on either a high 
fat diet containing 45%kcal fat (D12451, Research Diets Inc, New Brunswick, USA; Appendix 
2).  Control animals were maintained on a 10% kcal fat (D01060501, Research Diets Inc, New 
Brunswick, USA; Appendix 2).  Chemotherapy was commenced after 6 weeks using the 
protocol described above and the mice were maintained on their allocated diet throughout. 
The addition of either 3% N-Acetylcysteine or 0.7% Butylated Hydroxyanisole to the 
D01060501 diet was performed by the manufacturer.  These diets were started 1 week prior 
to commencing chemotherapy. 
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4.2  Cell Culture 
The MCA38 colorectal cancer cell line was used in all experiments in this thesis since it was 
derived in the C57BL/6J mouse and could therefore be used in vivo without eliciting an 
immune response.  The cell line was supplied as a gift by Dr Mario Paolo Colombo (Istitutio 
Tumori, Milan, Italy). 
Cells were cultured in 10% Dulbecos Modified Eagles Medium (Life Technologies Ltd, 
Paisley, UK) supplemented with 10% fetal calf serum, 100u/ml Penicillin, 100µg/ml 
streptomycin and 2mM L-Glutamine unless otherwise stated. 
4.2.1 In Vitro FOLFOX Treatment 
Prior to chemotherapy treatment cells were plated overnight and allowed to adhere 
overnight before exchanging it for that supplemented with 10µM Folinic Acid.  Cells were 
then treated with the IC50 concentration of Oxaliplatin (7µM) and 2 hours later the IC50 
concentration of 5-FU (14µM) in the presence of 10µM Folinic Acid as has been previously 
described in the literature.(Fischel, Formento et al. 2002)  
The IC50 concentration was determined for both Oxaliplatin and 5-FU using the MTT assay.  
To do this 2000 cells were plated in 90 wells of a 96 well plate leaving 6 wells to serve as 
blanks.  After being allowed to adhere overnight the media was replaced and supplemented 
with the drug of interest in a range of concentrations from 1nM to 1mM with control cells 
being treated with the vehicle alone.  There were 6 wells for each condition to act as 
technical repeats.  Cells were cultured for 48 hours before adding 20µL of a 5mg/ml MTT 
stock solution (Sigma-Aldrich, Dorset, UK) and incubating the cells for a further 4 hours.  
Plates were then centrifuged at 400G for 5 minutes and the media exchanged for 200µL of 
DMSO.  After incubation at room temperature on a rocker for 30 minutes absorbance was 
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measured at 570nm and a curve of drug concentration against % cell viability plotted from 
which the IC50 was derived. 
4.2.2 Production of Stably Transfected Luciferase Reporting MCA38 Cells 
For in vivo tumour implantation experiments it was necessary to produce MCA38 cells stably 
transfected with a luciferase reporting vector.  For this purpose the pGL4.51 vector 
(Promega, Southampton, UK) was chosen which has a CMV promoter and a luciferase 2 
gene which when transfected produces a constitutively active luciferase 2 expressing cell 
(for vector map see Appendix 4). 
JM109 competent cells were placed on ice for 30minutes in a buffer containing 10mM 
MOPS, 10mM Rubidium chloride, 75mM calcium chloride and 15% glycerol w/v (All Sigma-
Aldrich, Dorset, UK) in 100µL aliquots with 1µg of vector per aliquot.  The aliquots were 
subsequently placed in a water bath preheated to 42
o
C for 45 seconds before placing back 
on ice.  Cells were subsequently plated on agar supplemented with 100µg/ml Ampicillin 
(Sigma-Aldrich, Dorset, UK) and cultured overnight at 37
o
C. 
The next morning colonies were picked and grown in flasks of LB media (Sigma-Aldrich, 
Dorset, UK) again supplemented with 100µg/ml Ampicillin for a further 24 hours.  Plasmid 
DNA was then extracted from the cells using the QIAprep Spin Miniprep Kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions. Isolated DNA was quantified on a 
spectrophotometer before storage at -20
o
C. 
MCA38 cells were harvested and resuspended in PBS at a concentration of 10
7 
cells per ml 
for transfection by electroporation. To do this 1ml of the cell solution was placed in a 4mm 
cuvette (Harvard Apparatus Inc, Holliston, USA) with 30µg of the isolated vector before 
electroporation with 4 pulses each of 1msec duration at 475V using an 
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ElectroSquarePorator (Harvard Apparatus Inc, Holliston, USA).  Cells were then cultured in 
10% Dulbecos Modified Eagles Medium supplemented as above with the addition of the 
antibiotic G418 (Sigma-Aldrich, Dorset, UK) at a concentration of 1mg/ml.  Prior to use in the 
in vivo experiments cells were cultured in the absence of G418 supplementation for a 
minimum of 48 hours. 
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4.3  Western Blot 
Tissue samples were lysed in an appropriate volume of RIPA buffer containing protease 
inhibitors (Roche Diagnostics Ltd, Burgess Hill, UK) and phosphatase inhibitors (Sigma-
Aldrich, Dorset, UK) before incubation at 4
o
C for 30 minutes.  Samples were then passed 
through a QIAshredder homogenisation column (Qiagen, Crawley, UK) before centrifugation 
at 13,000rpm at 4
o
C in a benchtop centrifuge.  The supernatant was transferred to a new 
tube before quantification using a modified Bradford assay according to the manufacturer’s 
instructions (DC Protein Assay, Bio-Rad Laboratories, Hemel Hempstead, UK).  Samples were 
subsequently stored at -80
o
C prior to use. 
For western blot 50µg of each protein sample was diluted to 25µL in RIPA buffer before 
adding 5µL of sample loading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% 
bromophenol blue, 0.125M Tris HCl).  Samples were heated to 105
o
C to denature before 
loading onto 9% Acrylamide gels for separation by SDS-PAGE. Once adequately separated 
proteins were transferred onto nitrocellulose membrane for 1 hour at room temperature.  
The adequacy of transfer was confirmed by staining the membrane with Ponceau Red 
solution (Sigma-Aldrich, Dorset, UK). 
After washing in 0.01% Tween-TBS to remove all evidence of Ponceau red membranes were 
blocked with either 5% skimmed milk or, in the case of phosphorylated proteins, 5% bovine 
serum albumin (Sigma-Aldrich, Dorset, UK) for 1 hour at room temperature.  Primary 
antibodies were then added as outlined in Table 5 and membranes incubated overnight at 
4
o
C on a rocking platform. 
The following morning membranes were washed thoroughly in 0.01% Tween-TBS before 
incubation for 2 hours with a HRP conjugated secondary antibody appropriate for the 
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species in which the primary antibody was raised.  After further washing with 0.01% Tween-
TBS before detecting bands with an enhanced chemo-luminescence system (Thermo-
Scientific, Rockford, USA).  In the early part of the project β-Actin was used as the loading 
control before a change in laboratory policy when GAPDH was used. 
Target Concentration Supplier 
Total p53 1:1000 Abcam 
p-p53 1:1000 Cell Signalling Technology 
p21 1:1000 Abcam 
γH2AX 1:1000 Cell Signalling Technology 
NRF2 1:1000 Abcam 
Total STAT3 1:1000 Cell Signalling Technology 
p-STAT3 1:1000 Cell Signalling Technology 
GAPDH 1:2500 Abcam 
β-Actin 1:5000 Sigma-Aldrich 
 
Table 5 - Primary antibodies for western blot 
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4.4  Histology / Immunohistochemistry 
All histological analysis was performed on 5µm thick formalin fixed paraffin embedded 
tissue sections unless otherwise stated. 
4.4.1 Haematoxylin and Eosin Staining 
Sections were de-waxed by immersion in Xylene (Sigma-Aldrich, Dorset, UK) for 10 minutes 
followed by rehydration for 2 minutes in 100% ethanol and 2 minutes in 95% ethanol.  
Sections were then washed thoroughly in tap water before immersion in Mayers 
Haematoxylin for 5 minutes.  After blueing in Scott’s water for 30 seconds the sections were 
washed and immersed in Eosin until adequately counterstained.  The sections were then 
dehydrated by immersion in increasing concentrations of ethanol (50%, 75%, 95% and 
100%) before placing in Xylene until clear and mounting with DPX (Cellpath LTD, Powys, UK). 
Haematoxylin and eosin stained sections were assessed for the presence of sinusoidal 
dilatation according to the method of Rubbia-Brandt (Rubbia-Brandt, Audard et al. 2004; 
Table 6).  In addition disruption and loss of the endothelial layer within the hepatic sinusoid 
was graded as either absent or present.  All histological scoring was carried out by Professor 
Alastair Burt (Dean of Clinical Medicine & Honorary Consultant Histopathology, Newcastle 
University & The Newcastle upon Tyne Hospitals NHS Trust). 
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Grade Description 
0 Sinusoidal dilatation absent 
1 Sinusoidal dilatation limited to one third of the lobular surface 
2 Sinusoidal dilatation extending to two thirds of the lobular surface 
3 Sinusoidal dilatation involving the entire lobule 
 
Table 6 - Semi-quantitative scoring system for assessment of sinusoidal dilatation as 
propsoed by Rubbia-Brandt (Rubbia-Brandt, Audard et al. 2004) 
4.4.2 p21CIP1/WAF1 Immunohistochemistry 
Sections were de-waxed in Clearene (Leica Microsystems Ltd, Milton Keynes, UK) for 10 
minutes followed by rehydration in 100% and 70% industrial methylated spirits each for 5 
minutes.  Endogenous peroxidase activity was then blocked by immersion in methanol with 
2% hydrogen peroxide (Sigma-Aldrich, Dorset, UK).  Antigen retrieval was performed by 
immersing sections in sodium citrate solution pH6 (Vector Laboratories, Burlingame, USA) 
and heated in a microwave on full power for 15minutes before being allowed to cool.  
Sections were mounted in a sequenza and washed with PBS before inhibiting non-specific 
binding using an Avidin/Biotin blocking kit (Vector Laboratories, Burlingame, CA).  After 
incubation in 20% swine serum for 20 minutes at room temperature with the primary 
antibody (ab2961, Abcam, Cambridge, UK) at 4
o
C overnight.    
The following morning the sections were washed with PBS before incubation with an anti-
rabbit biotinylated secondary antibody (Dako UK Ltd, Ely, UK) at a concentration of 1:200 for 
2 hours at room temperature.  After a further PBS wash sections were incubated with a 
streptavidin biotin-peroxidase complex (Vector Laboratories, Burlingame, USA) for 45 mins 
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before visualising positive cells with 3,3’-daminobenzidine tetrahydrochloride (DAB) (Vector 
Laboratories, Burlingame, USA).  Counterstaining was performed with Meyers haematoxylin 
before dehydrating sections in increasing concentrations of industrial methylated spirits and 
mounting in Pertex(Cellpath LTD, Powys, UK). 
4.4.3 γH2AX Immunohistochemistry 
The protocol used was identical to that for p21
CIP1/WAF1
 except for the following variations : 
- Antigen retrieval was by immersing sections in 1mM EDTA pH 8.0 and 
microwaving on full power for 15 minutes 
- The primary antibody was used at a concentration of 1:100 (#9718, Cell Signalling 
Technology, Beverley, USA) 
4.4.4 p-STAT3 Immunohistochemistry 
The protocol used was identical to that for γH2AX except the primary antibody was used at 
a concentration of 1:400 (#9145, Cell Signalling Technology, Beverley, USA). 
4.4.5 Tissue Factor Immunohistochemistry 
The protocol used was identical to that for p21
CIP1/WAF1
 except the primary antibody was 
used at a concentration of 1:100 (ab104513, Abcam, Cambridge, UK). 
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4.5  Determination of Hepatic Triglyceride Content 
A sample of liver tissue was weighed and homogenised in 5% Triton-X100 (Sigma-Aldrich, 
Devon, UK).  The homogenate was then heated to 80
o
C for 5 minutes before being allowed 
to cool slowly to room temperature before repeating the heating a second time.  The 
homogenate was centrifuged at 13000 rpm for 5 minutes before recovering the supernatant 
and diluting this 10 fold with distilled water.   
The remainder of this assay was performed with a commercial kit (ab65336, Abcam, 
Cambridge, UK).  In brief a 96 well plate was set up with standards of known triglyceride 
concentration along with serial dilutions of the experimental samples all diluted in the 
provided assay buffer.  To each sample and standard 2µl of lipase was added along with a 
further 46µl of assay buffer, 2µl of triglyceride probe and 2µl of triglyceride enzyme mix.  
The plate was then incubated for 60 minutes at room temperature protected from light 
before measuring absorbance at 570nm.  Using the generated standard curve the 
triglyceride content in each experimental sample was derived and corrected for the original 
weight of tissue used in the assay. 
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4.6  Oxidised/Reduced Glutathione Assay 
A known weight of liver tissue was homogenised in RIPA buffer (as described for sample 
preparation for western blot).  The remainder of the assay was performed using a 
commercial kit (GT40, Oxford Biomedical, Rochester Hills, USA).   
To determine the concentration of reduced glutathione (GSH) 50µL of the lysate above was 
mixed with 350µL of 5% Metaphosphoric acid (MPA) solution by vortexing before 
centrifugation at 1000g for 10 minutes at 4
o
C.  25µl of the supernatant was added to 1.5ml 
of the provided assay buffer and the prepared sample stored on ice until ready to use. 
To determine the concentration of oxidised glutathione (GSSG) 130µl of the tissue lysate 
was incubated at room temperature for 10 minutes before mixing with 270µL of 5% MPA by 
vortexing before centrifugation at 1000g for 10 minutes.  50µL of the supernatant was then 
added to 700µL of the provided assay buffer and placed on ice until ready to use. 
Standards were prepared as per the manufacturer’s instructions and a 96 well plate set up 
with 50µl of both these and the experimental samples repeated in duplicate.  To each well 
50µL of lyopholised 5,5’-dithiobis-2-nitrobenzoic acid and 50µl of recombinant glutathione 
reductase were subsequently added before incubating on a shaker at room temperature for 
5 minutes.  50µl of NADPH was then added to each well before measuring absorbance at 
412nm every minute for 10 minutes. The net rate of change in absorbance over time was 
determined for each sample and a standard curve constructed from which the 
concentration of GSH and GSSG were derived for each experimental sample. 
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It should be noted that this method only applies to the GSH/GSSG assay described in 
chapter 5.  That presented in chapter 7 was performed by a collaborator (Dr Aphrodite 
Vasilaki, Faculty of Health & Life Sciences, University of Liverpool). 
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4.7  PCR 
4.7.1 Quantitative Real Time PCR 
Total RNA was extracted from both tissue and cell samples using the RNeasy purification 
system (Qiagen, Crawley, UK) according to the manufacturers instructions and quantified on 
a spectrophotometer.  RNA integrity was assured by only using samples which had an OD 
260/280 of greater than 1.8.  Samples were stored at -80
o
C. 
All reagents for cDNA synthesis were from Promega, Southampton, UK.  1µg of RNA was 
diluted to 8µl in nuclease free water before adding 1µl each of DNAse and DNAse buffer and 
incubating at 37
o
C for 30 minutes.  1µl of DNAse stop solution was then added to each 
sample and incubated at room temperature for 2 minutes before adding 0.5µl of a random 
hexamer primer and a further 2µ of nuclease free water.  The samples were heated to 72
o
C 
for 5 minutes before placing onto ice.  To each sample was then added 0.5µL of RNA 
synthase inhibitors, 1µl of MMLV-RT, 4µl of MMLV-RT buffer and 1µl of dNTPs. The final 
mixture was heated for 42
o
C for 1 hour before diluting to a final volume of 50µL with 
nuclease free water. 
qRT-PCR was performed using SYBR-green reagents (Sigma-Aldrich, Dorset, UK) on an ABPI 
7500 fast machine (Applied Biosystems, Foster City, USA).  The PCR reaction consisted of 
6.5µl of the 2x concentrated SYBR-green reaction master mix, 1µl of the cDNA sample 
generated above, 1µl each of forward and reverse primers diluted and 3.5µl of nuclease free 
water.  Each experimental sample was run in triplicate.  The PCR cycle consisted of a 
denaturation step at 95
o
C for 5 seconds, annealing at an appropriate temperature for the 
primer pair for 30 seconds and elongation at 72
o
C for 30 seconds.  This cycle was repeated 
40 times before melt curve analysis was performed to validate the results.  GAPDH was used 
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as the internal control for all PCR experiments and the fold change in mRNA expression 
calculated using the ∆∆CT method.  A list of all primer sequences used in this study is 
provided in Table 7. 
Product Forward Primer Sequence Reverse Primer Sequence 
PAI-1 gatgctatgggattcaaagtca tccacctgtttcaccatagtct 
p21
Cip1
 atgtccaatcctggtgatgt tgcagcagggcagaggaagt 
TXN1 catgccgaccttccagtttta tttccttgttagcaccggaga 
NQO1 tggccgaacacaagaagctg tgggaactgaaatatcaccaggt 
CXCL1 ggctgggattcacctcaag gcgaccattcttgagtgtg 
CXCL2 ccaaccaccaggctacagg gcgtcacactcaagctctg 
CXCL5 tgccctacggtggaagtca gtgcattccgcttagctttc 
CCL 2 aggtccctgtcatgcttctg tctggacccattccttcttg 
CCL 5 tgctgctttgcctacctctcc tggcacacacttggcggtttc 
αSMA tcagcgcctccagttcct aaaaaaaaccacgagtaacaaatcaa 
Pro Coll 1 ttcacctacagcacgcttgtg gatgactgtcttgccccaagtt 
TIMP1 tccccagaaatcaacgagacc cttcactgcggttctgggact 
MMP2 ccgatgctgatactgacact gtcactgtccgccaaataaa 
MMP9 tcactttcccttcaccttcg caaagatgaacgggaacaca 
TGF β  cccgaacccccattgctgtcc aggcgtatcagtgggggtcag 
IL-6 gaggataccactcccaacagacc aagtgcatcatcgttgttcataca 
Factor X gccctaaacaccagcgacagt gccacccacaatccgaacaag 
PAR-1 ggtgctcattggctttttcta tgccttcttcctggggtgtcc 
PAR-2 ctgctgtttgtggttggtgta cccagttgttgccattgagat 
vWF cgggaagagtgtgatggttgac agcatctcccacagcattcacc 
GAPDH gcacagtcaaggccgagaat gccttctccatggtggtgaa 
 
Table 7 - Primer sequences used in qRT-PCR 
 
 
4.7.2 Real Time PCR 
For standard real time PCR cDNA was prepared as described above.  The PCR reaction 
consisted of 12.5µl of PCR Master Mix (Promega, Southampton, UK), 1µl of cDNA, 1µl of 
each forward and reverse primers and 9.5µl of nuclease free water to give a total reaction 
volume of 25µl.  The PCR reaction was carried out on a bench top thermal cycler using an 
initiation step of 95
o
C for 30 seconds followed by 35 cycles of 95
o
C denaturing for 5 seconds, 
30 seconds of the appropriate annealing temperature and 30 seconds at 72
o
C for 
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elongation.  This was followed by a further final elongation step of 72
o
C for 7 minutes.  The 
PCR product was subject to electrophoresis on a 1% agarose gel before staining with 
ethidium bromide and visualisation under an ultraviolet lamp.  The sequences of primers 
used for RT-PCR are listed in Table 8. 
Product Forward Primer Sequence Reverse Primer Sequence 
CTR1 gatgatgatgcctatgacctt cgaatgctgacttgagacttt 
CTR2 gccgtgcttctctttgatttc gggtcctattgtctgaagttg 
ATP7A tgctaaccccctccctgtctt catcccttccactttcatctt 
ATP7B ccgatggagtagaggagaatg gaacagatgaggcacaggtaa 
TS gaggcattttggagcagagta tgtaggtgagcagagcatagc 
TP cccgagaactggcaaagatgt gtttccgcctgtccgctaatc 
DPD ttttggctcggttgggctatt tatggtcctttttgggttctg 
β-Actin tggaatcctgtggcatccat taaaacgcagctcagtaaca  
 
Table 8 - Primer sequences used in RT-PCR 
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4.8  Measurement of Extracellular ATP 
The extracellular ATP content in the media from FOLFOX treated MCA38 cells was 
determined using the ENLITEN ATP assay system (Promega, Southampton, UK) using the 
manufacturer’s instructions.  In brief 100µl of either experimental sample or standard was 
placed into a tube to which 100µL of Enliten Luciferase/Luciferin Reagent was added.  
Emission was measured on a luminometer (average of three readings) and a standard curve 
constructed from which the ATP concentration in the experimental samples was 
determined. 
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4.9  CXCL1 ELISA 
This assay was developed using the reagents and antibodies supplied in the R&D Systems 
CXCL1 ELISA development kit according to the manufacturer’s instructions (R&D Systems, 
Abingdon, UK).  In summary a 96 well plate was coated overnight at room temperature with 
50µl of the capture antibody.  The next morning the plate was washed in 0.05%Tween-PBS 
before blocking the plate for 1 hour at room temperature with 1% bovine serum albumin in 
PBS.  After washing the plate again 50µl of either standard or experimental sample were 
added to the plate in triplicate, the plate was covered and incubated for 2 hours at room 
temperature. 
The samples were washed from the plate in 0.05% Tween-PBS and 50µL of the detection 
antibody added to each well for 2 hours at room temperature.  After a further wash 100µl of 
streptavidin-HRP conjugate was added to each well for 20 minutes at room temperature.  
100µl of substrate solution was then added to each well for a further 20 minutes before 
adding 50µl of 2N H2SO4.  The absorbance was then measured at 450nm with correction at 
540nm and a standard curve constructed from which the CXCL1 concentration in the 
experimental samples was derived.  
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4.10  Statistical Analysis 
It was assumed that all continuous data were non-parametric and were therefore assessed 
with a Mann-Whitney U-Test using GraphPad Prism software (GraphPad Software, La Jolla, 
USA).  Statistical significance was set at a p-value of <0.05.  Statistical significance is denoted 
on figures as follows *=<0.05, **=<0.01, ***=<0.001.  
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Chapter 5   
Initial In Vivo Models 
 
The first aim of this project was to establish a reproducible in vivo experimental model of 
CALI which accurately reflects events in patients who receive chemotherapy prior to 
resection of colorectal liver metastases.  After careful consideration I elected to establish a 
murine model for the following reasons: 
- Mice are widely utilised in therapeutic and toxicity studies utilising 
chemotherapeutic agents suggesting that they are sensitive to their toxic 
effects(Boughattas, Levi et al. 1989) 
- The mouse has been widely utilised in other models of liver pathophysiology, e.g. 
liver fibrosis, and responds in a manner that is broadly similar to the human 
liver(Starkel and Leclercq 2011) 
- Laboratory mouse strains are inbred eradicating the effects of genetic variability 
and allowing a reduction in the number of animals required to obtain statistical 
significance(Justice, Siracusa et al. 2011) 
- Laboratory reagents such as antibodies are widely available for murine tissues 
and cells enabling ease of analysis in an experimental study 
Furthermore, owing to the large number of knockout strains available, which may be of 
benefit in the future for interrogating particular pathways involved in the pathophysiology 
of CALI, I opted to use the C57BL/6J strain of mouse. 
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5.1  Assessment of Direct Drug Induced Liver Toxicity 
Initially I wished to determine the maximum dose of Oxaliplatin which could be 
administered to a mouse without running the risk of drug induced mortality.  Fortunately 
much of the pre-clinical work to establish toxicity and efficacy of these drugs has been 
performed in this species and a review of the literature demonstrated that Oxaliplatin doses 
of up to 10mg/kg, via the intraperitoneal (i.p.) route, were well tolerated whereas doses 
much in excess are associated with a significant risk of animal death.(Boughattas, Levi et al. 
1989; Louvet, Coudray et al. 2000; Cividalli, Ceciarelli et al. 2002; Mathieu, Remmelink et al. 
2004) Twice weekly administration of low dose Oxaliplatin for four weeks has been 
demonstrated to cause peripheral neuropathy in mice, a complication which typically affects 
10 – 40% of patients treated with Oxaliplatin based chemotherapy regimens. (Ghirardi, Lo 
Giudice et al. 2005; Gauchan, Andoh et al. 2009; Melisi, Ossovskaya et al. 2009; Renn, 
Carozzi et al. 2011) As a consequence it was determined that 4 weeks would be an 
appropriate initial time course for drug administration in my model. 
On the background of these studies I performed an initial pilot experiment whereby mice 
(n=3 per group) were treated with Oxaliplatin 5mg/kg i.p. twice weekly for four weeks, or 
vehicle control, and culled 4 days after the final dose.  Whilst the mean body weight was 
broadly similar in the control and treatment groups at the beginning of the experiment (24.8 
± 0.2 vs. 23.97 ± 0.73) the mice treated with Oxaliplatin failed to gain weight over the course 
of the experiment, unlike those in the control arm (27.53 ± 0.22 vs. 24.07 ± 0.25; Fig 7A) 
indicating systemic toxicity of the drug regimen.  This difference did not reach statistical 
significance as a result of the small number of animals in each group.  Despite this systemic 
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effect, H&E stained sections of the liver failed to demonstrate any evidence of injury (Fig 
7B). 
As already discussed Oxaliplatin is rarely, if ever, administered to patients with colorectal 
liver metastases as mono-therapy but rather is given in combination with a fluoropyrimidine 
because of the proven increased efficacy of this regimen. (de Gramont, Figer et al. 2000; 
Giacchetti, Perpoint et al. 2000)  After examination of the literature it was decided to 
administer 5-FU at half of the reported maximum tolerated dose in rodents (i.e. 50mg/kg) 
since it has been reported that, when co-administered with other chemotherapeutics, doses 
greater than this result in animal death. (Cao, Frank et al. 1996; Cao and Rustum 2000)  5-FU 
was administered alongside 90mg/kg of Folinic acid (leucovorin, LV) as this has been 
demonstrated to enhance both the efficacy and toxicity of 5-FU.(Nadal, van Groeningen et 
al. 1989; Wright, Dreyfuss et al. 1989)  This initial FOLFOX regimen therefore consisted of 
5mg/kg Oxaliplatin, 50mg/kg 5-FU and 90 mg/kg Folinic acid all by i.p. injection.  It was 
decided to administer the Oxaliplatin 2 hours prior to 5-FU/LV as the combined volume of 
the drugs would be excessive for a single i.p. injection. 
In order to test the viability of this regimen a further pilot study was set up this time with 5 
animals per group treated with the above FOLFOX regimen on a twice weekly basis however 
this was associated with a 50% mortality by week 2 and as such the experiment was 
terminated on the grounds of animal welfare. 
Following on from this experiment I elected to move to a once weekly drug administration 
protocol.  At this time a paper was published by Keizman et al. which described an animal 
model of chemotherapy induced steatohepatitis whereby C57BL/6J mice had been treated 
on a once weekly basis with 6mg/kg Oxaliplatin.(Keizman, Maimon et al. 2010)   As a result 
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the FOLFOX regimen used was amended to a weekly i.p. injection of 6mg/kg Oxaliplatin 
followed two hours later by 50mg/kg 5-FU and 90mg/kg LV for four weeks.  Six mice were 
treated with this regimen and 6 received vehicle control.  The mice in the FOLFOX arm failed 
to gain weight at the same rate as the control arm mice confirming the systemic toxicity of 
this regimen (mean total weight gain 2.94±0.41g vs. 1.18±0.35g; p<0.05; Fig 8A).  This 
regimen was not associated with the development of hepatic toxicity, as demonstrated by 
review of H&E stained sections of the liver (Fig 8B). 
 
Figure 7 - Chronic Oxaliplatin administration is associated with a failure to gain weight (A) 
indicating systemic toxicity but there is no evidence of liver injury (i.e. Rubbia-Brandt 
grade 0) on H&E stained Sections  (B; 10x magnification) 
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In view of the lack of histological changes I wished to determine if these drugs were actually 
reaching the liver and having any effect at a molecular level.  Both 5-FU and Oxaliplatin 
exert their effects through DNA damage the presence of which is associated with a typical 
cellular response directed at either repairing the damage, or if the damage is excessive, 
causing programmed cell death.  To facilitate DNA damage repair the chromatin structure at 
the site of the damaged DNA is modified to allow localisation of repair proteins.  A key event 
in this chromatin modification is phosphorylation of the histone variant H2AX (known as 
γH2AX) which when present is often considered to be pathognomic of DNA damage. (Polo 
and Jackson 2011) A key regulator of the DNA damage response is the tumour suppressor 
p53 which when activated by phosphorylation is able to regulate the transcription of a 
variety of genes involved in regulation of the cell cycle and apoptosis.(Yoshida and Miki 
2010)  One such target gene is the negative regulator of the cell cycle p21
CIP1/WAF1
 which 
plays a role in cell cycle arrest and inhibition of DNA synthesis following DNA 
damage.(Cazzalini, Scovassi et al. 2010) 
In order to determine if there was any evidence of DNA damage in the liver of FOLFOX 
treated animals whole liver protein extracts were made and Western Blot performed with 
antibodies directed against γH2AX, the phosphorylated form of p53 and total p21
CIP1/WAF1
 
protein.  I was able to detect increased expression of both γH2AX and p21
CIP1/WAF1
, but not 
phosphorylated p53, in the liver of FOLFOX treated animals as compared to vehicle controls 
(Figure 8C).  This confirmed that the chemotherapy was reaching the liver and causing DNA 
damage but that this alone was not sufficient, in this context, to result in histological 
changes associated with SOS. 
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Figure 8 – FOLFOX administration for 4 weeks is associated with a failure to gain weight 
(A) as compared to vehicle controls.  Despite the lack of histological evidence of liver 
injury (B; Rubbia-Brandt grade 0 all groups) there is evidence of FOLFOX induced DNA 
damage in whole liver extracts of treated animals (C) with up regulation of γH2AX and p21 
but not phos-p53. 
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Keizman et al. claim that mice treated with Oxaliplatin 6mg/kg weekly for four weeks 
develop steatohepatitis.  Interestingly the authors stated that they could not detect any 
changes on H&E stained sections (neither fat or inflammatory infiltrates) but rather based 
this diagnosis on elevated liver total fat content as measured in a biochemical assay which 
was subsequently demonstrated, on HPLC, to consist predominantly of triglycerides.  The 
authors stated that this change was also reflected in Oil Red O stained sections of the liver 
but did not formally analyse this as frozen tissue sections were not available for the majority 
of mice.(Keizman, Maimon et al. 2010)  To determine if these findings could be replicated in 
this model the hepatic triglyceride content, as measured from whole liver extract, was 
compared between animals treated with FOLFOX or its vehicle control however no 
difference was detectable (11.96 ± 1.42nM vs. 11.78 ± 1.49nM; p = 0.699; Fig 9A). 
 
 
Figure 9 - FOLFOX administration is not associated with changes in either hepatic 
triglyceride content (A) or glutathione concentration (B) 
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As mentioned previously Oxaliplatin exposure might be expected to deplete intracellular 
glutathione (GSH) concentrations.(Zhang, Mack et al. 1998)  Indeed this has also been 
proposed as a mechanism through which Monocrotaline administration results in the 
development of SOS.(Wang, Kanel et al. 2000) In order to assess if this was occurring in mice 
treated with FOLFOX the GSH concentration was measured in whole liver extracts however 
no difference was detected between treatment groups (1851 ± 116.8µM vs. 2079 ± 173.5 
µM; p = 0.484; Fig 9B).  This does not completely exclude specific depletion of sinusoidal 
endothelial cell glutathione which may be masked in this assay by the high concentration of 
glutathione present within hepatocytes.  It should be observed that all animals in this study 
were not culled in a fasted state. 
Following systemic administration Oxaliplatin will clearly not only be taken up by the liver 
but by a wide variety of organs.  Boughattas et al. measured the platinum concentration in a 
variety of tissues 24 hours after the intravenous injection of 17mg/kg Oxaliplatin and 
demonstrated that the drug was predominantly taken up in the spleen.(Boughattas, Levi et 
al. 1989)  On this basis H&E stained sections of the spleen were examined.  There was a 
striking reduction in the size of the germinal centres within the spleen noted in FOLFOX 
treated animals with the red pulp making up proportionately more of the tissue mass (Fig 
10). 
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Figure 10 - FOLFOX administration to C57BL/6J mice for 4 weeks results in injury to the 
spleen 
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5.2  Is tumour death a silent event? 
The lack of liver injury in mice treated with FOLFOX for 4 weeks led to the question of 
whether other factors, rather than direct drug toxicity alone, might be involved in the 
development of SOS.  In a similar experiment to that described in the first part of this 
chapter Rickenbacher et al. also failed to demonstrate any evidence of liver injury following 
administration of high dose chemotherapy to C57BL/6J mice.  In the conclusion to their 
paper they proposed the hypothesis that a “second hit” was required for the development 
of liver injury although they did not allude to what this hit might consist of.(Rickenbacher, 
DeOliveira et al. 2011) 
The obvious difference between the model used thus far and the human situation is the 
absence of colorectal liver metastases in the mice.  Chemotherapeutics, including 
Oxaliplatin and 5-FU, exert their effects on tumours by causing sufficient DNA damage to 
result in apoptotic cell death.(Zitvogel, Casares et al. 2004) Classically the response to 
apoptotic cells is thought to be immunologically silent which, in part, is mediated by the 
local release of anti-inflammatory mediators such as TGF-β and prostaglandins.(Chen, Frank 
et al. 2001; Savill, Dransfield et al. 2002) In addition it has been demonstrated that in vitro 
exposure of phagocytic cells to apoptotic bodies results in down-regulation of the pro-
inflammatory cytokines TNF-α, IL-1β and IL-12 and up-regulation of the anti-inflammatory 
cytokine IL-10.(Voll, Herrmann et al. 1997) 
In contrast to this Tesniere et al. reported that Oxaliplatin induced apoptosis of colorectal 
cancer cells is not immunologically silent and an immune response is indeed required for 
effective tumour killing.  In order to demonstrate this they established a subcutaneous 
tumour in BALB/C mice using the syngeneic CT26 colorectal cancer cell line.  Treatment of 
114 
 
tumours in these mice with Oxaliplatin resulted in significant shrinkage but when this 
experiment was repeated in immunodeficient nu/nu mice no such effect was 
seen.(Tesniere, Schlemmer et al. 2009)  The authors proposed two mechanisms that might 
be responsible for mediating this immunogenic cell death : 
1) Treatment of colorectal cancer cell lines with Oxaliplatin leads to expression of 
Calreticulin on the cell surface which then targets the cell for phagocytosis and 
enables it to interact with Dendritic cells.(Zeng, Aldridge et al. 2006; Obeid, 
Tesniere et al. 2007)  When the exposure of calreticulin is inhibited in CT26 cells 
then Oxaliplatin loses its in vivo efficacy(Tesniere, Schlemmer et al. 2009) 
2) Oxaliplatin treatment of CT26 cells results in the release of HMGB1 which is a 
ligand for the Toll Like Receptor 4 (TLR4) and is capable of initiating an innate 
immune response.(Park, Gamboni-Robertson et al. 2006)  TLR4 knockout mice 
exposed to apoptotic CT26 cells fail to initiate an immune response unlike mice 
with intact TLR4 signalling.(Tesniere, Schlemmer et al. 2009) 
This evidence led me to question whether tumour cell death in response to FOLFOX may 
result in the local release of factors which contribute to the development of SOS. 
In order to test this hypothesis I elected to establish an in vivo model of colorectal liver 
metastases. Prior to doing this I wished to determine what effect FOLFOX treatment of 
colorectal cancer cells had on the production of chemokines and other factors implicated in 
wound healing and inflammation.  For this I utilised the murine MCA38 colorectal cancer cell 
line which was established from a chemically induced colorectal cancer in C57BL/6J mice 
thereby making it syngeneic and suitable for use in subsequent in vivo experiments without 
the potential for the development of an allogenic immune response.   
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Cells were treated in vitro with IC50 doses of Oxaliplatin and 5-FU, as determined by MTT 
assay, in the presence of 10µM Folinic Acid.  The IC50 dose of these agents was based upon 
treatment for 48 hours.  In order to determine the effect of this chemotherapy regimen on 
the production of chemokines I wished to look at live cells, rather than cells that had already 
undergone apoptosis, and therefore subsequent experiments were performed on cells 
treated with FOLFOX for 24 hours. 
One of the most striking findings in these experiments was a more than 30 fold increase in 
the expression of CXCL1 mRNA in FOLFOX treated cells (p<0.001; Fig 11A).  An ELISA 
performed on cell culture supernatants confirmed this finding with a 3 fold increase in the 
secretion of soluble CXCL1 protein (p<0.001; Fig 11B).  CXCL1 is the murine homologue of 
the human chemokine CXCL8 (IL-8).  Both of these chemokines are highly active on the 
vascular endothelium and play key roles in vascular angiogenesis and expression of matrix 
remodelling enzymes such as MMP-2.(Strieter, Burdick et al. 2005)  Increased levels of 
circulating IL-8 have been detected in the serum of bone marrow transplant patients who 
have gone on to develop SOS.(Remberger and Ringden 1997; Schots, Kaufman et al. 2003)  
IL-8 has also been demonstrated to play a pivotal role in hepatic vascular injury following 
insults such as ischaemia reperfusion.(Petreaca, Yao et al. 2007)   
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Figure 11 - Treatment of MCA38 with FOLFOX in vitro results in increased CXCL1 mRNA 
expression (A) which is reflected in the levels of secreted CXCL1 (B)  
 
In addition to CXCL1 I was also able to demonstrate up-regulation of other key inflammatory 
chemokines implicated in the wound healing response including CXCL5, CCL2 and CCL5 
(Figure 12A).  Martins et al. recently reported that colorectal cancer cell lines treated with a 
variety of chemotherapy agents, including Oxaliplatin, release extracellular ATP and that this 
contributes to mediating the immune response directed against dying tumour 
cells.(Martins, Tesniere et al. 2009)  Sinusoidal endothelial cells express high levels of the 
ectonucleotidase CD39 which is responsible for converting extracellular ATP to adenosine by 
hydrolysis.(Beldi, Wu et al. 2008)  When this system is exposed to high levels of ATP 
however it becomes overwhelmed and vascular injury can result.(Beldi, Enjyoji et al. 2008)  I 
was able to demonstrate that MCA38 cells also release extracellular ATP after exposure to 
FOLFOX with a 4 fold increase being detected in the culture supernatant (p<0.001; Fig 12B). 
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Figure 12 - In response to FOLFOX treatment MCA38 cells up-regulate transcription of 
CXCL5, CCL2 & CCL5 (A).  In addition there is release of extracellular ATP (B) 
 
On the basis of these preliminary in vitro experiments I felt confident that FOLFOX treated 
MCA 38 cells were producing chemokines and other modulators of the extracellular 
environment and, as such, it was worthwhile to proceed with an in vivo model to explore 
the hypothesis that these tumour related factors may contribute to the development of 
SOS. 
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5.3  Does tumour death contribute to the development of SOS? 
 In order to determine what affect tumour related factors might have on the development 
of SOS, I developed a model of experimental colorectal liver metastases in C57BL/6J mice.  A 
commonly utilised method for developing experimental metastases is through intraportal or 
intrasplenic injection of tumour cells however the disadvantage of this technique is that it 
may result in the rapid development of disseminated metastatic disease.  An alternative 
technique is to implant tumour cells directly into the liver, either through subcapsular 
injection of a suspension of tumour cells or by implantation of a fragment of solid tumour 
tissue from another mouse.  The advantage of this technique is that it allows for the 
development of localised metastatic disease but has the disadvantage that it misses out 
many of the early processes involved in metastasis development such as cell arrest, 
extravasation and liver colonisation.(Heijstek, Kranenburg et al. 2005)  
I elected to use the technique of subcapsular hepatic injection of MCA38 cells to establish 
experimental metastases, for the following reasons: 
1) The intention of this model was not to study the process of metastatic tumour 
formation but rather the effect of the tumour on the hepatic micro-environment 
once it was established 
2) If the model were to be successful I would consider performing experiments to 
look at the effect of SOS on liver regeneration, using models such as 70% partial 
hepatectomy, and therefore a localised tumour would better enable this 
In order to be able to monitor the development of tumours MCA38 cells were stably 
transfected with the pGL4.51 luciferase reporting vector.  Prior to in vivo experiments the 
expression of luciferase in these cells was confirmed in vitro using a luminometer (Fig 13A). 
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Initial experiments were performed to determine the optimum number of cells for 
implantation and the time taken for solid tumour development.  Mice were injected with 
either 10
6
, 10
5
 or 10
4
 cells and tumour development measured at 1 week both by in vivo 
imaging and post-mortem examination.  Those animals injected with 10
6
 cells all had large 
tumours present which in the majority of cases had begun to metastasise to the lungs. In 
contrast those mice injected with 10
4
 cells had either failed to develop tumours or they 
were less than 5mm in diameter.  As a result 10
5
 cells was selected as the optimum number 
for injection.   
The next pilot study sought to determine the time taken for tumour development in mice 
injected with 10
5
 cells.  Following subcapsular injection of cells in vivo imaging was 
performed on a daily basis.  Five days following implantation tumour was detectable in 5 out 
of 6 mice (83%).  One week later the mouse with no tumour detectable on day 5 had no 
measurable tumour either by in vivo imaging or on post-mortem examination.  It was 
therefore decided that 5 days following tumour implantation would be the time point for 
determining if tumour was present and at that point to commence experiments. 
To examine the effect of tumour related factors on the development of chemotherapy 
induced SOS 10
5
 MCA 38 cells were injected beneath the liver capsule of 12 C57BL/6J mice 
via midline laparotomy.  A further 12 mice underwent laparotomy alone to form the sham 
operated control groups.  On post-operative day 5 the presence of solid tumour within the 
liver was confirmed by in vivo imaging (Fig 13B).  At this point mice were subdivided into 
four groups as follows: 
- Sham Control & Vehicle (n=6) 
- Sham Control & FOLFOX (n=6) 
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- Tumour Implantation & Vehicle (n=6) 
- Tumour Implantation & FOLFOX (n=6) 
FOLFOX chemotherapy was commenced on day 5 using the previously described protocol.  
The initial intention was to repeat this for four weeks however due to rapid tumour growth 
in the tumour bearing animals not receiving chemotherapy it was necessary to terminate 
the experiment early because of animal welfare.  As a consequence mice were culled and 
organs harvested 24 hours after the 3
rd
 dose of FOLFOX. 
 
 
Figure 13 - Luciferase expression in stably transfected MCA38 cells was confirmed in vitro 
(A).  In vivo imaging confirming the presence of tumour 5 days following implantation of 
105 MCA38 cells (B) 
 
Both sham operated and tumour bearing animals treated with FOLFOX lost weight as 
compared to vehicle controls confirming systemic drug toxicity in a similar manner to 
previous experiments.  It can be seen that the mean weight gain over the course of the 
experiment was much greater in the tumour bearing vehicle controls as compared to the 
sham operated vehicle controls which is a reflection of the rapid tumour growth in this 
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group, although this difference did not reach statistical significance (3.78 ± 2.80g vs. 10.33 ± 
2.51g; p = 0.132; Fig 14A).  In contrast the tumour growth in the FOLFOX treated animals 
was clearly much less (Fig 14B) and this was reflected by a lower tumour to body weight 
ratio (0.147 ± 0.042 vs. 0.045 ± 0.010; p < 0.05) and tumour volume (5.90 ± 1.85cm
3
 vs. 1.86 
± 0.53cm
3
; p = 0.062) in this group (Fig 14C).  Review of H&E stained sections of the liver did 
not reveal histological evidence of SOS.(Fig 14D). 
Despite the lack of convincing histological changes of SOS on H&E stained sections of the 
liver I felt it would be appropriate to go ahead and look for surrogate molecular markers in 
the liver which might be expected during the development of an SOS phenotype.  This was 
done using a qRT-PCR based screen in the first instance as it allows for multiple biological 
pathways to be interrogated in a time efficient manner.  The choice of target genes was 
guided by a micro-array study performed by Rubbia-Brandt et al. on a small number of 
patients with Sinusoidal Obstruction Syndrome.  Whilst this study was underpowered, and 
therefore difficult to interpret, it is the only paper which has directly attempted to discover 
the pathophysiological processes which underpin SOS induced by Oxaliplatin containing 
chemotherapy.(Rubbia-Brandt, Tauzin et al. 2011)   
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Figure 14 - FOLFOX treatment is associated with weight loss in both sham operated and 
tumour bearing groups (A).  FOLFOX is effective in slowing the rate of tumour growth (B 
and C).  H&E stained sections of the liver fail to demonstrate changes of SOS (D; 10x  
magnification; Rubbia-Brandt grade 0 all groups) 
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Remodelling of the extracellular matrix is a key event in the development of SOS following 
Monocrotaline administration and in keeping with this Rubbia-Brandt et al. demonstrated 
up-regulation of a variety of genes implicated in this process in patients with Oxaliplatin 
induced SOS.(Deleve, Wang et al. 2003; Rubbia-Brandt, Tauzin et al. 2011)  Following 
administration of Monocrotaline the extracellular matrix is disrupted through the actions of 
the gelatinases MMP-2 and MMP-9 thereby allowing extravasation of blood cells into the 
space of Disse.  As already discussed inhibition of MMP’s, by the antibiotic doxycycline, 
prevents SOS developing in this model.(Deleve, Wang et al. 2003)  In keeping with these 
findings I was able to demonstrate that, in the presence of experimental liver metastases, 
there was a 13 fold up-regulation of MMP2 gene expression (p<0.01).  This compared to a 5 
fold increase in sham operated animals treated with FOLFOX (p<0.01). Hepatic MMP2 
expression was also up-regulated 5 fold simply by the presence of tumour within the liver 
(p<0.01) suggesting that the large increase in expression in the tumour bearing animals is a 
result of both drug effect and tumour related factors (Fig 15A).    FOLFOX treatment also 
resulted in a marked up-regulation of MMP9 expression. Whilst this was most marked in 
sham operated animals the difference between tumour bearing animal groups was not 
statistically significant (p=0.126; Fig 15B). 
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Figure 15 - Both MMP2 (A) and MMP 9 (B) are up-regulated both as an effect of FOLFOX 
administration and an effect of tumour related factors 
 
The effects of the gelatinases are counteracted by their inhibitors – the tissue inhibitors of 
metalloproteinases (TIMP) and it is the balance between MMP and TIMP expression that 
modulate the process of tissue remodelling.  The livers of FOLFOX treated tumour bearing 
animals demonstrated a 67 fold increase in TIMP1 (p<0.01) expression which was not seen 
in sham operated animals treated with the drug combination.  Again the presence of 
tumour alone was associated with a 10 fold increase in the expression of TIMP1 (p<0.01) 
suggesting that tumour related factors may be playing a key role in its regulation (Figure 
16A). 
One of the key sources of TIMP1 in the liver is the hepatic stellate cell.(Olivie, Lepanto et al. 
2007)  Hepatic stellate cells are normally present in the hepatic sinusoid in a quiescent state 
but when activated they take on the phenotype of a myofibroblast and play a pivotal role in 
matrix remodelling and in particular fibrogenesis.(Friedman 2008) Activation of hepatic 
stellate cells has been reported in patients with SOS(Rubbia-Brandt, Audard et al. 2004)and 
125 
 
in keeping with this I was able to detect a 9.5 fold increase in αSMA transcript levels in 
FOLFOX treated tumour bearing animals (p<0.05; Fig 16B) which was supported by 
increased numbers of αSMA positive cells being detected on immunohistochemistry (Fig 
16C).  One of the key roles of activated stellate cells is to lay down collagen and in support 
of this there was a 16 fold increase in liver Procollagen I transcript (p<0.01; Fig 16D).  
Transforming growth factor β is regarded as the master regulator of liver fibrosis and indeed 
it appears that this is playing a role in the process of matrix remodelling in response to 
FOLFOX with a 4 fold increase in transcript level being detected in tumour bearing animals 
(Fig 16E). 
These findings support the concept that tumour related factors may contribute to the up-
regulation of genes involved in the pathogenesis of SOS, in particular those concerned with 
matrix remodelling and hepatic fibrogenesis.  Clearly the balance between the expression of 
MMP’s and TIMP will determine the effect of these enzymes on the liver parenchyma.  If the 
balance was in favour of increased MMP activity then this would favour destruction of the 
extracellular matrix as has been implicated in the sinusoidal injury seen in SOS. (Deleve, 
Wang et al. 2003).  In contrast if the increased TIMP expression in FOLFOX treated animals 
resulted in MMP inhibition then this would tend to favour the deposition of extracellular 
matrix such as occurs in liver fibrosis. (Friedman 2008)  
With the benefit of hindsight it would have been desirable to include assays to determine 
the relative activity of MMPs (e.g. gelatin zymography) in FOLFOX treated tumour bearing 
animals.  Should it have been possible to continue this model for a longer period of time it 
would seem reasonable to expect there would have been evidence of parenchymal injury 
although it is not possible to predict, with the current data, the likely nature of this. 
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Figure 16 Tumour bearing mice treated with FOLFOX demonstrate up-regulation of the 
pro-fibrogenic TIMP1 transcript (A).  In keeping with this there is increased expression of 
αSMA at a transcript level (B) and on immunohistochemistry (C).  Increased levels of 
procollagen I transcript support a pro-fibrotic environment (D) and it is likely that this is 
driven by TGFβ (E). 
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5.4  Is the Murine Liver Resistant to FOLFOX 
The lack of histological changes in the liver following administration of Oxaliplatin, either 
alone or in combination with 5-FU, leads one to ask if C57BL/6J mice are resistant to the 
effects of these drugs.  Before making further attempts to establish an animal model I 
elected to answer this question by looking at expression, at an RNA level, of key members of 
the pathways involved in the handling and metabolism of Oxaliplatin and 5-FU. 
5.4.1 Oxaliplatin Metabolism 
At a cellular level the uptake and excretion of platinum based drugs is regulated by copper 
transport proteins.  Initial observations linking cellular platinum handling to these proteins 
were made by Katano et al. who demonstrated that ovarian cancer cell lines selected as 
being resistant to Cisplatin were cross resistant to high concentrations of copper 
sulphate.(Katano, Kondo et al. 2002)  Subsequently it was shown that the kinetics of influx 
and efflux of platinum compounds mirrors that of copper.(Safaei, Katano et al. 2004) 
 Copper transporter 1 (CTR1) is a plasma membrane bound transport protein that regulates 
the influx of copper into the cell.  It has been demonstrated that cell lines which do not 
express CTR1 are resistant to platinum based chemotherapeutics, even at high 
doses.(Holzer, Manorek et al. 2006; Larson, Blair et al. 2009)  High intracellular platinum 
(and copper) concentrations lead to the degradation of CTR1 thereby limiting the 
cytotoxicity of these compounds.(Holzer and Howell 2006) High expression levels of CTR1 
have been shown to mediate the sensitivity of dorsal root ganglia, in rats, to the toxic 
effects of Oxaliplatin whereas ganglia expressing low levels of CTR1 are relatively 
resistant.(Liu, Jamieson et al. 2009)   
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Copper transporter 2 (CTR2) is much less well characterised in terms of platinum handling.  
One study examined the expression of CTR1 and CTR2 in patients with ovarian cancer 
treated with platinum based chemotherapy.  When CTR2 was the predominant copper 
transporter expressed in the cancer tissue, with low levels of expression of CTR1, then 
response to chemotherapy was poor.(Lee, Choi et al. 2011)  This finding supports the results 
of in vitro studies using ovarian cancer cell lines whereby knockdown of CTR2 resulted in 
increased sensitivity to platinum based chemotherapy.(Blair, Larson et al. 2009; Blair, Larson 
et al. 2010) 
 The key copper efflux transporters are the ATPases ATP7A and ATP7B.  It has been 
demonstrated that both of these transporters play roles in regulating intracellular platinum 
concentrations.    Increased expression of both ATP7A and ATP7B is a key feature of 
platinum resistant cancer cell lines preventing intracellular accumulation of 
platinum.(Komatsu, Sumizawa et al. 2000; Katano, Kondo et al. 2002; Samimi, Safaei et al. 
2004)  The validity of these in vitro observations has been confirmed in patients with 
colorectal cancer treated with Oxaliplatin based chemotherapy in whom high levels of 
expression of ATP7B are associated with an increased risk of disease progression (Hazard 
Ratio 3.56; 95% Confidence Interval 1.6 – 7.9; p = 0.002)(Martinez-Balibrea, Martinez-
Cardus et al. 2009)  
 In mice with experimental liver metastases treated with FOLFOX I have demonstrated that 
the spleen, along with the implanted tumour, are key sites of activity for this drug 
combination whereas the liver seems to be relatively in-sensitive in so far as no histological 
changes are seen.  In order to confirm this lack of drug effect immunohistochemistry for 
γH2AX, a marker of DNA damage, was performed.  It can be seen that the number of γH2AX 
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positive cells in the liver is very small when compared to both spleen and tumour following 
FOLFOX treatment. This suggests that there is, in reality, very little DNA damage in this 
organ (Fig 17A).  On the other hand FOLFOX treatment results in statistically significant 
increases in the number of γH2AX positive cells in both spleen and tumour tissue (Fig 17 B & 
C) confirming that they are particularly sensitive to this drug combination.  
 
 
Figure 17 – Counts of γH2AX positive cells in Liver (A), Spleen (B) and Tumour (C) from 
mice with experimental colorectal liver metastases (or shams) treated with FOLFOX 
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In order to explore if copper transport proteins may play a role in mediating this resistance 
to FOLFOX, and in particular Oxaliplatin, RNA was isolated from the liver, spleen and tumour 
tissue of chemotherapy naive mice.  RT-PCR performed was then performed to determine 
the expression of  copper influx (CTR1, CTR2) and efflux  (ATP7A, ATP7B) transporters.  
Whilst it might be argued that it would be better to look for expression of these receptors at 
a protein level there is a lack of good quality commercially available antibodies available for 
all of these receptors making this approach impractical. 
The expression of the influx transporters CTR1 and CTR2 within the liver follows the pattern 
that might be expected in Oxaliplatin sensitive tissue i.e. high CTR1 expression and low CTR2 
expression. This suggests that the liver is able to take up Oxaliplatin and as such this isn’t the 
cause of the resistance to drug induced injury.  On the other hand there is very high 
expression of the efflux transporter ATP7B, when compared to other tissues, suggesting that 
the liver is rapidly able to export Oxaliplatin and this may provide a mechanism through 
which the murine liver is able to limit its exposure to Oxaliplatin and thus minimise drug 
toxicity. 
In the human population genetic polymorphisms leading to loss of function in the ATP7B 
gene have been linked to the development of Wilsons disease which is characterised by 
excessive accumulation of copper within the liver. (Huster D 2010)  Polymorphisms in the 
ATP7B appear to be extremely common with the general population, the majority of which 
do not result in the development of clinically overt Wilsons disease.  In one study of 203 
cancer patients 61 were found to have polymorphisms in the ATP7B gene although the 
functional consequences of this were not explored. (Fukushima-Uesaka H, Saito Y et al. 
2009).  It is interesting to hypothesise that these polymorphisms may be associated with an 
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increases susceptibility to the toxic effects of Oxaliplatin based chemotherapy.  Before 
exploring this further in a clinical study it would be worthwhile administering FOLFOX to  
ATP7B gene knockout mice to determine the impact of this gene on the development of 
liver injury.   
 
 
Figure 18 - Expression of copper transporters in liver spleen and tumour tissue of mice 
with experimental colorectal liver metastases who had not received chemotherapy 
treatment (n=5 per group). β-Actin served as loading control. 
 
 
5.4.2 5-FU Metabolism 
The intracellular processing of 5-FU has already been summarised in Chapter 1 (see Figure 
2).  In brief on entry into the cell 5-FU is converted into the active products 
fluorodeoxyuridine and fluorouridine triphosphate by the enzyme thymidine phosphorylase 
(TP) resulting in DNA damage through inhibition of thymidilate synthase (TS).  Alternatively 
5-FU can be converted into the inactive metabolite dihydrofluorouracil by the enzyme 
dihydropyrimidine dehydrogenase (DPD).  High levels of expression of both DPD and TS are 
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associated with resistance to 5-FU based chemotherapy.(Ciaparrone, Quirino et al. 2006; 
Ishikawa, Miyauchi et al. 2008; Yamada, Iinuma et al. 2008)  In addition low levels of DPD 
mRNA expression in the liver have been reported in patients with chemotherapy induced 
injury.(Pilgrim, Brettingham-Moore et al. 2011) 
To assess the sensitivity of the liver to 5-FU, the expression of TS, TP and DPD was assessed 
at the RNA level by RT-PCR (Figure 19).  It can be seen that the liver expresses the highest 
levels of TP suggesting that it should be able to convert 5-FU into its active form.  In contrast 
the expression of DPD is similar to that seen in tumour tissue and TS levels are similar across 
all three tissues suggesting that resistance to 5-FU within the liver should not be a significant 
barrier to the development of liver injury in response to FOLFOX in C57BL/6J mice.  
 
Figure 19 - Expression of enzymes involved in 5-FU activity in liver spleen and tumour 
tissue of mice with experimental colorectal liver metastases who had not received 
chemotherapy treatment (n=5 per group). β-Actin served a loading control. 
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5.5  Summary of Key Findings 
• Administration of Oxaliplatin, either alone or in combination with 5-FU/LV, to 
C57BL/6J mice for 4 weeks leads to systemic drug toxicity but mice fail to develop 
evidence of liver injury 
• Colorectal cancer cells treated with 5-FU/LV and Oxaliplatin in vitro produce 
chemokines and other modulators of the extracellular environment    
• Tumour death within the liver may contribute to the up-regulation of genes involved 
in the development of SOS, especially those concerned with matrix remodelling and 
hepatic fibrogenesis 
• The murine liver expresses the necessary transporters and enzymes for the uptake 
and intracellular processing of both Oxaliplatin and 5-FU. High levels of ATP7B mRNA 
might mean that Oxaliplatin is rapidly cleared from the liver making it relatively 
resistant to Oxaliplatin as compared to other tissues. 
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Chapter 6  
Dietary Factors in the Development of FOLFOX Induced SOS 
 
6.1  Background 
 The development of SOS following treatment with Oxaliplatin based chemotherapy is not 
uniform but rather, from the meta-analysis data presented earlier, seems to occur in 
approximately in 1 in every 9 treated patients.  The animal model data presented in the 
previous chapter would seem to suggest that healthy C57BL/6J mice are resistant to 
Oxaliplatin based chemotherapy which raised the question of whether pre-existing liver 
injury may predispose to the development of liver toxicity. 
Hepatic steatosis is the most common background abnormality in the liver and is present in 
up to a quarter of the UK adult population.(Anstee, McPherson et al. 2011) Whilst the 
presence of steatosis, per se, is not particularly troublesome it is widely acknowledged that 
it increases the risk of liver injury from a variety of insults.(Powell, Jonsson et al. 2005)  In 
mice with dietary induced steatosis there is up-regulation of TLR4 expression within the 
liver.  This increases the susceptibility of the liver to portal endotoxaemia with a resultant 
recruitment of leukocytes to the liver.(Shi, Kokoeva et al. 2006; Rivera, Gaskin et al. 2010)  
The enhanced inflammatory response in patients with steatosis that is thought to be one of 
the factors determining progression to steatohepatitis in patients with both NAFLD and 
alcohol induced liver disease.(Nagata, Suzuki et al. 2007; Rivera, Adegboyega et al. 2007; 
Olleros, Martin et al. 2008) 
One of the proposed mechanisms for the development of SOS following treatment with 
Oxaliplatin is the generation of oxidative stress as a result of glutathione depletion.(DeLeve, 
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Wang et al. 1996; Zhang, Mack et al. 1998; Wang, Kanel et al. 2000)  The presence of hepatic 
steatosis is associated with an increased susceptibility to oxidative stress and this has been 
linked to the more rapid progression of liver fibrosis in patients with Hepatitis C virus 
infection.(Powell, Jonsson et al. 2005; Choi and Ou 2006) This susceptibility to oxidative 
stress is thought to arise as a result of lipid induced mitochondrial dysfunction and this plays 
a key role in the progression of NAFLD.(Pessayre, Fromenty et al. 2004; Pessayre 2007) The 
importance of this mechanism has been confirmed in several models of hepatic steatosis 
whereby mice treated with a glutathione precursor develop less severe 
disease.(Baumgardner, Shankar et al. 2008; de Oliveira, de Lima et al. 2008; Sinha-Hikim, 
Sinha-Hikim et al. 2011) 
  
136 
 
6.2  Does hepatic steatosis predispose to the development of SOS? 
To determine if a background liver injury could act as a predisposing factor for the 
development of Oxaliplatin induced SOS I elected to establish a model of hepatic steatosis 
again in C57BL/6J mice.  A variety of genetic knock-out models of hepatic steatosis exist, 
such as the leptin deficient ob/ob mice, but it is not known what impact the loss of these 
genes may have on the response to chemotherapy and so these were not considered 
suitable for use.  An alternative approach is to establish hepatic steatosis using dietary 
models.  One such model that is widely utilised is the Methionine and Choline deficiency 
(MCD) diet that leads to the rapid development of hepatic steatosis due to an induced 
defect in mitochondrial β-Oxidation.  This model however has several drawbacks, not least 
of which is that the animals lose large amounts of weight which may cause significant 
problems when used with systemic chemotherapy which also affects weight gain.(Koteish 
and Diehl 2001; Anstee and Goldin 2006) 
An alternative dietary approach is to feed mice a high fat diet which results in impaired 
hepatic glucose tolerance and insulin resistance with the subsequent development of 
hepatic steatosis.(Fraulob, Ogg-Diamantino et al. 2010; Eccleston, Andringa et al. 2011; 
Peng, Rideout et al. 2012) As this process most closely replicates the pathogenesis of NAFLD 
in human subjects I elected to adopt this approach to establish hepatic steatosis in mice 
before treatment with FOLFOX.  To this end 4 week old male C57BL/6J were commenced on 
either high fat (45%) diet or a control low fat (10%) diet for 10 weeks.  Review of H&E 
stained liver sections from high fat diet fed animals culled at this time point demonstrated 
pronounced lipid droplets within hepatocytes in keeping with the development of steatosis 
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confirming that this was an effective model (Figure 20).   The manufacturers’ analysis of the 
content of these diets is listed in Appendix 2. 
 
 
Figure 20 - Mice fed a high (45%) fat diet for 10 weeks show evidence of lipid droplets 
within hepatocytes when compared to mice fed control (10% fat) diet 
 
Following this pilot to assess diet efficacy mice were allocated to receive either high or low 
fat diet (n=20 per group) for 6 weeks.  At this point these groups were split and mice were 
treated with either FOLFOX or Vehicle control by intraperitoneal injection on a weekly basis 
(n=10 per group).  Following my earlier experiments which had demonstrated the relative 
resistance of the murine liver to the effects of Oxaliplatin I wished to treat the mice with 
chemotherapy for 6 weeks to increase the likelihood of SOS developing.  This was not 
possible due to 3 deaths in the high fat diet fed FOLFOX group in the week following the 5
th
 
treatment. The experiment was therefore terminated 1 week following the 5
th
 dose of 
FOLFOX.  There were no deaths in the low fat diet group treated with FOLFOX suggesting 
the high fat diet was associated with increased systemic drug toxicity.   
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It can be seen from Figure 21 that body weights between the control diet and high fat diet 
groups differed significantly at baseline (25.53 ± 1.99 vs. 31.15 ± 2.94g; p <0.0001) as would 
be expected.  Whilst the vehicle only animals in each group continued to gain weight over 
the course of the experiment those treated with FOLFOX lost weight in keeping with 
systemic toxicity.  This weight loss in response to chemotherapy was more dramatic in those 
receiving the high fat  (7.3 ± 3.82 g) as  compared to the low fat diet (1.6 ± 1.75g; p <0.01) 
again suggesting the high fat diet was associated with greater systemic toxicity. 
 
 
Figure 21 - Body weight over the course of FOLFOX administration demonstrates weight 
loss in FOLFOX treated animals which was most marked on the high fat diet 
 
Next H&E stained sections of the liver were reviewed in conjunction with a liver pathologist 
(Professor Alastair Burt) to determine if there was evidence of liver injury.  It can be seen in 
Figure 2 that mice treated with FOLFOX, both in the low and high fat diet groups, had 
marked sinusoidal dilatation and evidence of atrophy of peri-venular hepatocytes in keeping 
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with the early stages of SOS.  The severity of these changes was, if anything, more modest in 
those fed the high fat diet.  It was striking that those in the high fat group treated with 
vehicle alone had significant hepatic steatosis evident which was not present in the FOLFOX 
group confirming the results of the meta-analysis in data presented in chapter 2 that this 
chemotherapy regimen is not associated with hepatic steatosis or steatohepatitis.  Blinded 
scoring of H&E stained tissue sections from animals maintained on a low fat diet revealed 
that sinusoidal dilatation was universally of Rubbia-Brandt grade 1 in FOLFOX treated 
animals as compared to grade 0 in vehicle controls (p<0.0001; Table 9).  Similarly 
endothelial disruption was identified in all FOLFOX treated animals but not in controls 
(p<0.0001; Table 9). 
 Vehicle (n=9) FOLFOX (n=9) p-Value 
Rubbia-Brandt Grade    
0 9 0  
1 0 9 p < 0.0001 
2 0 0  
3 0 0  
Endothelial Disruption Present 0 9 p < 0.0001 
 
Table 9 - Semi-quantitative scoring of H&E stained sections from animals maintained on a 
low fat diet treated with either FOLFOX or Vehicle Control 
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Figure 22 – 10x magnification H&E stained sections of the liver from FOLFOX treated 
animals demonstrate sinusoidal dilatation and peri-venular hepatocyte atrophy which 
occurs irrespective of dietary background (A).  These changes can be seen more clearly in 
20x magnification images from low fat diet animals (B). 
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Liver enzymes were measured in the serum of mice from all four groups as an alternative 
marker of injury.  It can be seen that, in animals on the low fat diet, FOLFOX administration 
was associated with an elevated ALT (42.7 ± 4.52 U/L vs. 76.0 ± 14.5 U/L; p<0.05; Fig 22A) 
and AST (225 ±31 U/L vs. 478 ± 77 U/L; p<0.05; Fig 22B) but not ALP (72.2 ± 2.66 U/L vs. 68.7 
± 2.93 U/L; Fig 22C) when compared to vehicle controls.  It is noteworthy that these changes 
were not demonstrated in the high fat diet animals treated with FOLFOX suggesting the 
degree of hepatocellular injury is worse in the low fat diet group.  This may be a result of the 
most severely injured animals in the high fat group dying earlier than expected.  In any case 
it is clear that, in terms of FOLFOX induced liver injury, there is little evidence that 
background steatosis has any effect on its development.   
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Figure 23 – FOLFOX administration is associated in an elevated ALT (A), AST (B) but not 
ALP (C) in control diet animals but not those fed a high fat diet 
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6.3 Validation of Matrix Remodelling Gene Expression in SOS 
Development 
As previously discussed matrix remodelling appears to play a pivotal role in the 
development of Monocrotaline induced SOS and increased expression of these genes was 
demonstrated in a micro-array study performed on a small number of patients with 
Oxaliplatin induced SOS.(Deleve, Wang et al. 2003; Rubbia-Brandt, Tauzin et al. 2011)   
Given that I now had a model in which there were definitive histological changes of SOS I 
wished to validate this gene expression pattern for the following reasons : 
1) To confirm that increased expression of these matrix remodelling genes is 
temporally associated with the development of SOS 
2) To validate the conclusions made based on this gene expression signature in my 
previous models 
Since the presence of steatosis within the liver had no effect on SOS development I used 
liver RNA extracts only from those animals who received the low fat diet for this analysis. 
In keeping with previous models mice with FOLFOX induced SOS demonstrated a 2.63 fold 
increase in expression of MMP2 (p<0.001; Fig 24A) and an 8.47 fold increase in MMP 9 
transcript (p<0.001; Fig 24B). This was associated with a 16.3 fold increase in TIMP1 
expression (p<0.001; Fig 24C) and a 5.84 fold increase in Collagen I expression (p<0.001; Fig 
24D).   As previously discussed it is likely that TGFβ is playing a key role in driving this 
process of matrix remodelling with a 3.62 fold increase in its expression (p<0.001, Fig 24E). 
When mice with an experimental colorectal liver metastases were treated with FOLFOX the 
change in expression of matrix remodelling genes following FOLFOX treatment was  
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Figure 24 - FOLFOX induced SOS is associated with up-regulation of matrix remodelling 
genes including MMP2 (A), MMP9 (B), TIMP1 (C), Pro-Collagen I (D) and TGFβ(E).  There is 
no increase in expression of the stellate cell marker αSMA (F) suggesting that these 
changes are arising predominantly from the sinusoidal endothelium. 
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associated with 9.5 fold increase in αSMA transcript, suggesting activation of hepatic stellate 
cells, and this finding was corroborated by immunohistochemistry (Figure 16).  In contrast, 
despite the presence of SOS, I was not able to demonstrate a statistically significant up-
regulation of αSMA transcript in FOLFOX treated animals (1.94 fold; p = 0.195; Fig 24F) and 
nor was there evidence on H&E stained sections of peri-sinusoidal fibrosis which would be 
in keeping with stellate cell activation (Fig 22).   This was a somewhat surprising result as 
stellate cell activation has been demonstrated to be a feature of human SOS.(Rubbia-
Brandt, Audard et al. 2004) There are two possible explanations for these findings : 
1) The early events in SOS development are driven by damaged sinusoidal 
endothelium and stellate cell activation occurs later in the disease process 
perhaps as an attempt to limit injury to the sinusoid  
2) Endothelial injury is a direct consequence of drug induced injury whereas stellate 
cell activation occurs as a consequence of tumour related factors. 
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6.4 Are dietary factors protective for the development of SOS in a murine 
model? 
From the results presented thus far in this Chapter it is clear that a high fat diet does not 
lead to accelerated development of SOS following FOLFOX treatment.  It does however 
seem that mice fed with the low fat diet regimen seem to have an increased susceptibility to 
SOS development as compared to mice maintained on a standard chow diet.  It is important 
to note that the current experiment differed in several key ways to the experiment 
presented in Chapter 5 section 1: 
- Mice receiving standard animal house care are given sunflower seeds as a treat.  
It is standard practice when using dietary models to not provide this treat in 
order that these are not consumed in preference to the experimental diet. 
- It is common to maintain mice on sterile water to minimise the risk of exposure 
to environmental pathogens and this was the case in the original experiment 
unlike in the current experiment where mice were maintained on standard tap 
water. 
- Mice were treated with FOLFOX for 5 weeks as compared to a 4 week maximum 
in earlier experiments.   
It is plausible that any of these variables, in addition to the diet itself, may have contributed 
to the development of SOS in the current experiment.  To understand further what might be 
responsible the experimental model outlined in section 1 of this chapter was repeated with 
stepwise substitution of each of the identified variables to determine which, if any of these, 
may protect against the development of SOS.  This gave 4 groups of animals (n=6 per group) 
as follows : 
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- Control Diet, No Sunflower seeds, Standard tap water 
- Control Diet, No Sunflower seeds, Sterile water 
- Control Diet, Sunflower seeds ad libitum, standard tap water 
- Standard chow, No Sunflower seeds, standard tap water. 
Mice were treated with FOLFOX IP for 5 weeks and culled one week following the final dose.   
On review of H&E stained sections of the liver it became apparent that features of SOS 
developed in all groups of animals to a similar extent except for those fed with standard 
chow (Figure 25) which appeared to offer a protective effect. 
In order to determine if standard chow completely protected against the development of 
SOS or merely slowed its development 10 week old C57BL/6J mice, maintained on this diet, 
were treated with FOLFOX IP (or vehicle control) weekly for either 5 or 7 weeks (n=6 per 
group).  Mice were culled 1 week following the final dose of chemotherapy. 
H&E stained sections of the liver were again reviewed to assess for the development of 
features in keeping with SOS.  As already alluded to mice treated with FOLFOX for 5 weeks 
have very minimal changes of SOS with, at worst, mild sinusoidal dilatation present in a few 
sinusoids scattered throughout the liver parenchyma.  In contrast mice treated with FOLFOX 
for 7 weeks showed widespread sinusoidal dilatation with associated hepatocyte atrophy in 
keeping with SOS.  The histological changes at this time point are indistinguishable from 
those in mice treated with FOLFOX on the experimental low fat diet for 5 weeks (Figure 26).   
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Figure 25 - A Standard Chow diet appears to protect against the development of FOLFOX 
induced SOS 
 
It is not immediately apparent why a standard chow diet would slow the development of 
FOLFOX induced SOS although there are several potential explanations for this.  A key 
difference between chow diets and the purified ‘low fat’ diet is that the former are 
manufactured from plant materials whereas the latter are manufactured with refined 
ingredients.  The result of this is that chow diets can contain large quantities of 
phytoestrogens which have been shown to interfere with a large number of biological 
processes including the development of hepatic steatosis and fibrosis.(Ascencio, Torres et 
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al. 2004; McCarty, Barroso-Aranda et al. 2009)  Other possibilities include differing nutrient 
levels, e.g. of naturally occurring anti-oxidants, which may have protective effects.  Whilst 
nutritional content sheets are available for both diet types (See Appendices 2&3) it is 
impossible to directly compare the two since those for chow diets report minimal nutritional 
content whereas those for purified diets report precise nutrient levels.  It would be of 
interest to determine the mechanism underpinning the protective effects of a chow diet but 
this is beyond the scope of the current body of work. 
 
Figure 26 - Standard Chow delays but does not protect from the development of FOLFOX 
induced SOS with animals treated with 7 weeks developing changes of similar severity to 
those treated for 5 weeks on the experimental diet 
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6.5  What is the Natural History of FOLFOX induced SOS? 
In order to establish the natural history of the morphological changes in the liver 
parenchyma following FOLFOX treatment mice on fed with the experimental low fat diet 
were treated with FOLFOX for 5 weeks and then left to recover for a total of 5 weeks before 
culling (n=6).  To confirm that SOS had developed a further 6 mice were treated FOLFOX for 
5 weeks and culled 1 week after the final dose (n=6).  Control animals received drug vehicle 
alone for 5 weeks and were culled 5 weeks after the final dose (n=6). H&E stained sections 
of the liver confirmed the presence of SOS at 5 weeks following FOLFOX treatment which 
had completely resolved in mice allowed to recover for 5 weeks with the appearances of the 
liver being identical to that of those animals which received vehicle alone (Figure 27).   
In the current model mice do not develop the more severe changes associated with SOS 
such as peri-sinusoidal fibrosis and nodular regenerative hyperplasia.  In an effort to see if 
these changes could be reproduced mice, maintained on the experimental diet, were 
treated with FOLFOX for 6 weeks (with the intention of continuing for longer).  
Unfortunately in the week following the 6
th
 dose of FOLFOX 3 out of 6 mice were found 
dead.  I suspect these deaths were as a consequence of systemic toxicity, most likely bone 
marrow failure with subsequent profound anaemia, as reflected by marked peripheral pallor 
and weight loss in the preceding days.  It may be that increasing the time interval between 
doses of chemotherapy may allow for more prolonged treatment and thus more advanced 
SOS however time did not allow me to undertake these experiments. 
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Figure 27 - The features of SOS induced by 5 weeks of FOLFOX treatment can be reversed 
by allowing mice to recover for 5 weeks 
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6.6  Summary of Key Findings 
• Mice fed a purified, rather than chow, diet develop SOS after 5 weeks treatment with 
FOLFOX with H&E stained sections of the liver demonstrating sinusoidal dilatation and 
hepatocyte atrophy. 
• The presence of hepatic steatosis is not associated with an increased risk of developing 
SOS following FOLFOX treatment 
• FOLFOX treated mice with histological changes of SOS demonstrate up-regulation of key 
matrix remodelling genes (MMP2, MMP9, TIMP1, TGFβ, Pro-Collagen 1) 
• A standard chow diet protects against, but does not prevent, the development of 
FOLFOX induced SOS with histological changes occurring after prolonged drug exposure 
• FOLFOX induced SOS, at least in its earlier stages, appears to be reversible in mice  
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Chapter 7   
The Pathogenesis of FOLFOX Induced SOS 
 
7.1 A central role for PAI-1? 
 
Having established a reproducible model of FOLFOX induced SOS I was able to begin a 
search to identify the pathophysiological processes underpinning the development of this 
condition so as to identify potential therapeutic targets for its prevention.   In a micro-array 
study of changes in gene expression within the liver of patients with SOS one of the most 
highly up regulated transcripts was PAI-1 (Plasminogen Activation Inhibitor-1; 
SERPINE1).(Rubbia-Brandt, Tauzin et al. 2011)  In response to this observation qRT-PCR was 
performed on whole liver extracts from mice with FOLFOX induced SOS which demonstrated 
that this was dramatically up-regulated (2816 fold; p<0.0001; Fig 28).   
 
Figure 28 - FOLFOX induced SOS is associated with a 2816 fold increase in liver expression 
of PAI-1 mRNA (p<0.0001) 
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PAI-1 belongs to the serine protease inhibitor family (serpin) and was initially described as 
an inhibitor of both tissue-type plasminogen activator (tPA) and urokinase-type 
plasminogen activator (uPA).  Through inhibition of these enzymes PAI-1 prevents the 
conversion of plasminogen into plasmin and thus functions as an inhibitor of fibrinolysis and 
encourages the formation of thrombus.(Andreasen, Egelund et al. 2000; Kietzmann and 
Andreasen 2008)  
More recently it has been recognised that mice deficient in PAI-1 (PAI-1
-/-
) demonstrate 
increased activity of the collagenase MMP9 with a subsequent reduction in the 
development of liver fibrosis in response to bile duct ligation and angiotensin II 
administration.(Bergheim, Guo et al. 2006; Wang, Zhang et al. 2007; Beier, Kaiser et al. 
2011)  As already discussed increased MMP 9 activity is thought to play a key role in the 
pathogenesis of SOS and it may be that an increase in PAI-1 serves to dampen down the 
activity of this enzyme thereby protecting from SOS development.  If this were to be true 
then one might expect that PAI
-/-
 mice would develop SOS more rapidly following SOS 
treatment however since these mice were not available to me this hypothesis was not 
explored further. 
In addition to its roles in matrix remodelling and thrombosis PAI-1 has also been reported to 
play a role in cell cycle regulation and cell death.(Kortlever and Bernards 2006; Balsara and 
Ploplis 2008)  Both cancer cell lines and human umbilical vein endothelial cells have been 
shown to be resistant to spontaneous and camptothecin induced apoptosis when cultured 
in the presence of PAI-1.(Kwaan, Wang et al. 2000) In cells subject to DNA damage an 
alternative response to apoptosis is to enter a state of cell cycle arrest in G1 phase – known 
155 
 
as senescence – a process for which PAI-1 is thought to be essential.(Kortlever, Higgins et al. 
2006) 
Given the dramatic up-regulation of PAI-1 in mice with FOLFOX induced SOS it seemed 
logical to explore some of the processes in which this protein is involved, particularly cell 
cycle regulation and thrombus formation, and the role they may play in the pathogenesis of 
this condition. 
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7.2 Endothelial Senescence 
 
Cellular sensecence is a phenomenon which was originally described by Hayflick et al. in 
1961 when he observed that normal human fibroblasts maintained in optimal growth 
conditions lost their proliferative capacity after a finite number of divisions.(Hayflick and 
Moorhead 1961)  The first described cause of senescence was telomere shortening in 
response to repeated replication however since this time numerous other causes of cellular 
senescence have since been described including DNA damage, damage to the structure of 
chromatin, oxidative stress, lack of sufficient nutrients and oncogenic muations.(Ben-Porath 
and Weinberg 2005) 
There are two key independent pathways involved in the generation of a senescence 
response.  The first of these commences with nuclear translocation of the tumour 
suppressor p53 which results in activation of key transcriptional targets, in particular 
p21
CIP1/WAF1
.  The p21
CIP1/WAF1 
protein interacts with cyclins D and E to function as a negative 
regulator of G1 to S phase progression in the cell cycle.   
The alternative pathway for senescence induction involves up-regulation of the Cyclin D 
inhibitor p16
INK4A
 which is normally expressed at low levels in healthy tissues.  Activation of 
both the p53/p21
CIP1/WAF1
 and p16
INK4A
 pathways results in increased activity of the 
retinoblastoma protein which serves to inhibit the activity of the transcription factor E2F 
leading to diminished transcription of its target genes the majority of which play important 
roles in cell cycle progression.(Ben-Porath and Weinberg 2005; Evan and d'Adda di Fagagna 
2009; Larsson 2011)  These pathways are summarised in Figure 29. 
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Figure 29 - Summary of the signalling pathways that lead to the induction of cellular 
sensecence 
 
Both of these pathways may be active in the senescence process or alternatively one 
pathway may be activated whilst the other is unaffected – a pattern which varies between 
cell types but also upon the nature of the senescence inducing stimulus.  To determine if 
either of these pathways were activated in the liver of animals with FOLFOX induced SOS 
qRT-PCR was performed to determine the activity of the p21
CIP1/WAF1
 and p16
INK4A
 genes.  
This demonstrated that in animals with SOS there was a 21 fold increase in the expression of 
p21
CIP1/WAF1
 transcript (p<0.001; Fig 30A) whereas p16
INK4A
 transcript was not detectable in 
either control or FOLFOX treated animals.   
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The increased expression of p21
CIP1/WAF1
 in FOLFOX induced SOS was confirmed by western 
blot of whole liver protein extracts (Fig 30B).  Immunohistochemistry for p21
 CIP1/WAF1
 
demonstrated that this increased expression was limited to what appeared to be rounded 
up endothelial cells in the areas of sinusoidal dilatation (Fig 30C). 
 
Figure 30 - FOLFOX induced SOS is associated with up regulation of hepatic p21
WAF1/CIP1 
at 
both a transcript (A) and protein (B) level in whole liver.  Immunohistochemistry (C; 20x 
magnification) demonstrates that this up regulation occurs predominantly in endothelial 
cells in injured sinusoids (yellow arrows) 
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As discussed the main mode of action of both 5-FU and Oxaliplatin is to induce DNA damage 
a process which can lead to phosphorylation of p53 at serine 15.  This phosphorylation 
event is associated with transcriptional up regulation of p21
CIP1/WAF1
 by p53.(Jung, Qian et al. 
2010)  Western blot of whole liver protein extract from the liver of animals with FOLFOX 
induced SOS confirmed that this pathway was likely implicated in the regulation of 
p21
CIP1/WAF1
 in this model (Fig 31A).  Immunohistochemistry for γH2AX, a marker of DNA 
damage, demonstrated increased staining within endothelial cells at the site of sinusoidal 
injury in the same manner as p21
CIP1/WAF1
 suggesting that drug induced DNA damage was, at 
least in part, contributing to the induction of senescence in these cells (Fig 31B). 
 
Figure 31 - FOLFOX induced SOS is associated with increased phosphorylation of p53 at 
serine 15 (A) and positive γ H2AX staining in damaged endothelium (B; 20x magnification) 
suggesting that DNA damage is at least in part driving senescence in this model (yellow 
arrows). 
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The process of cellular senescence has been associated with the production and 
extracellular secretion of a wide variety of pro-inflammatory cytokines and chemokines 
which may play important roles in maintaining the senescent phenotype.(Acosta, O'Loghlen 
et al. 2008; Kuilman, Michaloglou et al. 2008; Novakova, Hubackova et al. 2009) qRT-PCR of 
whole liver extracts demonstrated up regulation of CXCL1 (6.6 fold; p<0.001), CXCL2 (4.2 
fold, p<0.001), CCL2 (12.5 fold, p<0.001) and IL-6 (2.0 fold, p<0.05) in animals with FOLFOX 
induced SOS (Fig 32). 
 
Figure 32 - FOLFOX Induced SOS is associated with up regulation of liver CXLC1, CXCL2, 
CCL2 and IL-6 transcript expression in keeping with a pro-inflammatory senescence 
phenotype 
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It has been suggested that IL-6, signalling through STAT1, may contribute to the 
maintenance of a senescent phenotype in cancer cell lines subject to genotoxic 
stress.(Novakova, Hubackova et al. 2009)  This is in contrast to the more traditional view 
that IL-6 is a pro-proliferative cytokine which signals via STAT3 to facilitate increased 
transcription of a variety of genes involved in cell growth and proliferation.  The IL-6/STAT3 
pathway has been shown to play a pivotal role in hepatocyte regeneration following liver 
injury.(Drucker, Gewiese et al. 2009; Wang, Lafdil et al. 2011) 
Western blot of whole liver protein extracts from mice with FOLFOX induced SOS 
demonstrated increased phosphorylation of STAT-3 as compared to those receiving vehicle 
alone suggesting a role for pro-proliferative IL—6 signalling (Fig 33A).  
Immunohistochemistry demonstrated that the site of STAT3 phosphorylation was not in the 
areas of sinusoidal injury but rather in hepatocytes surrounding the portal tracts (Fig 33B).  
More advanced SOS is associated with the development of nodular regenerative hyperplasia 
which arises in the peri-portal areas and it seems likely therefore that this is driven by IL-6 
mediated activation of STAT3.  This hypothesis is supported by the work of Horiguchi et al. 
who demonstrated increased STAT3 phosphorylation within regenerative nodules of 
patients with liver cirrhosis.(Horiguchi, Ishac et al. 2007) 
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Figure 33 - FOLFOX induced SOS is associated with phosphorylation of the STAT3 
transcription factor (A) within the liver.  Immunohistochemistry demonstrates that this 
occurs predominantly in peri-portal hepatocytes (B) 
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7.3 Oxidative Stress 
 
Whilst the pattern of staining for γH2AX closely mirrors that of p21 it should be noted that 
only a minority of the p21 positive cells in areas of sinusoidal injury demonstrate evidence 
of DNA damage suggesting that this is not the only mechanism contributing to cellular 
senescence.  As already discussed an alternative mechanism of senescence induction is 
through the action of reactive oxygen species (ROS).(Passos, Nelson et al. 2010)  It is also 
known that Oxaliplatin exposure can lead to depletion of intracellular glutathione which, in 
the Monocrotaline model, is a key mechanism underpinning the development of 
SOS.(Zhang, Mack et al. 1998; Wang, Kanel et al. 2000)  To explore the relevance of this 
mechanism to FOLFOX induced SOS the total and oxidised glutathione levels were 
determined in snap frozen liver samples.  This demonstrated a statistically significant 
reduction in total hepatic glutathione (95.4 vs. 76.9 µmoles/g protein; p<0.05; Fig 34) but no 
overall difference in the proportion of oxidised glutathione (1.4% vs. 1.2%; p=0.132; Fig 34).    
 
Figure 34 - FOLFOX induced SOS is associated with a reduction in the total liver 
glutathione concentration but not the proportion of oxidised glutathione (Analysis 
performed by Dr Aphrodite Vasilaki, Faculty of Health & Life Sciences, University of 
Liverpool) 
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Interpretation of this data is difficult.  The reduction in total liver glutathione concentration 
would suggest an increased susceptibility to oxidative stress.  In the face of significant 
oxidative stress one would expect an increase in the proportion of oxidised glutathione 
which is not seen in these animals.  It should be remembered that the major site of drug 
induced injury appears to be the sinusoidal endothelial cell which makes up only 3% of the 
liver parenchymal volume and therefore this result more likely reflects what is happening 
within hepatocytes which make up the bulk of the liver parenchymal volume.(Blouin, 
Bolender et al. 1977) To assess events in the sinusoidal endothelium individually one would 
need to isolate these cells however since this process in itself would also induce cellular 
stress this was not considered a strategy worthy of pursuing. 
To assess whether an anti-oxidant strategy may be of value in preventing the development 
of SOS in patients receiving Oxaliplatin based chemotherapy the current experiment was 
repeated utilising two different anti-oxidant strategies. The first of these was dietary 
supplementation with 3% N-Acetylcysteine (NAC). The rate limiting step in the de novo 
synthesis of glutathione is the availability of the amino acid cysteine.(Davis, Ronai et al. 
2001)  NAC is a synthetic thiol which serves to increase the intracellular cysteine 
concentration with subsequent increased glutathione synthesis.(Zafarullah, Li et al. 2003)  If 
endothelial toxicity arises solely as a consequence of glutathione deprivation then one 
would expect this strategy to be effective. 
The second anti-oxidant strategy was dietary supplementation with 0.7% butylated 
hydroxyanisole (BHA).  BHA belongs to a group of compounds known as phenolic anti-
oxidants which exerts its effect by increasing the activity of the transcription factor NRF2 
(Nuclear factor erythroid 2-related factor).(Higgins and Hayes 2011)  NRF2 regulates the 
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expression of a wide variety of genes implicated in the response to oxidative stress through 
the binding of antioxidant response elements (AREs) in the promoter region of target genes 
thereby leading to their transcription.(Reisman, Yeager et al. 2009)  
The antioxidant drugs were added to the base 10% fat purified diet used in previous 
experiments by the manufacturer.  Treatment with the drug containing diets was started a 
week prior to commencing chemotherapy treatment and continued until the time animals 
were culled.  A dietary supplementation strategy was chosen over either parenteral 
administration or oral gavage since both of these techniques are associated with a degree of 
morbidity which if carried out on a daily basis for 6 weeks might lead to a considerable risk 
to the animals.  Furthermore a parenteral strategy was not considered appropriate as it is 
unlikely that this route would be acceptable to patients receiving multiple courses of 
chemotherapy and therefore any intervention would need to be effective when 
administered via an oral route. 
 To determine the effectiveness of these antioxidant strategies H&E stained sections of the 
liver from FOLFOX treated and vehicle control mice were examined to determine the extent 
of sinusoidal injury.  It can be seen in Figure 35 that NAC treatment had no effect on the 
development of SOS as compared to animals fed the control diet whereas BHA treatment 
resulted in a much less severe injury to the hepatic sinusoid with at worst very minor 
sinusoidal dilatation being present, although in some animals there was no evidence of 
injury at all.  This was reflected in the histological scoring of H&E stained tissue sections with 
the incidence of endothelial disruption being reduced to only 25% in FOLFOX treated 
animals receiving BHA treatment (p<0.05; Table 10).    
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The observation that NAC administration does not prevent the development of FOLFOX 
induced SOS is an unexpected finding that appears to contradict the findings of Wang et al. 
in the Monocrotaline model.(Wang, Kanel et al. 2000)  It should be noted that in this study 
NAC was administered by intraportal infusion and it may be that the oral route is not 
sufficient for adequate drug delivery to the target tissue.    
 Control Diet  0.7% BHA  
 Vehicle 
(n=5) 
FOLFOX 
(n=5) 
Vehicle 
(n=5) 
FOLFOX 
(n=4) 
Rubbia-Brandt Grade     
0 5 0 5 1 
1 0 4 0 3 
2 0 1 0 0 
3 0 0 0 0 
Endothelial Disruption Present 0 5 0 1 
 
Table 10 - The impact of BHA treatment on the histological scoring of H&E stained liver 
sections from FOLFOX treated animals (Scoring by Professor Alastair Burt) 
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Figure 35 - Representative H&E stained liver sections from FOLFOX or Vehicle control 
treated animals with antioxidant dietary supplementation 
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In keeping with reduced sinusoidal injury in animals fed a BHA supplemented diet qRT-PCR 
of whole liver RNA extracts demonstrated decreased expression of p21 and PAI-1 following 
FOLFOX treatment (Fig 36). 
 
 
Figure 36 - In accordance with a lesser degree of sinusoidal injury there is a reduction in 
FOLFOX induced p21 and PAI-1 expression in animals on a BHA supplemented diet 
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To confirm that BHA was mediating its effects through NRF2 a western blot was initially 
performed on whole liver extracts to determine changes in protein expression following 
FOLFOX administration.  This assay revealed that the presence of SOS is associated with 
reduced overall expression of NRF2, a finding which has not been previously reported.  This 
reduction in NRF2 protein expression is prevented in animals maintained on a 0.7% BHA diet 
(Fig 37A).   
To assess the effect of these changes on gene transcription qRT-PCR was performed to 
determine the expression of TXN1 (Thioredoxin1) and NQO1 (NAD(P)H dehydrogenase 1) 
both of which play important roles in the elimination of ROS and are classically recognised 
as being regulated by NRF2.(Taguchi, Motohashi et al. 2011)  This demonstrated that SOS 
was associated with a 3 fold reduction in TXN1 expression (p<0.01) an effect that was 
prevented by feeding with a BHA diet, which in itself led to a 2 fold increase in baseline 
TXN1 expression (p<0.01; Fig 37B).  SOS was not associated with a reduction in NQO1 
expression however a BHA diet was associated with a 19 fold increase in NQO1 expression 
(p<0.01) suggesting increased protection from ROS in these animals (Fig 37C). 
In summary the current data support the notion that oxidative stress is important in the 
pathogenesis of FOLFOX induced SOS.  Anti-oxidant strategies that increase NRF2 
transcriptional activity may be particularly useful in trying to prevent this complication of 
chemotherapy. 
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Figure 37 - FOLFOX induced SOS is associated with decreased expression of the 
transcription factor NRF2 which is prevented by administration of a diet supplemented 
with 0.7% BHA (A).  This prevents the FOLFOX induced reduction in thioredoxin 
transcription (B) and increased basal NQO1 transcription (C) thereby resulting in increased 
protection from ROS 
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7.4 The Coagulation Cascade in SOS Development 
 
There is indirect evidence to suggest that abnormalities in the clotting cascade may 
contribute to the development of SOS in patients.  In a series of 146 patients undergoing 
resection of colorectal liver metastases Brouquet et al. demonstrated histological features 
of SOS in 50 of whom the majority had received pre-operative Oxaliplatin based 
chemotherapy.  On multivariate analysis they identified that those taking regular Aspirin 
had a lower risk for developing SOS (Hazard Ratio 0.44; p=0.03) as compared to those who 
were not.(Brouquet, Benoist et al. 2009)  In patients who develop severe SOS following 
myeloablative chemotherapy prior to bone marrow transplantation the fibrinolytic agent 
defibrotide has been reported to be of modest benefit in improving 
outcome.(Benimetskaya, Wu et al. 2008) 
It is widely acknowledged that both platinum based chemotherapeutics and 5-FU have pro-
thrombotic effects on vascular endothelium.(Cwikiel, Eskilsson et al. 1996; Nuver, De Haas 
et al. 2010) In the Monocrotaline model of SOS it has been shown that activation of the 
clotting cascade with deposition of fibrin along the sinusoid is a key feature.(Copple, Banes 
et al. 2002)  The clotting cascade consists of two separate pathways – the intrinsic and 
extrinsic pathways – which converge on a common pathway whereby Factor X is cleaved to 
the active form, Factor Xa, which subsequently cleaves thrombin from its precursor 
molecule prothrombin.  Thrombin is then able to convert fibrinogen to fibrin resulting in the 
formation of clot.(Ganong 1997) 
In support of activation of the clotting cascade there was a 1.9 fold increase in expression of 
Factor X transcript in the liver of mice with FOLFOX induced SOS (p<0.001; Fig 38A).   Tissue 
factor is a key component of the extrinsic coagulation pathway.  Upon injury cells express 
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tissue factor on their surface which is able to come into contact with circulating Factor VII 
which together form a complex which then activate Factor X.(Ganong 1997; Usui, Kuriyama 
et al. 2009)  Immunohistochemistry demonstrated increased expression of tissue factor 
within injured hepatic sinusoids (Fig 38B) suggesting this may be a relevant mechanism of 
clotting cascade activation in SOS. 
 
 
Figure 38 - In support of coagulation cascade activation there is increased expression of 
Factor X in the liver of mice with FOLFOX induced SOS (A).  Coagulation cascade activation 
is likely occurring via the extrinsic pathway as a consequence of increased tissue factor 
expression in areas of sinusoidal injury (B) 
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As already discussed FOLFOX administration is associated with splenic injury in mice (Figure 
10; Chapter 3).  Further review of H&E stained sections of the spleen in the current model 
revealed the presence of large clusters of Megakaryocytes in mice with FOLFOX induced SOS 
(3.8 vs. 1.3 cells per HPF; p<0.001; Fig 39 A & B) suggesting that perhaps significant numbers 
of platelets are being released directly into the portal circulation.  This was also associated 
with a 1.9 fold increase in hepatic von Willebrand Factor (vWF) expression in the liver of 
these animals suggestive of an increased potential for platelet adhesion and activation 
(p<0.01; Fig 39 C). 
 
Figure 39 - FOLFOX induced SOS is associated with the presence of large clusters of 
Megakaryocytes within the spleen (A & B).  In addition there is increased hepatic 
expression of vWF mRNA suggesting an increased propensity of platelet adherence and 
activation within the liver. 
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In addition to its roles in thrombus formation Factor X is also able to interact with and 
activate pathways involved in matrix remodelling which it achieves by signalling through the 
protease activated receptors PAR1 and PAR2.  It is noteworthy that mRNA expression of 
both of these receptors is increased in the liver of FOLFOX treated mice (Fig 40). 
 
Figure 40 - Increased mRNA expression of the Factor X activated receptors PAR1 and PAR2 
in the liver of mice with FOLFOX induced SOS 
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7.5  Summary of Key Findings 
• FOLFOX induced SOS is associated with cellular senescence in the injured sinusoidal 
endothelium which expresses high levels of the cyclin dependent kinase inhibitor p21.  
This process seems to be driven by activation of the transcription factor p53. 
• This process is associated with increased expression of the cytokine IL-6 which appears 
to result in increased phosphorylation of the oncogenic transcription factor STAT3 in 
peri-portal hepatocytes suggesting this is the driver of SOS associated regenerative 
hyperplasia 
• SOS is associated with depletion of intracellular glutathione and diminished expression 
of the anti-oxidant transcription factor NRF2.   
• Treatment of mice with the NRF2 activating anti-oxidant BHA prevents the 
development of FOLFOX induced SOS 
• The development of SOS appears to be associated with a pro-thrombotic environment.  
Manipulation of this may be beneficial as a therapeutic target to prevent the 
development of SOS  
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Chapter 8  
Discussion 
 
The primary aim of this study was to establish a reproducible in vivo model of SOS induced 
by Oxaliplatin based chemotherapy. This has been achieved and represents a significant 
move forward for translational research relating to this condition.  The only model in 
existence prior to this work was that of Monocrotaline administration to rats however for 
the reasons outlined in the Introduction to this thesis it was felt that this was poorly suited 
to study the pathogenesis of SOS in the current context and was therefore acting as a 
barrier to the development of effective therapeutics. 
Perhaps the most surprising finding in the current study is that mice maintained on a 
standard chow diet seem to be relatively protected from developing a sinusoidal injury in 
response to FOLFOX as compared to those fed a purified diet despite identical drug 
treatment.  Whilst exploring the mechanisms behind this observation is beyond the scope of 
the current study it is nonetheless interesting to hypothesise as to why this might be.   
Purified diets, such as the one used in this study, are manufactured in a factory with refined 
ingredients of a known quantity and purity.  In contrast chow diets are manufactured with 
plant materials and are designed to meet a minimum nutritional standard although the 
precise content is not known.  The result of this is that chow diets will often contain high 
levels of phytoestrogens and these are well known to have protective effects on the 
development of a variety of liver diseases including steatosis and fibrosis.(Ascencio, Torres 
et al. 2004; McCarty, Barroso-Aranda et al. 2009)  
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It appears that the murine liver is relatively resistant to developing SOS after FOLFOX 
treatment since, even in animals fed a purified diet, I was not able to replicate the more 
advanced histological features seen in patients e.g. nodular regenerative hyperplasia 
despite high dose drug administration.  As already discussed it may be that high expression 
of the ATP7B transporter, responsible for the cellular export of platinum, is in part 
responsible for this.  The importance of this observation is that it highlights a potential role 
for pharmacogenomics in determining susceptibility to SOS.  A recent study examined the 
genomic DNA of peripheral blood leukocytes in 203 cancer patients and identified 
polymorphisms of the ATP7B gene in 61 patients suggesting that these are relatively 
common in the general population.(Fukushima-Uesaka, Saito et al. 2009)  None of these 
patients were reported to have clinical features of Wilson’s disease which occurs as a 
consequence of specific mutations in this gene. 
One of the unanswered questions regarding SOS is why some patients develop severe 
histological changes after a solitary short course of chemotherapy whilst others who receive 
multiple prolonged courses of chemotherapy do not.  It is possible that pharmacogenomics, 
in particular the effect of functional polymorphisms in the ATP7B gene, could explain this 
observation by altering individual susceptibility to Oxaliplatin.  This concept is not new, for 
example it has long been recognised that patients with polymorphisms in the UGT1A1 gene 
demonstrate increased toxicity to Irinotecan and as such it is common place to reduce the 
dose of drug given to these patients.(Kweekel, Guchelaar et al. 2008; Marsh and Hoskins 
2010)  On this basis it would seem appropriate to establish further studies in patients 
exploring the relationship between ATP7B polymorphisms and SOS development.   
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An alternative explanation for the varying individual susceptibility to SOS may be found in 
the tumour response to chemotherapy and indeed in this study I have shown that the 
presence of tumour within the liver accelerates gene expression changes associated with 
the development of SOS.  The concept that tumour death in response to chemotherapy is 
immunologically silent with no effect on the external environment has been challenged and 
it is now acknowledged that a wide variety of chemotherapeutic agents are able to illicit an 
immune reaction by stimulating an inflammatory response by the tumour.(Tesniere, Apetoh 
et al. 2008; Martins, Tesniere et al. 2009) In support of the hypothesis for tumour death 
contributing to the development of SOS it has been shown that patients with a higher 
tumour burden are more likely to develop SOS independently of the number of 
chemotherapy cycles received.(Tamandl, Klinger et al. 2011)   
A potential explanation of how the tumour response might contribute to the development 
of SOS is provided by the cytokine CXCL1, the murine IL-8 equivalent.  This cytokine is 
produced in high quantities by FOLFOX treated MCA38 cells as well as being elevated in the 
serum of patients with SOS.(Schots, Kaufman et al. 2003) Acting through the CXCR2 receptor 
CXCL1 is able to increase the transcription of genes implicated in matrix remodelling and 
angiogenesis in SOS such as MMP2 and VEGF-A.(Li, Dubey et al. 2003; Li, Varney et al. 2005)  
Furthermore IL-8 signalling in human endothelial cells is reported to increase the expression 
of PAI-1 which this study has demonstrated to be strongly implicated in the pathogenesis of 
SOS.(Cheng, Li et al. 2008) 
The marked elevation in PAI-1 expression in FOLFOX treated mice resulted in the 
identification of replicative senescence within the damaged sinusoidal endothelium as a 
potential mechanism involved in SOS pathogenesis.  Rather than being a passive marker of 
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senescence, as was previously thought, it is now recognised that it is essential both for the 
induction and maintenance of this condition by down regulating signalling in the mitogenic 
PI3K-PKB pathway which is common to many pro-proliferative growth factors.(Kortlever, 
Higgins et al. 2006)   On the basis of the evidence presented in this study it would seem that 
endothelial senescence arises as a consequence of both direct drug induced DNA damage 
and oxidative stress.  In reality it would not be plausible to target DNA damage 
therapeutically to prevent SOS development without having a negative impact on tumour 
response and therefore oxidative stress was pursued instead. 
Working with the Monocrotaline model SOS Wang et al. reported that intra-portal infusion 
of both NAC and glutathione were effective in preventing the development of SOS.(Wang, 
Kanel et al. 2000) In contrast to this I was not able to demonstrate any therapeutic benefit 
to dietary supplementation with 3% NAC.  One explanation for this discrepancy may be that 
the route of administration chosen in the current study was not appropriate to allow 
sufficient concentrations of NAC to reach the liver however this seems unlikely since it is 
well recognised that NAC is well absorbed from the gut and directly enters the portal 
circulation.(Smilkstein, Knapp et al. 1988)  It may be that the administration of 
chemotherapy impairs the absorption of NAC from the gut – it is well recognised that 5-FU 
administration is associated with mucositis and the subsequent development of diarrhoea in 
patients.(Petrelli, Cabiddu et al. 2012)   
For the first time we have shown that the development of SOS after FOLFOX treatment is 
associated with down regulation of the antioxidant transcription factor NRF2.  Furthermore 
mice receiving the NRF2 activating antioxidant BHA alongside FOLFOX treatment do not 
develop histological features of SOS suggesting that targeting this pathway may be of some 
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translational value.  One of the key concerns when developing drugs to prevent the 
complications of systemic chemotherapy is that one does not have a negative impact on the 
cytotoxic effect.  The NRF2 pathway is particularly attractive in this regard since it has been 
shown that the Curcumin, an NRF2 activator, can actually increase the cytotoxicity of 
conventional chemotherapeutics and is currently the subject of several clinical trials in this 
regard.(Patel, Gupta et al. 2010)  To have an agent that could both reduce the incidence of 
SOS and increase the cytotoxicity of Oxaliplatin would be a major breakthrough and this is 
an area that should be pursued in more detail in further studies. 
An alternative pathological process identified in this study which is of potential relevance to 
the development of SOS is generation of a pro-thrombotic environment within the liver.  
There is some evidence from clinical studies to support this hypothesis in that patients 
treated with Oxaliplatin whilst taking regular Aspirin appear to have a lower incidence of 
SOS.(Brouquet, Benoist et al. 2009)  In addition in patients receiving myeloablative 
chemotherapy prior to bone marrow transplantation the fibrinolytic agent defibrotide has 
demonstrated some success in treating SOS.(Benimetskaya, Wu et al. 2008)  The most 
obvious explanation for how a pro-thrombotic environment contributes to the development 
of SOS would be that it leads to the generation of thrombi within the hepatic sinusoid 
resulting in microvascular occlusion.  It should be noted however that there is significant 
cross talk between the coagulation system and a variety of cellular processes including 
matrix remodelling which is mediated via the PAR receptors.  For example Factor Xa acting 
via the PAR1 receptor is able to convert TGFβ from its latent to active form thereby 
contributing to the development of liver fibrosis.(Fiorucci, Antonelli et al. 2004; Rullier, 
Gillibert-Duplantier et al. 2008; Scotton, Krupiczojc et al. 2009)  Whilst it may be attractive 
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to consider anticoagulation as a strategy to reduce the incidence of SOS it is possible that 
this would lead to an increase in tumour related bleeding complications and as such further 
work should proceed cautiously. 
In conclusion the studies presented in this thesis describe a reproducible model of 
Oxaliplatin induced SOS which more closely replicates events in patients treated with these 
regimens.  Using this model I have identified several pathological processes involved in the 
development of this condition.  In particular through manipulation of the NRF2 pathway I 
have identified a therapeutic target which may be of value in reducing the incidence of SOS.  
It is hoped that further work using this model will validate these findings and quickly lead to 
the first studies in patients. 
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Reference Year Study 
Type 
Comparisons n NOS Evidence 
Level 
Key Findings Overlap with Other Studies 
Adam et al.(Adam, 
Bhangui et al. 2010)  
2010 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery Alone 
1471 7 2b The use of pre-operative 
chemotherapy does not seem to 
offer any benefit to patients with a 
solitary metachronous colorectal 
liver metastases 
Data from LiverMet survey (i.e. 
multiple centres) 
Aloia et al.(Aloia, 
Sebagh et al. 2006) 
2006 CS(R) Neoadjuvant (OHP based) 
Chemotherapy vs. Surgery 
Alone 
75 8 2b The main hepatic injury following 
OHP based chemotherapy is vascular 
not steatosis.  The risk of 
complications is related to the 
duration of chemotherapy. 
 
Aloysius et 
al.(Aloysius, Zaitoun 
et al. 2007) 
2007 CC(R) Neoadjuvant (FOLFOX-4) 
Chemotherapy vs. Surgery 
Alone 
50 7 3b The use of neoadjuvant FOLFOX-4 is 
associated with hepatic steatosis 
and sinusoidal dilatation 
 
D’Angelica et 
al.(D'Angelica, 
Kornprat et al. 2007) 
2006 CC(R) Neoadjuvant Chemotherapy 
vs. Neoadjuvant 
Chemotherapy & 
Bevacizumab 
32 8 3b The use of pre-operative 
Bevacizumab is not associated with 
an increase in peri-operative 
complications 
 
Nordlinger et 
al.(Nordlinger, 
Sorbye et al. 2008) 
2008 RCT Peri-operative (FOLFOX) 
Chemotherapy vs. Surgery 
Alone 
364  1b Preoperative FOLFOX-4 
chemotherapy increases the risk of 
peri-operative complications but 
improves progression free survival 
Multi-centre RCT 
Folprecht et 
al.(Folprecht, 
Gruenberger et al. 
2010) 
2010 RCT Pre-operative FOLOX & 
Cetuximab vs. FOLFIRI & 
Cetuximab 
45  1b There is little difference in morbidity 
between the two groups 
Multi-centre RCT 
Gomez et al.(Gomez, 
Malik et al. 2007) 
2007 CS(R) Hepatic Steatosis vs. No 
Hepatic Steatosis 
386 8 2b Hepatic steatosis increases the 
morbidity of liver resection  
(Malik, Farid et al. 2007) 
Gomez-Ramirez et 
al. 
2010 CS(P) Neoadjuvant Chemotherapy 
vs. Surgery alone 
45 6 2b Neoadjuvant Irintocean is associated 
with an increased risk of 
steatohepatitis 
 
Hewes et al.(Hewes, 
Dighe et al. 2007) 
2007 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
67 8 2b Neoadjuvant OHP based 
chemotherapy increases the risk 
associated with liver resection 
 
Hubert et al.(Hubert, 2010 CS(R) Neoadjuvant Chemotherapy 114 8 2b Neoadjuvant chemotherapy is  
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Fervaille et al. 2010) vs. Surgery alone associated with sinusoidal 
congestion but has no impact on 
peri-operative outcome 
Kandutsch et 
al.(Kandutsch, 
Klinger et al. 2008) 
2008 CS(R) Neoadjuvant (OHP based) 
Chemotherapy vs. Surgery 
Alone 
63 8 2b Sinusoidal obstruction but not 
steatohepatitis occurs as a 
consequence of OHP based 
chemotherapy 
(Klinger, Eipeldauer et al. 2009; 
Tamandl, Klinger et al. 2011) 
Karoui et al.(Karoui, 
Penna et al. 2006) 
2006 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery Alone 
67 7 2b Prolonged chemotherapy injures the 
hepatic parenchyma and increases 
the morbidity of liver resection 
when performed under total 
vascular exclusion 
 
Kesmodel et 
al.(Kesmodel, Ellis et 
al. 2008) 
2008 CS(R) Neoadjuvant Chemotherapy 
vs. Neoadjuvant 
Chemotherapy & 
Bevacizumab 
125 8 2b The use of pre-operative 
Bevacizumab in conjunction with 
traditional chemotherapy is not 
associated with an increase in 
surgical morbidity 
(Vauthey, Pawlik et al. 2006; 
Ribero, Wang et al. 2007; Kishi, 
Zorzi et al. 2010; Rubbia-Brandt, 
Lauwers et al. 2010) 
Kishi et al.(Kishi, 
Zorzi et al. 2010) 
2010 CS(R) Neoadjuvant FOLFOX vs. 
Neoadjuvant FOLFOX & 
Bevacizumab 
219 8 2b Extended pre-operative 
chemotherapy increases the risk of 
parenchymal injury without 
improving pathological response 
(Vauthey, Pawlik et al. 2006; 
Ribero, Wang et al. 2007; 
Kesmodel, Ellis et al. 2008; 
Rubbia-Brandt, Lauwers et al. 
2010) 
Klinger et al.(Klinger, 
Eipeldauer et al. 
2009) 
2009 CS(R) Neoadjuvant (OHP based) 
Chemotherapy vs. 
Neoadjuvant (OHP) based 
chemotherapy & 
Bevacizumab 
99 7 2b Bevacizumab protects against 
sinusoidal obstruction syndrome but 
does not improve tumour response 
to OHP based chemotherapy 
(Kandutsch, Klinger et al. 2008; 
Tamandl, Klinger et al. 2011) 
Komori et 
al.(Komori, Beppu et 
al. 2010) 
2010 CS(R) Neoadjuvant (FOLFOX) 
Chemotherapy vs. Surgery 
alone 
27 8 2b FOLFOX use results in parenchymal 
injury but has no effect on peri-
operative morbidity and mortality 
 
Konopke et 
al.(Konopke, 
Kersting et al. 2009) 
2009 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
240 8 2b Preoperative chemotherapy is an 
independent risk factor for post-
operative complications in patients 
undergoing major liver resection 
 
Lubezky et 
al.(Lubezky, Geva et 
2009 CS(R) Neoadjuvant Chemotherapy 
vs. Adjuvant Chemotherapy 
56 8 2b Post-operative morbidity is higher in 
patients receiving neoadjuvant 
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al. 2009) chemotherapy 
Mahfud et 
al.(Mahfud, 
Breitenstein et al. 
2010) 
2010 CS(R) Neoadjuvant Chemotherapy 
vs. Neoadjvuant 
Chemotherapy & 
Bevacizumab 
90 8 2b The addition of Bevacizumab to 
conventional chemotherapy does 
not impact on peri-operative 
outcome 
(Nakano, Oussoultzoglou et al. 
2008) 
Makowiec et 
al.(Makowiec, 
Mohrle et al. 2011) 
2011 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
102 7 2b Neither pre-operative chemotherapy 
or the presence of parenchymal 
injury affect peri-operative outcome 
 
Malik et al.(Malik, 
Farid et al. 2007) 
2007 CC(R) Neoadjuvant (OHP Based) 
Chemotherapy vs. Surgery 
alone 
155 8 3b Neoadjuvant chemotherapy had no 
impact on peri-operative outcome 
(Gomez, Malik et al. 2007) 
Mehta et al.(Mehta, 
Ravikumar et al. 
2008) 
2008 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
173 6 2b Oxaliplatin based chemotherapy is 
associated with a vascular injury to 
the liver parenchyma but this has no 
effect on peri-operative outcome 
 
Nakano et 
al.(Nakano, 
Oussoultzoglou et al. 
2008) 
2008 CS(R) Neoadjuvant (OHP Based) 
Chemotherapy vs. 
Neoadjuvant (Other 
regimens) Chemotherapy 
90 8 2b OHP based chemotherapy is 
associated with an increased 
incidence of sinusoidal injury.  
Sinusoidal injury is associated with a 
poorer outcome after major 
hepatectomy. 
(Mahfud, Breitenstein et al. 
2010) 
O’Rourke et 
al.(O'Rourke, Welsh 
et al. 2009) 
2009 CS(P) Neoadjuvant Chemotherapy 
vs. Surgery alone 
37 8 2b Liver specific MRI can accurately 
predict the severity of parenchymal 
injury 
(Welsh, Tilney et al. 2007) 
Ouaissi et 
al.(Ouaissi, 
Moutardier et al. 
2006) 
2006 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
40 6 2b Pre-operative chemotherapy does 
not influence the outcome of liver 
resection 
 
Pawlik et al.(Pawlik, 
Olino et al. 2007) 
2007 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
212 8 2b Neoadjuvant chemotherapy is 
associated with parenchymal injury 
in 20 – 30% of patients.  The nature 
of the injury is regimen specific. 
 
Reddy et al.(Reddy, 
Morse et al. 2008) 
2008 CS(R) Neoadjuvant Chemotherapy 
vs. Neoadjuvant 
Chemotherapy & 
Bevacizumab 
96 8 2b The addition of Bevacizumab to 
conventional chemotherapy does 
not increase  morbidity following 
liver resection 
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Ribero et al.(Ribero, 
Wang et al. 2007) 
2007 CS(R) Neoadjuvant (OHP Based) 
Chemotherapy vs. 
Neoadjuvant (OHP Based) 
Chemotherapy & 
Bevacizumab 
105 8 2b The addition of Bevacizumab to OHP 
based chemotherapy reduces the 
incidence of sinusoidal injury and 
increases tumour response to 
chemotherapy as assessed 
histologically 
(Vauthey, Pawlik et al. 2006; 
Kesmodel, Ellis et al. 2008; 
Kishi, Zorzi et al. 2010; Rubbia-
Brandt, Lauwers et al. 2010) 
Rubbia-Brandt et 
al.(Rubbia-Brandt, 
Audard et al. 2004) 
2004 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
153 6 2b Neoadjuvant OHP based 
chemotherapy is associated with 
sinusoidal obstruction syndrome 
(Rubbia-Brandt, Lauwers et al. 
2010) 
Rubbia-Brandt et 
al.(Rubbia-Brandt, 
Lauwers et al. 2010) 
2010 CS(R) Neoadjuvant (OHP Based) 
chemotherapy vs. 
Neoadjuvant (OHP Based) 
chemotherapy & 
Bevacizumab vs. Surgery 
alone 
385 6 2b OHP based chemotherapy is 
associated with sinusoidal 
obstruction syndrome the incidence 
of which is reduced if used alongside 
Bevacizumab 
(Rubbia-Brandt, Audard et al. 
2004; Vauthey, Pawlik et al. 
2006; Ribero, Wang et al. 2007; 
Kesmodel, Ellis et al. 2008; 
Kishi, Zorzi et al. 2010) 
Ryan et al.(Ryan, 
Nanji et al. 2010) 
2010 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
334 8 2b Neoadjuvant chemotherapy is 
associated with a vascular injury to 
the hepatic parenchyma but not 
steatohepatitis 
(Sahajpal, Vollmer et al. 2007) 
Sahajpal et 
al.(Sahajpal, Vollmer 
et al. 2007) 
2007 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
96 7 2b Neoadjuvant chemotherapy does 
not affect short term outcomes 
following liver resection 
(Ryan, Nanji et al. 2010) 
Scoggins et 
al.(Scoggins, 
Campbell et al. 
2009) 
2008 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
186 8 2b Neoadjuvant chemotherapy does 
not affect the morbidity associated 
with liver resection 
 
Tamandl et 
al.(Tamandl, Klinger 
et al. 2011) 
2011 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
196 8 2b OHP induced sinusoidal obstruction 
is associated with poorer overall and 
disease specific survival 
(Kandutsch, Klinger et al. 2008; 
Klinger, Eipeldauer et al. 2009) 
Vauthey et 
al.(Vauthey, Pawlik 
et al. 2006) 
2006 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
406 8 2b Neoadjuvant Irinotecan based 
chemotherapy is associated with the 
development of steatohepatitis 
(Ribero, Wang et al. 2007; 
Kesmodel, Ellis et al. 2008; 
Kishi, Zorzi et al. 2010; Rubbia-
Brandt, Lauwers et al. 2010) 
Welsh et al.(Welsh, 
Tilney et al. 2007) 
2007 CS(R) Neoadjuvant Chemotherapy 
vs. Surgery alone 
497 8 2b Liver resection is safe following 
neoadjuvant chemotherapy 
(O'Rourke, Welsh et al. 2009) 
Yebidela et 2005 CC(R) Neoadjuvant Chemotherapy 64 8 3b Neoadjuvant chemotherapy does  
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al.(Yebidela, Elad et 
al. 2005) 
vs. Surgery alone not increase surgical morbidity or 
mortality 
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Dietary Constituents 
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Appendix 3  
FOLFOX Dosing Schedule 
 
Weight (g) Dose (ug) Volume of Stock Solution (uL) 
20 120 120 
21 126 126 
22 132 132 
23 138 138 
24 144 144 
25 150 150 
26 156 156 
27 162 162 
28 168 168 
29 174 174 
30 180 180 
Volume of Oxaliplatin 1mg/ml stock solution to administer according to body weight (6mg/kg 
dose) 
 
Weight (g) Dose (ug) Volume of Stock Solution (uL) 
20 1000 100 
21 1050 105 
22 1100 110 
23 1150 115 
24 1200 120 
25 1250 125 
26 1300 130 
27 1350 135 
28 1400 140 
29 1450 145 
30 1500 150 
Volume of 5-FU 10mg/ml stock solution according to administer according to body weight 
(50mg/kg dose) 
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Weight (g) Dose (ug) Volume of Stock Solution (uL) 
20 1800 144 
21 1890 151.2 
22 1980 158.4 
23 2070 165.6 
24 2160 172.8 
25 2250 180 
26 2340 187.2 
27 2430 194.4 
28 2520 202 
29 2610 208.8 
30 2700 216 
Volume of Folinic Acid 12.5mg/ml stock solution to administer according to body weight 
(90mg/kg dose)  
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Appendix 4 
Vector Map pGL4.51 
 
 
 
 
 
Map downloaded from Promega On-Line Catologue (www.promega.com) 
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Appendix 5 
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The work contained within this thesis has been presented at a variety of regional, national 
and international meetings (see Appendix 6) where it has been awarded the following 
prizes: 
 
AUGIS BJS Prize (for best original research presentation) 
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